# EDGAR Filing Document

**Accession Number:** 0001764046
**File Stem:** 0001764046-26-000046
**Filing Date:** 2026-4
**Character Count:** 269796
**Document Hash:** 9043c6fc082046d7814ad2065b59a881
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001764046-26-000046.hdr.sgml**: 20260401

**ACCESSION NUMBER**: 0001764046-26-000046

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 38

**CONFORMED PERIOD OF REPORT**: 20260514

**FILED AS OF DATE**: 20260401

**DATE AS OF CHANGE**: 20260401

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CLARIVATE PLC
- **CENTRAL INDEX KEY:** 0001764046
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Y9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38911
- **FILM NUMBER:** 26824730

**BUSINESS ADDRESS:**
- **STREET 1:** 4TH FLOOR, ST. PAUL'S GATE
- **STREET 2:** 22-24 NEW STREET
- **CITY:** ST. HELIER
- **STATE:** Y9
- **ZIP:** JE14TR
- **BUSINESS PHONE:** (207) 433-4000

**MAIL ADDRESS:**
- **STREET 1:** 70 ST. MARY AXE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** EC3A 8BE

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CLARIVATE Plc
- **DATE OF NAME CHANGE:** 20200507

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Clarivate Analytics PLC
- **DATE OF NAME CHANGE:** 20190108

?xml version='1.0' encoding='ASCII'? clvt-20260401

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934**

---

| | | | | |
|:---|:---|:---|:---|:---|
| Filed by the Registrant | Filed by the Registrant | ☒ | Filed by a party other than the Registrant | ☐ |
| Check the appropriate box: | Check the appropriate box: | Check the appropriate box: | Check the appropriate box: |  |
| ☐ | Preliminary Proxy Statement | Preliminary Proxy Statement | Preliminary Proxy Statement |  |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |  |
| ☒ | Definitive Proxy Statement | Definitive Proxy Statement | Definitive Proxy Statement |  |
| ☐ | Definitive Additional Materials | Definitive Additional Materials | Definitive Additional Materials |  |
| ☐ | Soliciting Material Pursuant to Section 240.14a-12 | Soliciting Material Pursuant to Section 240.14a-12 | Soliciting Material Pursuant to Section 240.14a-12 |  |

---

---

| | |
|:---|:---|
| **CLARIVATE PLC** | **CLARIVATE PLC** |
| **(Name of Registrant as Specified in Its Charter)** | **(Name of Registrant as Specified in Its Charter)** |
| **N/A** | **N/A** |
| **(Name of Person(s) Filing Proxy Statement if other than the Registrant)** | **(Name of Person(s) Filing Proxy Statement if other than the Registrant)** |
| Payment of Filing Fee (Check all boxes that apply): | Payment of Filing Fee (Check all boxes that apply): |
| ☒ | No fee required. |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11 |

---

![Proxy Cover PRINT (1) FNL.jpg](clvt-20260401_g1.jpg)

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

![lg_clarivatetm-4clr - Clarivate Logo.jpg](clvt-20260401_g2.jpg)

**DEAR FELLOW SHAREHOLDERS:**

On behalf of our Board of Directors, I am pleased to invite you to the 2026 Annual General Meeting of

Shareholders of Clarivate Plc (the "Annual Meeting"), which will be held on Thursday, May 14, 2026, at the

Clarivate corporate headquarters located at 70 St. Mary Axe, London EC3A 8BE, United Kingdom, starting

at 1:00 p.m. BST.

The enclosed Notice of the 2026 Annual General Meeting of Shareholders and Proxy Statement describe

the business that we will conduct at the meeting and the proposals that the shareholders of Clarivate will

consider and vote upon.

All shareholders of record of our ordinary shares at the close of business on March 16, 2026, the Record

Date, are entitled to receive notice of, and to vote at, the Annual Meeting, or any continuation,

postponement, or adjournment thereof. If you plan to attend the Annual Meeting in person, we encourage

you to request an admission ticket in advance. You can request a ticket in advance by following the

instructions under "Admission Procedure" in the Proxy Statement. Failure to request an admission ticket in

advance will not preclude your attendance at the Annual Meeting in person. However, in each case, an

individual must have evidence of ownership of the Company's ordinary shares as of the Record Date and

a valid government-issued photo identification (e.g., a driver's license or a passport) and should arrive in

advance, with sufficient time to be admitted to the Annual Meeting.

Whether or not you plan to attend the Annual Meeting in person, it is important that your shares be

represented and voted at the meeting. If you have elected to receive your proxy materials by mail, please

mark, sign, date, and return the proxy card in the envelope accompanying the proxy materials. If you

received your proxy materials through the internet, please submit your voting instructions by internet or

otherwise in accordance with the instructions provided in the notice of internet availability of proxy

materials that you received in the mail. You may also submit your proxy by sending a scanned PDF

version of the original proxy card by email to **Company.Secretary@clarivate.com**. If your shares are

held in the name of a bank or broker, submitting your voting instructions by mail, telephone, or internet will

depend on the processes of the bank or broker, and you should follow the instructions you receive from

your bank or broker.

Returning the proxy card or otherwise submitting your proxy does not deprive you of your right to attend

the Annual Meeting and vote. If you decide to attend the Annual Meeting, you will be able to revoke your

proxy and vote. Any signed proxy returned and not completed will be voted by management in favor of all

proposals presented in the Proxy Statement.

Remember that your shares cannot be voted unless you submit your proxy or attend the Annual Meeting

in person. Your participation is important, so please review these materials carefully and submit your

voting instructions.

Thank you for your continued support of Clarivate.

Sincerely,

![sg_andysnyder-bw - Signature.jpg](clvt-20260401_g3.jpg)

**Andy Snyder**

**Chair of the Board**

April 1, 2026

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Notice of 2026 Annual General Meeting of Shareholders**

NOTICE IS HEREBY GIVEN that the 2026 Annual General Meeting of Shareholders (the "**Annual Meeting**") of Clarivate

Plc ("**Clarivate**" or the "**Company**") will be held at the following date, time, and place:

---

| | |
|:---|:---|
| **Date** | **Place** |
| Thursday, May 14, 2026 | Clarivate Plc Headquarters |
|  | 70 St. Mary Axe |
|  | London EC3A 8BE, United Kingdom |
| **Time** | **Record Date** |
| 1:00 p.m. BST | March 16, 2026 |

---

**Items of Business**

**1.**Re-elect ten directors to serve on the Board of Directors until the next annual general meeting of shareholders or until

their respective successors are duly elected and qualified: Jane Okun Bomba, Kenneth Cornick, Usama N. Cortas,

Suzanne Heywood, Adam T. Levyn, Anthony Munk, Wendell Pritchett, Saurabh Saha, Matti Shem Tov, and Andrew

Snyder.

**2.**Adopt a resolution, on an advisory, non-binding basis, to approve the compensation of the Company's named

executive officers.

**3.**Reappoint PricewaterhouseCoopers LLP as our auditors, ratify their appointment as our independent registered public

accountants for the fiscal year 2026 on a non-binding and advisory basis, and authorize the Company's Board of

Directors, acting through its Audit Committee, to determine the fees to be paid to the auditors.

**4.**Transact such other business, if any, as may properly come before the Annual Meeting or any continuation,

postponement, or adjournment thereof.

---

| |
|:---|
| **Registered shareholders of the Company as of the close of business on the Record Date are eligible to vote at the** <br>**meeting.** |
| **Registered shareholders of the Company as of the close of business on the Record Date are eligible to vote at the** <br>**meeting.** |

---

**You may cast your vote in one of the following ways:**

---

| | | |
|:---|:---|:---|
| **Internet** | ![Image_3.jpg](clvt-20260401_g4.jpg) | Online at **www.proxyvote.com** |
| **Email** | ![Image_4.jpg](clvt-20260401_g5.jpg) | Scan a PDF copy of the original voted proxy card and submit via email to <br>**Company.Secretary@clarivate.com**<br>|
| **Mail** | ![Image_5.jpg](clvt-20260401_g6.jpg) | Mail your completed and signed proxy card in the postage-paid envelope <br>provided to:<br>**Vote Processing, c/o Broadridge**<br>**51 Mercedes Way, Edgewood, NY 11717**<br>|
| **In Person** | ![Image_6.jpg](clvt-20260401_g7.jpg) | Vote in person at the Annual Meeting<br>(see *How You Can Vote* below for further information)<br>|

---

**Any shareholder who is entitled to vote at the Annual Meeting is entitled to appoint one or more proxies to attend** 

**and vote instead of that shareholder. A proxy need not be a shareholder.**

Clarivate's Board of Directors has fixed the close of business on **March 16, 2026** as the record date (the "**Record Date**")

for the determination of the shareholders entitled to receive notice and to vote at the Annual Meeting or any continuation,

postponement, or adjournment thereof.

For ten days prior to the Annual Meeting, a complete list of shareholders entitled to vote at the Annual Meeting will be

available for shareholders to review for purposes relevant to the meeting. To arrange to review that list, please send a

written request to General Counsel, c/o Legal Department, Clarivate Plc, 70 St. Mary Axe, London EC3A 8BE, United

Kingdom or by email to **Company.Secretary@clarivate.com**.

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

The Company's audited consolidated financial statements for the year ended December 31, 2025, together with the

auditor's report thereon, will be presented at the Annual Meeting.

**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING TO** 

**BE HELD ON MAY 14, 2026**: The Proxy Statement and our 2025 Annual Report are available at **<u>ir.clarivate.com</u>**. To

receive a printed copy of the Proxy Statement and our Annual Report free of charge by mail, please send a request to

Clarivate Plc, Attention: General Counsel, 70 St. Mary Axe, London EC3A 8BE, United Kingdom or by email to

**Company.Secretary@clarivate.com** or call +44 207 4334000.

We hope that you will promptly vote and submit your proxy by dating, signing, and returning the enclosed Proxy Card by

mail or by email, or by following the instructions for internet voting provided on the Proxy Card, or, if you hold your shares

in the name of a bank or broker, by following the instructions you receive from your bank or broker. Casting a vote by

proxy will not limit your rights to vote at the Annual Meeting.

**By order of the Board of Directors,**

![JD signature.jpg](clvt-20260401_g8.jpg)

**John Doulamis**

**General Counsel**

April 1, 2026

**i**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| | **Page** |
| [Information Concerning Voting and Proxy Solicitation](#i4d1987239dbc4a93b1fc759704cab4f3_16) | [1](#i4d1987239dbc4a93b1fc759704cab4f3_16) |
| **[Proposal 1: Re-Election of Directors](#i4d1987239dbc4a93b1fc759704cab4f3_64)** | [7](#i4d1987239dbc4a93b1fc759704cab4f3_64) |
| [Corporate Governance and Board of Directors](#i4d1987239dbc4a93b1fc759704cab4f3_76) | [9](#i4d1987239dbc4a93b1fc759704cab4f3_76) |
| [Executive Officers](#i4d1987239dbc4a93b1fc759704cab4f3_136) | [22](#i4d1987239dbc4a93b1fc759704cab4f3_136) |
| **[Proposal 2: Advisory Approval of Executive Compensation](#i4d1987239dbc4a93b1fc759704cab4f3_139)** | [24](#i4d1987239dbc4a93b1fc759704cab4f3_139) |
| [Report of the Human Resources and Compensation Committee](#i4d1987239dbc4a93b1fc759704cab4f3_148) | [26](#i4d1987239dbc4a93b1fc759704cab4f3_148) |
| [Compensation Discussion and Analysis](#i4d1987239dbc4a93b1fc759704cab4f3_151) | [27](#i4d1987239dbc4a93b1fc759704cab4f3_151) |
| [Executive Compensation Tables](#i4d1987239dbc4a93b1fc759704cab4f3_265) | [41](#i4d1987239dbc4a93b1fc759704cab4f3_265) |
| [Executive Employment Agreements](#i4d1987239dbc4a93b1fc759704cab4f3_280) | [45](#i4d1987239dbc4a93b1fc759704cab4f3_280) |
| [Potential Payments Upon Termination or Change in Control](#i4d1987239dbc4a93b1fc759704cab4f3_286) | [47](#i4d1987239dbc4a93b1fc759704cab4f3_286) |
| [CEO Pay Ratio](#i4d1987239dbc4a93b1fc759704cab4f3_289) | [48](#i4d1987239dbc4a93b1fc759704cab4f3_289) |
| [Pay Versus Performance](#i4d1987239dbc4a93b1fc759704cab4f3_292) | [49](#i4d1987239dbc4a93b1fc759704cab4f3_292) |
| **[Proposal 3: Ratification of Appointment of Independent Registered Public Accountants](#i4d1987239dbc4a93b1fc759704cab4f3_295)** | [52](#i4d1987239dbc4a93b1fc759704cab4f3_295) |
| [Report of the Audit Committee](#i4d1987239dbc4a93b1fc759704cab4f3_310) | [54](#i4d1987239dbc4a93b1fc759704cab4f3_310) |
| [Beneficial Ownership](#i4d1987239dbc4a93b1fc759704cab4f3_418) | [55](#i4d1987239dbc4a93b1fc759704cab4f3_418) |
| [Certain Relationships and Related Person Transactions](#i4d1987239dbc4a93b1fc759704cab4f3_427) | [58](#i4d1987239dbc4a93b1fc759704cab4f3_427) |
| [Section 16(A) Compliance](#i4d1987239dbc4a93b1fc759704cab4f3_457) | [60](#i4d1987239dbc4a93b1fc759704cab4f3_457) |
| [Shareholder Proposals for the 2027 Annual General Meeting](#i4d1987239dbc4a93b1fc759704cab4f3_460) | [60](#i4d1987239dbc4a93b1fc759704cab4f3_460) |
| [Admission Procedure](#i4d1987239dbc4a93b1fc759704cab4f3_475) | [63](#i4d1987239dbc4a93b1fc759704cab4f3_475) |
| [Other Matters](#i4d1987239dbc4a93b1fc759704cab4f3_490) | [64](#i4d1987239dbc4a93b1fc759704cab4f3_490) |
| [Appendix A — Non-GAAP Financial Measures](#i4d1987239dbc4a93b1fc759704cab4f3_496) | [65](#i4d1987239dbc4a93b1fc759704cab4f3_496) |

---

**1**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

![lg_clarivatetm-4clr - Clarivate Logo.jpg](clvt-20260401_g2.jpg)

**Proxy Statement for the 2026 Annual General Meeting of Shareholders** 

**of Clarivate Plc to be held on May 14, 2026**

**INFORMATION CONCERNING VOTING AND PROXY SOLICITATION**

This proxy statement ("**Proxy Statement**") is being furnished to you in connection with the solicitation by the Board of

Directors of Clarivate Plc (the "**Board**"), a company limited by shares incorporated under the laws of Jersey, Channel

Islands, of proxies for the 2026 Annual General Meeting of Shareholders (the "**Annual Meeting**") and any continuation,

postponement, or adjournment thereof.

This Proxy Statement, the accompanying proxy card, and the Clarivate 2025 Annual Report, which includes our annual

report on Form 10-K for the fiscal year ended December 31, 2025 (the "**Annual Report**" and collectively with the Proxy

Statement and the accompanying proxy card, the "**Proxy Materials**") are first being distributed or made available to

shareholders on or about April 1, 2026.

We are providing notice and electronic access to the Proxy Materials to our shareholders. The Notice of Internet

Availability of Proxy Materials ("**Notice of Internet Availability**") will be mailed on or about April 1, 2026. The Notice of

Internet Availability contains instructions regarding how to access and review the Proxy Materials through the internet or

receive a hard copy. The Notice of Internet Availability also provides instructions regarding how to submit a proxy via the

internet. We believe that this process allows us to provide shareholders with important information in a timely manner

while also reducing the environmental impact and lowering the costs of printing and distributing our proxy materials. If you

have not received, but would like to receive, a copy of the Proxy Materials in paper format, please follow the instructions

for requesting such materials contained in the Notice of Internet Availability.

As used herein, the terms "Company," "Clarivate," "we," "us," or "our" refer to Clarivate Plc and its consolidated

subsidiaries unless otherwise stated or the context otherwise requires.

Our ordinary shares are listed on the New York Stock Exchange ("**NYSE**") under the symbol "CLVT."

**Date, Time, and Location of the Annual Meeting**

The Annual Meeting will be held on **Thursday, May 14, 2026, at 1:00 p.m. BST** (8:00 a.m. EDT) at the Clarivate

corporate headquarters located at **70 St. Mary Axe, London EC3A 8BE, United Kingdom**.

**How You Can Attend the Annual Meeting**

To attend the Annual Meeting in person, you must be entitled to vote, as described below.

If you plan to attend the Annual Meeting in person, we encourage you to request an admission ticket in advance. You can

request a ticket in advance by following the instructions under "Admission Procedure" in this Proxy Statement. The

General Counsel should receive your written request for an admission ticket on or before May 11, 2026. If you hold your

Clarivate ordinary shares through a brokerage account (in "street name"), your request for an admission ticket should

include a copy of a brokerage statement reflecting share ownership as of the Record Date. Your ticket will be sent to you

prior to the meeting if you follow these instructions. Don't forget your ticket and government-issued photo identification.

Failure to request an admission ticket in advance will not preclude your attendance at the Annual Meeting in person.

However, in each case, an individual must have evidence of ownership of the Company's ordinary shares as of the

Record Date and a valid government-issued photo identification (e.g., a driver's license or a passport) and should arrive in

advance, with sufficient time to be admitted to the Annual Meeting.

Contact us if we can explain any of these matters or otherwise help you with your voting instructions or attending the

Annual Meeting.

**2**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

If you cannot attend the Annual Meeting in person, you can listen to the Annual Meeting via a listen-only webcast at the

event address set forth below:

https://bit.ly/2026ClarivateAGM

or

https://teams.microsoft.com/l/meetup-

join/19%3ameeting_MzI1MWNkODEtNWFmZS00NGI3LWI1MWQtMDM4MGIxMTBjZjM0%40thread.v2/0?context=%7b

%22Tid%22%3a%22127fa96e-00b4-429e-95f9-72c2828437a4%22%2c%22Oid%22%3a%2246aacd31-fc35-47a7-

bbbd-04d15e7d7415%22%7d

Because the webcast will be listen-only, listening to the webcast will not constitute formal attendance at the Annual

Meeting and you will not be able to vote or ask questions through the webcast. Please submit your proxy voting

instructions as soon as possible through one of the methods described below to ensure your votes are counted at the

Annual Meeting.

**Purpose of the Annual Meeting**

The purpose of the Annual Meeting is to vote on the following items described in this Proxy Statement:

✔**Proposal 1:** Re-Election of Directors

✔**Proposal 2:** Advisory Approval of Executive Compensation

✔**Proposal 3:** Ratification of Appointment of Independent Registered Public Accountants

**Who Can Vote**

Only shareholders who owned Clarivate ordinary shares at the close of business on **March 16, 2026** (the "**Record Date**")

are entitled to vote at the Annual Meeting.

All resolutions put to a vote at the Annual Meeting shall be decided on a poll. Each holder of our ordinary shares is entitled

to **one vote** for each share held as of the Record Date. As of the close of business on the Record Date, we had

**642,179,542** issued and outstanding ordinary shares, each of which entitles the holder to one vote.

If, at the close of business on the Record Date, your shares were registered directly in your name with our transfer agent,

Continental Stock Transfer & Trust, you are a "shareholder of record." If you are a shareholder of record, notice of the

meeting was sent directly to you. If your shares are held in the name of your bank, broker, nominee, or other holder of

record, your shares are held in "street name" and you are considered the "beneficial owner." Notice of the meeting has

been forwarded to you by your bank, broker, nominee, or other holder of record, who is considered, with respect to those

shares, the shareholder of record. As the beneficial owner, you have the right to direct your bank, broker, nominee, or

other holder of record how to vote your shares by using the voting instructions you received. See "How You Can Vote"

below for further information.

There is no cumulative voting in the election of directors.

**Appointment of Proxy Holders**

The Board asks you to appoint the following individuals as your proxy holders to vote your shares at the Annual Meeting:

❖**Andrew Snyder,** *Chair of the Board*

❖**Matti Shem Tov,** *Chief Executive Officer*

❖**Jonathan Collins,** *Executive Vice President and Chief Financial Officer*

❖**John Doulamis,** *Senior Vice President and General Counsel*

You may make this appointment by using one of the methods described below. If appointed by you, the proxy holders will

vote your shares as you direct on the matters described in this Proxy Statement. In the absence of your direction, they will

vote your shares as recommended by the Board.

Unless you otherwise indicate on the proxy card, you also authorize your proxy holders to vote your shares on any

matters not known by the Board at the time this Proxy Statement was printed and that, under our Articles of Association

(the "**Articles**"), may be properly presented for action at the Annual Meeting.

**3**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

If you do not wish to appoint the individuals named above as your proxies, you need not do so. Any shareholder who is

entitled to vote at the Annual Meeting is entitled to appoint one or more proxies to attend and vote instead of that

shareholder. A proxy need not be a shareholder. Any such appointment must be submitted to the Company in accordance

with the Articles.

**Quorum**

A quorum must be present to hold the Annual Meeting, which is shareholders holding in aggregate not less than a simple

majority of all voting share capital of the Company in issue present in person or by proxy and entitled to vote, provided

that there is present in person or by proxy at least two shareholders entitled to vote.

A quorum is calculated based on the number of shares represented by the shareholders attending in person and by their

proxy holders. If you indicate an abstention as your voting preference, your shares will be counted toward a quorum, but

they will not be voted on any given proposal. "Broker non-votes" (see "Required Vote" below) will be counted as ordinary

shares that are present for the purpose of determining the presence of a quorum but will have no effect with respect to

any matter for which a broker does not have authority to vote.

**How You Can Vote**

**Shareholders of record.** You are a shareholder of record if, at the close of business on the Record Date, your shares

were registered directly in your name with our transfer agent, Continental Stock Transfer & Trust.

You may vote your shares at the Annual Meeting in person or by proxy. Shareholders of record may appoint a proxy by

signing, dating, and returning the proxy card in the enclosed postage-paid return envelope or by email, or by following the

instructions for internet voting provided on the proxy card. Carefully review and follow the instructions on the enclosed

proxy card. The shares represented will be voted in accordance with the directions in the proxy card. A form of proxy

different from the enclosed proxy card may be submitted to the Company in the manner contemplated by the Articles.

You can submit your proxy using any of the methods described on your proxy card or below prior to the applicable

deadline described below. Proxies must be received by the deadlines set forth in the below table. **Any signed proxies** 

**returned without instructions will be voted FOR the proposals set forth in the Notice of 2026 Annual General** 

**Meeting of Shareholders.**

---

| | |
|:---|:---|
| **Via the internet:**  | Go to **www.proxyvote.com** to vote via the internet using the 16-digit control number you <br>were provided on your proxy card or Notice of Internet Availability. You will need to follow the <br>instructions on the website.<br>You must register your vote over the internet no later than 11:59 p.m. Eastern time on <br>May 13, 2026. <br>|
| **By email:**  | A scanned PDF copy of your original completed and signed proxy card may be sent via email <br>to **Company.Secretary@clarivate.com**.<br>A proxy card sent to us by email must be received no later than 11:59 p.m. Eastern time on <br>May 13, 2026. <br>|
| **By mail:**  | If you received the Proxy Materials in the mail, you may mark, sign, date, and return your <br>proxy card in the enclosed postage-paid return envelope or by mailing it to **Vote Processing,** <br>**c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717, USA** no later than April 28, <br>2026, in order for us to receive your proxy card by the May 13, 2026 deadline. <br>|
| **In person:**  | Shareholders of record may vote in person at the Annual Meeting. Submitting a proxy now will <br>not limit your right to change your vote at the Annual Meeting if you attend the Annual Meeting <br>in person.<br>For information about attending the Annual Meeting, please see "How You Can Attend the <br>Annual Meeting" above.<br>|

---

**Beneficial Owners.** Beneficial owners, that is, shareholders whose ordinary shares were not held directly in their name at

the close of business on the Record Date but rather in an account with a bank, broker, nominee, or other holder of record

(sometimes referred to as holding shares in "street name") have the right to instruct their broker on how to vote their

shares and will receive voting instructions from the holder of record. To do so, you must provide voting instructions to your

bank, broker, nominee, or other holder of record by the deadline provided in the Proxy Materials you receive from your

bank, broker, nominee, or other holder of record. You must follow the instructions of such bank, broker, nominee, or other

holder of record in order for your shares to be voted.

**4**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

If you are a beneficial owner and wish to vote in person, please advise the holder of record that you wish to attend the

Annual Meeting. The holder of record will provide you with evidence of ownership that will be required for admission to the

Annual Meeting.

**We hope that you will promptly vote and submit your proxy by dating, signing, and returning the enclosed proxy** 

**card by mail or by email, or by following the instructions for internet voting provided on the proxy card, or, if you** 

**hold your shares in the name of a bank, broker, nominee, or other holder of record, by following their** 

**instructions. Casting a vote by proxy will not limit your rights to vote at the Annual Meeting.**

**Revocation of Proxies**

Shareholders can revoke their proxies at any time before they are exercised in any of the following ways:

❖by voting in person at the Annual Meeting;

❖by submitting written notice of revocation to the General Counsel prior to 1:00 p.m. BST on May 13, 2026; or

❖by submitting another proxy — properly executed and delivered — on a later date, but prior to 1:00 p.m. BST on

May 13, 2026.

**Required Vote**

The table below summarizes the proposals that will be voted on, the votes required to approve each item, and how votes

are counted.

Please note that "vote cast" means a vote "*FOR*" or "*AGAINST*" a proposal. An abstention, or "*ABSTAIN*" vote, is not a

"vote cast" and will not factor into whether a proposal is passed.

---

| | | |
|:---|:---|:---|
| **Proposal** | **Vote required**  | **Voting**<br>**options** <br>|
| **Proposal 1**<br>Re-Election of Directors <br>| For each director nominee, a simple majority <br>of the votes cast by, or on behalf of, the <br>shareholders entitled to vote in person or <br>represented by proxy <br>| "FOR"<br>"AGAINST"<br>"ABSTAIN" <br>None<sup>(1)</sup> <br> No<sup>(2)</sup>  |
| **Proposal 2**<br>Advisory Approval of <br>Executive Compensation <br>| A simple majority of the votes cast by, or on <br>behalf of, the shareholders entitled to vote in <br>person or represented by proxy <br>| "FOR"<br>"AGAINST"<br>"ABSTAIN" <br>None<sup>(1)</sup> <br> No<sup>(2)</sup>  |
| **Proposal 3**<br>Ratification of Appointment <br>of Independent Registered <br>Public Accountants <br>| A simple majority of the votes cast by, or on <br>behalf of, the shareholders entitled to vote in <br>person or represented by proxy <br>| "FOR"<br>"AGAINST"<br>"ABSTAIN" <br>None<sup>(1)</sup> <br> Yes<sup>(3)</sup>  |

---

(1)A vote marked as "ABSTAIN" or a broker non-vote is not considered a vote cast and will, therefore, not affect the outcome of this proposal.

(2)As this proposal is not considered a discretionary matter, brokers lack authority to exercise their discretion to vote uninstructed shares on this

proposal.

(3)As this proposal is considered a discretionary matter, brokers are permitted to exercise their discretion to vote uninstructed shares on this proposal.

Please note that under NYSE rules, brokers may not vote your shares on certain "non-routine" matters without your voting

instructions. Accordingly, if you do not provide your bank, broker, or other nominee with instructions on how to vote your

shares, this will be considered a "broker non-vote" and your bank, broker, or nominee will not be permitted to vote those

shares on **Proposal 1** (Re-Election of Directors) or **Proposal 2** (Advisory Approval of Executive Compensation). Your

bank, broker, or nominee will be entitled to cast votes on **Proposal 3** (Ratification of Appointment of Independent

Registered Public Accountants). We encourage you to provide instructions to your bank, broker, or nominee regarding the

voting of your shares.

**5**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Shareholders Who Share an Address (Householding)**

Two or more Clarivate shareholders who share an address may receive only one copy of the Proxy Materials or the Notice

of Internet Availability, unless the shareholder gives instructions to the contrary.

We will deliver promptly a separate copy of the Proxy Materials to any Clarivate shareholder who resides at a shared

address and to which a single copy of the documents was delivered, if the shareholder makes a request by contacting the

**General Counsel, c/o Legal Department, Clarivate Plc, 70 St. Mary Axe, London EC3A 8BE, United Kingdom**, or by

telephone at **+44 207 4334000** or by email at **Company.Secretary@clarivate.com**.

**If a broker, bank, or other nominee holds your shares, please contact your broker, bank, or other nominee** 

**directly if you have questions about delivery of materials, require additional copies of the Proxy Materials, or** 

**wish to receive multiple copies of the Proxy Materials, which would require you to state that you do not consent** 

**to householding.**

**Solicitation of Proxies**

We pay the cost of printing and mailing the Notice of 2026 Annual General Meeting of Shareholders, the Annual Report,

and all Proxy Materials. We have retained D.F. King & Co., Inc. to aid in the solicitation of proxies by mail, telephone,

facsimile, email, and personal solicitation for a fee of $11,500, plus reasonable expenses. Our directors, officers, and

other employees may participate in the solicitation of proxies by personal interview, telephone, or email. No additional

compensation will be paid to our directors, officers, or other employees for solicitation. We will reimburse brokerage firms

and others for their reasonable expenses in forwarding solicitation materials to beneficial owners of our ordinary shares.

**Presentation of Accounts**

Under Jersey law, the directors are required to present the accounts of the Company and the reports of the auditors

before shareholders at a general meeting. Therefore, the accounts of the Company for the fiscal year ended

December 31, 2025, will be presented to the shareholders at the Annual Meeting.

**Final Voting Results of the Annual Meeting**

The preliminary voting results will be announced at the Annual Meeting. The final voting results will be disclosed by the

Company in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission (the "**SEC**")

within four business days following the Annual Meeting.

**Forward-Looking Statements**

This Proxy Statement includes statements that express our opinions, expectations, beliefs, plans, objectives,

assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-

looking statements" within the meaning of the "safe harbor provisions" of the Private Securities Litigation Reform Act of

1995. These forward-looking statements can generally be identified by the use of forward-looking terminology, including

the terms "believes," "estimates," "anticipates," "expects," "seeks," "projects," "intends," "plans," "may," "will," or "should,"

or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include

all matters that are not historical facts. The forward-looking statements contained in this Proxy Statement are based on

our current expectations and beliefs concerning future developments and their potential effects on us. There can be no

assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements

involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause

actual results or performance to be materially different from those expressed or implied by these forward-looking

statements. These risks and uncertainties include, but are not limited to, those factors described under the caption "Risk

Factors" in our Annual Report, along with our other filings with the SEC. Should one or more of these risks or uncertainties

materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those

projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking

statements, whether as a result of new information, future events, or otherwise, except as may be required under

applicable securities laws.

**6**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

![](clvt-20260401_g9.gif)

**Important Reminder**

**Please promptly provide your voting instructions by submitting your proxy in writing or by** 

**internet, or if you hold your ordinary shares through a bank, broker, or other nominee, as** 

**instructed by your bank, broker, or other nominee.**

**To appoint a proxy, you may sign, date, and return the enclosed proxy card in the postage-**

**paid return envelope, or email it to Company.Secretary@clarivate.com, or follow the** 

**instructions for internet voting provided on the proxy card. We must receive your proxy card** 

**or internet voting instructions by 11:59 p.m. Eastern time on May 13, 2026. If mailing, please** 

**mail your proxy card no later than April 28, 2026.**

**Submitting voting instructions by proxy will not limit your rights to attend or vote at the** 

**Annual Meeting.**

**7**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**PROPOSAL 1: RE-ELECTION OF DIRECTORS**

**2026 Nominees for Director**

Pursuant to the Articles, the Board has determined that it be composed of ten directors.

The Board has approved for nomination the following ten director nominees to be re-elected at the Annual Meeting. All the

director nominees currently serve on the Board.

Directors elected at the Annual Meeting will hold office until the next annual general meeting of shareholders in 2027, or

until their respective successors have been duly elected and qualified or their earlier resignation or removal.

For more information about each director nominee, see "Corporate Governance and Board of Directors — Business

Experience and Qualifications of Director Nominees" below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name and Principal Occupation**  | **Age**  | **Director** <br>**Since** <br>| **Independent**  | **Committee Memberships**  |
| **Andrew Snyder (Chair)**<br>Chief Executive Officer,<br>Cambridge Information Group <br>| 55 | 2021  | ✓ | ❖Nominating & Governance<br>❖Finance <br>|
| **Jane Okun Bomba**<br>President,<br>Saddle Ridge Consulting <br>| 63 | 2020  | ✓ | ❖Audit<br>❖Human Resources & Compensation <br>(Chair) <br>|
| **Kenneth Cornick**<br>Former President and Chief Financial Officer,<br>Clear Secure, Inc. <br>| 53 | 2025 | ✓ | ❖ Audit (Chair) |
| **Usama N. Cortas**<br>Partner,<br>Leonard Green & Partners, L.P. <br>| 48 | 2020  | ✓ | ❖Nominating & Governance<br>❖Finance (Chair) <br>|
| **Suzanne Heywood**<br>Chief Operating Officer,<br>Exor N.V. <br>| 57  | 2024  | ✓ | ❖Nominating & Governance<br>❖Finance <br>|
| **Adam T. Levyn**<br>Partner,<br>Leonard Green & Partners, L.P. <br>| 43  | 2020  | ✓ | ❖Human Resources & Compensation  |
| **Anthony Munk**<br>Vice Chairman,<br>Onex Corporation <br>| 66 | 2019  | ✓ | ❖Audit<br>❖Finance <br>|
| **Wendell Pritchett**<br>Riepe Presidential Professor of Law and Education,<br>University of Pennsylvania <br>| 61 | 2022  | ✓ | ❖Nominating & Governance (Chair)<br>❖Human Resources & Compensation <br>|
| **Saurabh Saha**<br>Former Chief Executive Officer,<br>Centessa Pharmaceuticals <br>| 49 | 2023  | ✓ | ❖Human Resources & Compensation  |
| **Matitiahu (Matti) Shem Tov**<br>Chief Executive Officer,<br>Clarivate Plc <br>| 65 | 2024  |  |  |

---

Each director nominee set forth above has consented to being named in this Proxy Statement as a nominee for re-

election as a director and has agreed to serve as a director, if re-elected. The Nominating and Governance Committee

reviewed the performance and qualifications of the director nominees and recommended to the Board, and the Board

approved, that each be recommended to shareholders for appointment to serve for a one-year term.

If any of the nominees becomes unavailable prior to the Annual Meeting, proxies in the enclosed form will be voted for a

substitute nominee or nominees designated by the Board, or the Board may reduce the number of directors to constitute

the entire Board, in its discretion.

Usama N. Cortas and Adam T. Levyn have been nominated pursuant to the Company's obligations under the Investor

Rights Agreement dated as of October 1, 2020, entered into in connection with the Company's acquisition of CPA Global.

**8**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

Suzanne Heywood has been nominated pursuant to the Company's obligations under the Investment Agreement dated as

of March 4, 2024, between the Company and Exor N.V.

Kenneth Cornick was elected to our Board effective July 22, 2025. If re-elected, Mr. Cornick will continue to serve as a

director for a one-year term.

**The text of the resolutions with respect to Proposal 1 (which are proposed as** 

**ordinary resolutions) is as follows:**

**"RESOLVED**,

❖That Andrew Snyder be re-elected as a director of the Company.

❖That Jane Okun Bomba be re-elected as a director of the Company.

❖That Kenneth Cornick be re-elected as a director of the Company.

❖That Usama N. Cortas be re-elected as a director of the Company.

❖That Suzanne Heywood be re-elected as a director of the Company.

❖That Adam T. Levyn be re-elected as a director of the Company.

❖That Anthony Munk be re-elected as a director of the Company.

❖That Wendell Pritchett be re-elected as a director of the Company.

❖That Saurabh Saha be re-elected as a director of the Company.

❖That Matti Shem Tov be re-elected as a director of the Company.

**RESOLVED**, that each director nominee re-elected to serve as a director of the Company shall serve until the 2027

Annual General Meeting of Shareholders, or until their successor is duly elected and qualified, or their earlier resignation

or removal."

**Vote Required and Recommendation**

A director will be re-elected if approved by a simple majority of the votes cast by, or on behalf of, the shareholders entitled

to vote in person or represented by proxy — that is, the number of shares voted "FOR" a director must exceed the number

of shares voted "AGAINST" that director.

You may instruct to vote "FOR," or "AGAINST," or "ABSTAIN" for each of the director nominees. If you "ABSTAIN" from

voting with respect to the proposal, your vote is not considered a vote cast and will have no effect for such proposal. If you

do not provide your bank, broker, or other nominee with instructions on how to vote your shares with respect to Proposal

1, your broker or nominee will not be entitled to cast votes and a "broker non-vote" on Proposal 1 will result. "Broker non-

votes" are not considered votes cast and will have no effect on the vote for this proposal.

---

| | |
|:---|:---|
| ![Image_56.jpg](clvt-20260401_g10.jpg) | **THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" THE RE-ELECTION OF** <br>**EACH OF THE DIRECTOR NOMINEES LISTED ABOVE.**<br>|

---

**9**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**CORPORATE GOVERNANCE AND BOARD OF DIRECTORS**

The Board is responsible for providing governance and oversight of the strategy, operations, and management of the

Company. The primary mission of the Board is to represent and protect the interests of our shareholders. The Board

oversees our senior management, to whom it has delegated the authority to manage the day-to-day operations of the

Company.

**Board Leadership Structure**

The Board believes strongly in the value of an independent board of directors to provide effective oversight of

management. Nine of our ten current Board members, who are also our director nominees, are independent. The Board

also has all independent members on its standing committees: the Audit Committee, the Human Resources and

Compensation Committee, the Nominating and Governance Committee, and the Finance Committee. The independent

members of the Board meet regularly without management, and such meetings are conducted by the Board Chair, whose

role is described further below.

The Board believes it is important to retain its flexibility to allocate the responsibilities of the offices of the Board Chair and

Chief Executive Officer ("**CEO**") in any way that it deems to be in the best interests of the Company. Currently, the

positions of Board Chair and CEO are separate, and Andrew Snyder, our Non-Executive Board Chair, is an independent

director. The Board Chair oversees the planning of the annual Board calendar, and, in consultation with the CEO,

schedules and sets the agenda for meetings of the Board and leads the discussion at such meetings. The Board Chair

also presides at executive sessions, serves as a liaison between the CEO and the independent directors, sees that

directors receive appropriate and timely information, assists the committee chairs in preparing agendas for the respective

committee meetings, chairs the annual general meetings of shareholders, is available in appropriate circumstances to

speak on behalf of the Board, and performs such other functions and responsibilities as set forth in the Company's

Corporate Governance Guidelines or as requested by the Board from time to time. Board members are encouraged to

suggest the inclusion of additional items on an agenda, and any director may request that an item be placed on an

agenda. The Board Chair is responsible for creating and maintaining an effective working relationship with the members of

management and the Board and encouraging dialogue between all directors and management.

Each of the Company's directors, except Mr. Shem Tov, is independent (see "Independence of Directors" below). The

Board believes that the independent directors, including its Non-Executive Board Chair, Mr. Snyder, provide effective

oversight of management.

**Corporate Governance Practices**

Clarivate has a history of strong corporate governance. The Company believes good governance is critical to achieving

long-term shareholder value. The following table summarizes certain highlights of our corporate governance practices and

policies:

---

| | |
|:---|:---|
| **Our Practices and Policies** | **Our Practices and Policies** |
| ❖Annual election of all directors | ❖Board takes active role in succession planning  |
| ❖100% independent Board committees  | ❖Regular shareholder engagement by our CEO, CFO, and Investor <br>Relations team <br>|
| ❖9 independent directors (out of 10)  | ❖Annual Board and committee self-evaluations  |
| ❖Regular executive sessions, where independent directors meet <br>without management present <br>| ❖Active Board oversight of strategy, risk management, and <br>sustainability matters <br>|
| ❖Director overboarding policy limiting service to three other public <br>company boards; no Audit Committee member may simultaneously <br>serve on the audit committee of more than two other public <br>companies; and our CEO and executive officers may only serve on <br>the board of one other public company <br>| ❖Robust director selection process resulting in a diverse and global <br>Board in terms of experience, perspectives, skills, and tenure<br>|

---

![](clvt-20260401_g11.gif)

**10**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**The Role of the Board of Directors in Risk Oversight**

We recognize that risk is inherent in innovation and the pursuit of long-term growth opportunities.

Management at Clarivate is responsible for day-to-day risk management activities. The Company has formed a risk

management committee to supervise these day-to-day risk management efforts, including identifying potential material

risks and appropriate and reasonable risk mitigation efforts. The Board, acting directly and through its committees, is

responsible for the oversight of the Company's risk management. With the oversight of the Board, we have implemented

practices and programs designed to help manage the risks to which we are exposed in our business and to align risk-

taking appropriately with our efforts to increase shareholder value. Each of the Board's four committees — Audit, Human

Resources and Compensation, Nominating and Governance, and Finance — has a role in assisting the Board in its

oversight of the Company's risk management, as set forth in the relevant committee charters.

In furtherance of the Board's risk oversight responsibilities and practices, the Board's Audit Committee brings additional

Board-level focus to the oversight of the Company's management of key risks, as well as the Company's guidelines,

policies, practices, and processes with respect to risk assessment, monitoring, and management. The Audit Committee

meets at least quarterly. Each standing Board committee also reports regularly to the full Board on its activities.

In addition, the Board participates in regular discussions among the Board and with senior management on many core

subjects, including strategy, operations, finance, information technology and cybersecurity, human resources, legal and

public policy matters, and any other subjects regarding which the Board or its committees consider risk oversight an

inherent element. The Board believes that the leadership structure described above under "Board Leadership Structure"

facilitates the Board's oversight of risk management because it allows the Board, with leadership from the independent

Board Chair and working through its independent committees, to participate actively in the oversight of management's

actions.

**11**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Business Experience and Qualifications of Director Nominees**

The following discussion presents information about the ten nominees for election at the Annual Meeting. The age of the

director nominees is as of the date of this Proxy Statement.

---

| | |
|:---|:---|
| **Andrew Snyder**<br>**Non-Executive Chair**<br>Director since December 2021<br>Independent<br>Age: 55<br>**Clarivate Board Committees**<br>❖Nominating & Governance<br>❖Finance<br>**Other Public Company** <br>**Directorships (within past** <br>**five years)**<br>❖None<br>| **Experience and Qualifications**<br>Mr. Snyder has been the non-executive Chair of our Board since October 2022. Mr. Snyder <br>has served as CEO of Cambridge Information Group ("CIG"), a family-owned investment <br>firm, since 2003. Mr. Snyder has built and managed the CIG portfolio, which today has a <br>primary focus on real estate and education, technology, and information services <br>companies. Mr. Snyder was responsible for building ProQuest LLC from a legacy company <br>of 190 employees to one of the leading providers of information and software solutions to <br>the global academic and research community with nearly 3,000 professionals. CIG sold <br>ProQuest to Clarivate in December 2021. Prior to joining CIG, Mr. Snyder spent seven years <br>at the Goldman Sachs Group where he focused on traditional media, technology, and <br>services investing for the firm's private equity fund. He also spent one year as the Assistant <br>to the Chairman and CEO of Goldman Sachs. Mr. Snyder serves on the New York-<br>Presbyterian Board of Trustees and the Board of Advisors of Penn Libraries. He formerly <br>served on the boards of Blucora, Inc., Shining Hope for Communities, and The Browning <br>School. Mr. Snyder graduated cum laude from the Wharton School at the University of <br>Pennsylvania, and earned a J.D. from Georgetown University Law Center, where he <br>graduated magna cum laude.<br>Mr. Snyder was selected to serve on the Board due to his strong leadership skills and <br>proven track record driving financial growth and product development.<br>|
| **Jane Okun Bomba**<br>Director since May 2020<br>Independent<br>Age: 63<br>**Clarivate Board Committees**<br>❖Human Resources & <br>Compensation (Chair)<br>❖Audit<br>**Other Public Company** <br>**Directorships (within past** <br>**five years)**<br>❖Brightview Holdings, Inc.<br>(since April 2019)<br>❖Service Source International, <br>Inc. (March 2020 to <br>August 2022)<br>| **Experience and Qualifications**<br>Ms. Okun Bomba has served as President of Saddle Ridge Consulting, LLC since <br>January 2018 and advises on a range of strategic issues. From 2004 to 2017, Ms. Okun <br>Bomba was an executive at IHS Markit Ltd (previously IHS Inc.), most recently as Executive <br>Vice President, Chief Administrative Officer, where she led 450 people in corporate functions <br>including human resources, marketing, communications, sustainability, and investor <br>relations. Prior to IHS Markit, she was a partner at Genesis, Inc. and headed investor <br>relations at Velocom, Inc.; MediaOne Group Ltd.; and Northwest Airlines, Inc. Ms. Okun <br>Bomba has held various management positions in corporate finance at Northwest Airlines <br>and American Airlines, Inc., and was a CPA at PricewaterhouseCoopers LLP. Ms. Okun <br>Bomba serves on the boards of directors of Brightview Holdings, Inc.; Aspire Healthy <br>Energy; and Pico AI Inc. She previously served on the board of directors of Service Source <br>International, Inc. Ms. Okun Bomba is a member of the International Women's Forum, <br>serves on the board of Kickstart International, and is a member of the University of <br>Michigan, Ross School of Business Dean's Advisory Board. Ms. Okun Bomba holds both a <br>Bachelor of General Studies and an M.B.A. from the University of Michigan at Ann Arbor. <br>She completed graduate studies at the Stockholm School of Economics.<br>Ms. Okun Bomba was selected to serve on the Board due to her significant experience in <br>human resources, finance and accounting, sustainability, and investor relations.<br>|
| **Kenneth Cornick**<br>Director since July 2025<br>Independent<br>Age: 53<br>**Clarivate Board Committees**<br>❖Audit (Chair)<br>**Other Public Company** <br>**Directorships (within past** <br>**five years)**<br>❖Clear Secure, Inc. (June 2021 to <br>June 2025)<br>| **Experience and Qualifications**<br>Mr. Cornick co-founded Clear Secure, Inc. ("CLEAR") in 2010 and served as President from <br>2010 to March 2025 and Chief Financial Officer from 2020 to March 2025 and from 2010 to <br>2017. Prior to CLEAR, Mr. Cornick was a Partner at Arience Capital from 2003 to 2009. He <br>has served on the board of Development Corporation for Israel, commonly known as Israel <br>Bonds, a FINRA member broker-dealer and underwriter for securities – Israel bonds – <br>issued by the State of Israel in the United States, since November 2024. Mr. Cornick <br>previously served on the board of directors of CLEAR from June 2021 until June 2025, on <br>the board of directors of Center ID Corp., an expense management software company, from <br>October 2022 until June 2025, and on the board of trustees of LREI, a progressive <br>independent school in New York City, from 2011 to June 2024. He holds a Bachelor of Arts <br>degree from Bowdoin College.<br>Mr. Cornick was selected to serve on the Board of Directors due to his significant experience <br>in corporate finance and governance, technology, and operations.<br>|

---

**12**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

---

| | |
|:---|:---|
| **Usama N. Cortas**<br>Director since October 2020<br>Independent<br>Age: 48<br>**Clarivate Board Committees**<br>❖Nominating & Governance<br>❖Finance (Chair)<br>**Other Public Company** <br>**Directorships (within past** <br>**five years)**<br>❖None<br>| **Experience and Qualifications**<br>Mr. Cortas is a Partner with Leonard Green & Partners, L.P. ("LGP"), a firm specializing in <br>private equity investments, where he serves on both LGP's Investment Committee and <br>Operating Committee. Prior to joining LGP in 2003, Mr. Cortas worked in the Investment <br>Banking Division of Morgan Stanley in their New York office from 2000 to 2003. Mr. Cortas <br>currently also serves on the boards of the following privately held companies or their <br>affiliates: Authentic Brands Group, Convergint, ECI Software Solutions, Jetro Cash & Carry, <br>Iris Software Group, Insight Global, and Prometheus Group, and he has served on the <br>boards of CCC Information Services, CPA Global, Ellucian, Tank Holdings Corp., The Sports <br>Authority, and United States Infrastructure Corporation, among others. Mr. Cortas earned a <br>Bachelor of Arts degree in Economics-Political Science from Columbia University.<br>Mr. Cortas was selected to serve on the Board due to his extensive experience in finance <br>and in the Technology and Intellectual Property Information Services sector.<br>|
| **Suzanne Heywood**<br>Director since May 2024<br>Independent<br>Age: 57<br>**Clarivate Board Committees**<br>❖Nominating & Governance<br>❖Finance<br>**Other Public Company** <br>**Directorships (within past** <br>**five years)**<br>❖CNHi N.V.<br>(since 2018)<br>❖Iveco Group N.V.<br>(since 2022) <br>| **Experience and Qualifications**<br>Ms. Heywood serves as the Chief Operating Officer of Exor N.V, a global holding company <br>listed in the Netherlands. She has held this position since November 2022, after previously <br>serving as Managing Director of Exor N.V. from 2016. Prior to Exor, Ms. Heywood was a <br>senior partner at McKinsey & Company, co-leading their global service line on organization <br>design and working on strategic issues with clients across different sectors. She has <br>published a book, *Reorg*, and multiple articles on these topics. Prior to McKinsey, <br>Ms. Heywood worked for the U.K. government, including as Private Secretary to the <br>Financial Secretary of the U.K. Treasury. Ms. Heywood currently serves as chair of the <br>boards of CNHi Industrial N.V. and of Iveco Group N.V. She also serves on the boards of <br>The Economist Group, Christian Louboutin LLC, Shang Xia, Quartz Associates, and the <br>Heywood Foundation. Ms. Heywood holds a Bachelor of Arts in science from Oxford <br>University and Ph.D. from Cambridge University. Prior to that she was self-educated, <br>growing up sailing around the world on the yacht *Wavewalker*.<br>Ms. Heywood was selected to serve on the Board due to her extensive global experience in <br>finance and strategic matters.<br>|
| **Adam T. Levyn**<br>Director since October 2020<br>Independent<br>Age: 43<br>**Clarivate Board Committees**<br>❖Human Resources & <br>Compensation<br>**Other Public Company** <br>**Directorships (within past** <br>**five years)**<br>❖Advantage Solutions, Inc.<br>(since October 2023) <br>| **Experience and Qualifications**<br>Mr. Levyn is a Partner with LGP. Prior to joining LGP in 2011, Mr. Levyn worked in private <br>equity at Kohlberg Kravis Roberts & Co. in its New York office from 2007 to 2009, and in the <br>Global Industrials Group of Bear, Stearns & Co. Inc. in its New York office from 2005 to <br>2007. Mr. Levyn serves on the board of directors of Advantage Solutions Inc. Mr. Levyn also <br>serves on the boards of the following privately held companies: CHG Healthcare Services, <br>Inc.; ExamWorks Group, Inc.; HUB International; and OMNIA Partners, Inc., and he has <br>served on the boards of CPA Global Limited; Parts Town LLC; Service Logic LLC; SRS <br>Distribution, Inc.; Tank Holdings Corp.; and United States Infrastructure Corporation. <br>Mr. Levyn earned a Bachelor of Arts degree in Economics from Princeton University and an <br>M.B.A. from Harvard Business School.<br>Mr. Levyn was selected to serve on the Board due to his extensive experience in finance <br>and investments.<br>|

---

**13**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

---

| | |
|:---|:---|
| **Anthony Munk**<br>Director since May 2019<br>Independent<br>Age: 66<br>**Clarivate Board Committees**<br>❖Audit<br>❖Finance<br>**Other Public Company** <br>**Directorships (within past** <br>**five years)**<br>❖Emerald Holding, Inc.<br>(since May 2020) <br>| **Experience and Qualifications**<br>Mr. Munk is Vice Chairman of Onex Corporation, which he joined in 1988, and is Chair of <br>Onex Partners' Private Equity Investment Committee. Mr. Munk serves on the board of <br>directors of Emerald Holding, Inc., as well as the board of WireCo Worldgroup Inc. Mr. Munk <br>previously served on the boards of directors of JELD-WEN Holding, Inc.; SGS&Co; Barrick <br>Gold; RSI Home Products; Husky Injection Molding Systems Ltd; Cineplex Inc.; SMG <br>Holdings, Inc.; Jack's Family Restaurants; and Save-A-Lot. Prior to joining Onex, Mr. Munk <br>was a Vice President with First Boston Corporation in London, England and an Analyst with <br>Guardian Capital Group in Toronto. Mr. Munk served as our Lead Independent Director from <br>May 2020 to October 2022. Mr. Munk holds a Bachelor of Arts (Honors) in Economics from <br>Queen's University.<br>Mr. Munk was selected to serve on the Board due to his financial expertise and significant <br>experience in a variety of strategic and financing transactions.<br>|
| **Wendell Pritchett, Ph.D.**<br>Director since July 2022<br>Independent<br>Age: 61<br>**Clarivate Board Committees**<br>❖Nominating & Governance <br>(Chair)<br>❖Human Resources & <br>Compensation<br>**Other Public Company** <br>**Directorships (within past** <br>**five years)**<br>❖Toll Brothers, Inc.<br>(since March 2018)<br>❖26North BDC, Inc.<br>(since February 2024) <br>| **Experience and Qualifications**<br>Dr. Pritchett is the Riepe Presidential Professor of Law and Education at the University of <br>Pennsylvania. Dr. Pritchett previously served as the Interim President of the University of <br>Pennsylvania from February 2022 to June 2022 and as the University Provost from 2017 to <br>December 2021. From 2018 to 2022, Dr. Pritchett served as Chairman of the Nominating <br>Panel of the Philadelphia School Board, appointed by Philadelphia Mayor James Kenney. <br>Dr. Pritchett first joined the University of Pennsylvania Law faculty in 2002, and served as <br>Associate Dean for Academic Affairs from 2006 to 2007 and as Interim Dean and <br>Presidential Professor from 2014 to 2015. Dr. Pritchett also served as Chancellor of Rutgers <br>University-Camden from 2009 to 2014. In 2008, Dr. Pritchett served as Deputy Chief of Staff <br>and Director of Policy for Philadelphia Mayor Michael Nutter, who also appointed him to the <br>School Reform Commission, where Dr. Pritchett served from 2011 to 2014. Dr. Pritchett <br>served as Chair of the Redevelopment Authority of Philadelphia and as President of the <br>Philadelphia Housing Development Corporation from 2008 to 2011. Dr. Pritchett serves on <br>the boards of 26North BDC, Inc. and Toll Brothers, Inc. He also serves as Chair of the Board <br>of Trustees of College Unbound and is a board member of the Philadelphia Foundation, <br>LifePoint Health, Forman Arts Initiative, and Reinvestment Fund. Dr. Pritchett holds a <br>Bachelor of Arts in political science from Brown University, a J.D. from Yale Law School, and <br>a Ph.D. in history from the University of Pennsylvania.<br>Dr. Pritchett was selected to serve on the Board due to his leadership and administrative <br>skills, and deep knowledge and experience in academia.<br>|

---

**14**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

---

| | |
|:---|:---|
| **Saurabh Saha, M.D., Ph.D.**<br>Director since May 2023<br>Independent<br>Age: 49<br>**Clarivate Board Committees**<br>❖Human Resources & <br>Compensation<br>**Other Public Company** <br>**Directorships (within past** <br>**five years)**<br>❖Centessa Pharmaceuticals plc<br>(January 2021 to January 2026) <br>| **Experience and Qualifications**<br>Dr. Saha served as the Chief Executive Officer of Centessa Pharmaceuticals plc from <br>January 2021 to January 2026 and has served as an advisor to Centessa since January <br>2026. Dr. Saha brings over 20 years of experience in the health and life sciences field. Prior <br>to joining Centessa, Dr. Saha was Senior Vice President of Research & Development and <br>Global Head of Translational Medicine for Bristol Myers Squibb Company from 2017 to <br>January 2021, where he led translational medicine research and development across all <br>therapeutic areas (hematology, oncology, cardiovascular, immunosciences, fibrosis, and <br>neuroscience) spanning discovery, development, and commercialization. From 2015 to <br>2017, Dr. Saha was a venture partner at Atlas Venture Life Science Advisors, LLC. Prior to <br>that, he served as President and Chief Executive Officer of Delinia, a biotechnology <br>company developing novel therapeutics for the treatment of autoimmune diseases. Earlier in <br>his career, Dr. Saha led the New Indications Discovery Unit at Novartis Institutes for <br>Biomedical Research, Inc. and was a strategic consultant with McKinsey & Company, <br>providing strategic advice for drug discovery research at the world's top biotech and <br>pharmaceutical companies. Dr. Saha serves on the board of directors of Centessa <br>Pharmaceuticals plc. He is also an associate member and global clinical scholar at Harvard <br>Medical School. Dr. Saha received a Bachelor of Science in Biology with Honors from <br>California Institute of Technology, an M.Sc. in Biochemistry from Oxford University, and an <br>M.D. and Ph.D. from The Johns Hopkins University School of Medicine. Over the course of <br>his career, Dr. Saha has published over 100 papers and patents (issued and pending).<br>Dr. Saha was selected to serve on the Board due to his significant experience and deep <br>expertise in the areas of health and life sciences.<br>|
| **Matti Shem Tov**<br>**Chief Executive Officer**<br>Director since August 2024<br>Age: 65<br>**Clarivate Board Committees**<br>❖None<br>**Other Public Company** <br>**Directorships (within past** <br>**five years)**<br>❖None <br>| **Experience and Qualifications**<br>Matti Shem Tov has served as our Chief Executive Officer since August 2024. Mr. Shem Tov <br>has over 30 years of global leadership experience with deep expertise in software, data, and <br>analytics, as well as in driving innovation and growth. From June 2022 until March 2024, <br>Mr. Shem Tov served as an operating partner at Lone View Capital, a private equity firm. <br>Prior to that, Mr. Shem Tov served as Chief Executive Officer of ProQuest LLC ("ProQuest"), <br>a provider of global data, analytics, and software, to academic, research, and national <br>institutions, from September 2017 to June 2022, including for a period following Clarivate's <br>acquisition of ProQuest in December 2021. From 2003 until 2017, Mr. Shem Tov served as <br>president and chief executive officer of Ex Libris Ltd., leading the company to become a <br>prominent developer of cloud-based software solutions for academic, national and research <br>institutions worldwide. Prior to joining Ex Libris, Mr. Shem Tov served as president of <br>Surecomp Limited, a global software company specializing in commercial banking solutions, <br>after serving in various leadership roles across the company. Mr. Shem Tov received a <br>Bachelor of Social Sciences and an M.B.A. from Bar-Ilan University.<br>Mr. Shem Tov was selected to serve on the Board due to his knowledge of the Company's <br>operations, strategy, and customers as well as his experience as a seasoned technology <br>executive.<br>|

---

**Organization of the Board of Directors**

The Board held seven formal meetings during fiscal year 2025 and held a number of additional informal update and

background calls. At each meeting, the Board Chair was the presiding director. Each director attended at least 75 percent

of the total regularly scheduled and special meetings of the Board and the committees on which he or she served, except

Michael Angelakis, who did not attend the May 2025 Board and committee meetings which preceded his retirement from

the Board following the 2025 annual general meeting of shareholders. Our Board expects each director to attend our

annual general meeting of shareholders, although attendance is not required. At the 2025 annual general meeting of

shareholders, ten of the then 11 directors on the Board (all except Mr. Angelakis) were in attendance.

Following the 2025 annual general meeting of shareholders on May 7, 2025, Mr. Angelakis retired from the Board,

reducing its size to ten members. On July 22, 2025, Kenneth Cornick was elected to the Board, increasing its size to 11

members. On December 31, 2025, Valeria Alberola resigned from the Board, reducing its size to ten members.

The Board has adopted Corporate Governance Guidelines, committee charters, and a Code of Conduct, which, together

with the Articles, form the governance framework for the Board and its committees. We believe good governance

strengthens the Board and management's accountability.

**15**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

The Board regularly (and at least annually) reviews its Corporate Governance Guidelines and other corporate governance

documents and revises them when it believes it serves the interests of the Company and its shareholders to do so.

---

| | |
|:---|:---|
| ![Image_98.jpg](clvt-20260401_g12.jpg) | **Key Corporate Governance Documents**<br>The following governance documents are accessible through the Investor Relations section of our website at <br>**ir.clarivate.com**:<br>❖Articles of Association<br>❖Corporate Governance Guidelines<br>❖Board Committee Charters<br>❖Code of Conduct<br>❖Insider Trading Policy<br>|

---

**Director Nomination Agreements**

In connection with Clarivate's acquisition of CPA Global in October 2020, Clarivate entered into an Investor Rights

Agreement (the "**Investor Rights Agreement**") with the owners of CPA Global, including affiliates of Leonard Green &

Partners, L.P. ("**LGP**"), and certain existing shareholders of Clarivate at the time, including affiliates of Onex Partners

Advisor LP ("**Onex**"), pursuant to which LGP was given the right to nominate two members of the Board for so long as

LGP maintains ownership of at least 10% of Clarivate, and one member of the Board for so long as LGP maintains

ownership of at least 5% of Clarivate. Mr. Cortas and Mr. Levyn have been nominated to the Board pursuant to the

Investor Rights Agreement.

In connection with Exor N.V.'s investment in the Company in March 2024, Clarivate entered into an Investment Agreement

with Exor (the "**Investment Agreement**"). Under the terms of the Investment Agreement, Clarivate agreed to include Ms.

Heywood in the Board's annual slate of nominee directors, or if Ms. Heywood becomes unavailable to continue her

service as director, another individual designated by Exor and reasonably acceptable to the Board (the "**Exor Designee**").

The Exor Designee will be required to promptly tender his or her resignation from the Board at such time at which Exor

beneficially owns less than 5% of Clarivate's issued and outstanding ordinary shares.

**Independence of Directors**

Under our Corporate Governance Guidelines and NYSE listing standards, a director is considered independent if such

director does not fall within certain bright-line tests and the Board affirmatively determines that such director "has no

material relationship" with the Company (either directly or as a partner, shareholder, or officer of an organization that has a

relationship with the Company). As part of the Board's annual review of director independence, the Board considers the

Nominating and Governance Committee's independence assessment and recommendation. The Board also reviews and

considers any relationships or transactions between any director or any member of his or her immediate family and the

Company, in accordance with our Corporate Governance Guidelines. In addition to the transactions described in "Certain

Relationships and Related Person Transactions" below, the Board has reviewed and deemed immaterial for purposes of

determining director independence certain transactions and relationships in the following categories: (i) transactions

between Clarivate and an entity where the director is an executive officer or a significant shareholder and where all

shareholders of the entity received the same consideration for the transaction and such transaction occurred at a time

where the director was not otherwise affiliated with Clarivate; (ii) customer relationships between Clarivate and an entity

where the director is a significant shareholder or serves as a non-management director which also fall below the

numerical thresholds in NYSE listing standards (or do not otherwise preclude independence under those standards), and

that are ordinary course, on arm's-length market terms; (iii) relationships between Clarivate and an entity where the

director is a significant shareholder and serves solely as a non-management director; and (iv) a director's significant direct

or indirect ownership stake in Clarivate.

Based on the Nominating and Governance Committee's independence assessment and recommendation, the Board

affirmatively determined that each member of the Board, other than Mr. Shem Tov, is independent under our Corporate

Governance Guidelines and NYSE listing standards. The Board determined that Ms. Alberola was independent through

her resignation from the Board in December 2025. Mr. Shem Tov is not independent due to his position as CEO of the

Company. In addition, the Board has determined that all members of each of the Audit Committee, Human Resources and

Compensation Committee, Nominating and Governance Committee, and Finance Committee of the Board meet the

independence requirements of the NYSE listing standards and SEC rules and regulations.

**Family Relationships**

There are no family relationships between any of Clarivate's executive officers and directors.

**16**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Compensation Committee Interlocks and Insider Participation**

During 2025, none of our executive officers served on the board of directors or compensation committee of a company

that has an executive officer that serves on the Board or the Human Resources and Compensation Committee.

**Simultaneous Service on Other Public Company Boards**

The Board does not believe that its members should be generally prohibited from serving on boards of other

organizations. However, as set forth in the Company's Corporate Governance Guidelines, the Board believes that

reasonable limits on such activity are advisable in order to ensure adequate time is available for Board members to focus

on the Company and its business. For that reason, the Board has determined that no non-management director may

serve on the board of more than three other public companies, and the Company's Chief Executive Officer and each of its

executive officers may only serve on the board of one other public company. In addition, as set forth in the Audit

Committee charter and the Company's Corporate Governance Guidelines, no Audit Committee member may

simultaneously serve on the audit committee of more than two other public companies, unless the Board determines that

such simultaneous service would not impair the ability of the member to effectively serve on the Audit Committee and this

determination is disclosed in accordance with NYSE rules.

In addition, other than with respect to any directors and director candidates designated pursuant to the Investor Rights

Agreement and the Investment Agreement (for so long as such agreements are in effect), for whom the Nominating and

Governance Committee does not provide a recommendation to the Board, the Nominating and Governance Committee

may take into account the nature of and time involved in a director's service on other boards and/or committees in

evaluating the suitability of individual director candidates and current directors.

**Code of Conduct**

Clarivate has adopted a Code of Conduct that applies to all its employees, officers, and directors. This includes the

Company's principal executive officer, principal financial officer, and principal accounting officer or controller, or persons

performing similar functions.

Our Code of Conduct is available on our website at **ir.clarivate.com**. If we approve any substantive amendment to our

Code of Conduct, or if we grant any waiver of our Code of Conduct to our directors or executive officers (including our

principal executive officer, principal financial officer, and principal accounting officer), we will post an update on the

Investor Relations page of our website within four business days following the date of the amendment or waiver,

describing the nature and date of the amendment or the nature of the waiver, the name of the person to whom it was

granted, and the date of the waiver, as the case may be.

**Director Share Ownership Guidelines**

We believe that our non-employee directors should have a significant equity interest in the Company. Our Board has

adopted an ownership policy in our Corporate Governance Guidelines that requires independent directors to hold ordinary

shares with a market value of at least five times the Board's annual cash Board retainer. Directors have five years from

their initial appointment to achieve the holding requirement. Mr. Cortas and Mr. Levyn, as affiliates of LGP, and Mr. Munk,

as an affiliate of Onex, do not receive compensation for their service as directors and are not subject to the holding

requirement. The share ownership guidelines applicable to our non-employee directors are described in more detail under

"Compensation Discussion and Analysis — Share Ownership Guidelines" below.

**Insider Trading Policy**

We have adopted an insider trading policy that governs the purchase, sale, and/or other dispositions of our securities by

directors, officers, employees, and other covered persons that we believe is reasonably designed to promote compliance

with insider trading laws, rules and regulations, and NYSE listing standards. A copy of our insider trading policy is filed as

Exhibit 19.1 to the Annual Report and is posted on our website at **ir.clarivate.com**.

Our insider trading policy prohibits executive officers, directors, employees, and consultants from entering into certain

forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts. Stock options granted

to employees under our equity compensation plans are not covered by the prohibition.

We also have a pledging policy for directors and senior executives (including executive officers) that prohibits them from

purchasing Clarivate securities on margin or holding Clarivate securities in a margin account, or otherwise pledging

Clarivate securities as collateral for a loan.

**17**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Board, Committee, and Individual Director Evaluations**

Each year, our Board and its committees perform a rigorous self-evaluation overseen by the Nominating and Governance

Committee. The performance evaluations solicit input from directors regarding the performance and effectiveness of the

Board and its committees and provide an opportunity for members of the Board to identify areas for improvement. The

Nominating and Governance Committee reviews the results and feedback from the evaluation process and makes

recommendations to the full Board. Each committee also reviews the results and feedback from its own evaluation

process. The Chair of the Nominating and Governance Committee leads a discussion of the evaluation results. Our Board

has successfully used this process to evaluate Board and committee effectiveness and identify opportunities to strengthen

the Board.

**Board Committees and Their Composition**

The Board has established four standing committees: Audit, Human Resources and Compensation, Nominating and

Governance, and Finance, each of which operates under a written charter that is posted on our website at

**ir.clarivate.com**.

The Board periodically reviews the needs of the Board and the Company in determining its standing committees. The

Board reviews the composition of the Board committees annually and considers the expertise of the directors with the

needs of the committees.

---

| | |
|:---|:---|
| **Audit Committee**  | **Audit Committee**  |
| **Committee Members**<br>❖Kenneth Cornick (Chair)<br>❖Jane Okun Bomba<br>❖Anthony Munk<br>❖Valeria Alberola<br>(until December 2025)<br>**Audit Committee Financial** <br>**Experts**<br>❖Kenneth Cornick (Chair)<br>❖Jane Okun Bomba<br>❖Anthony Munk<br>❖Valeria Alberola<br>(until December 2025)<br>**Number of meetings in 2025:** 6<br>| **Responsibilities**<br>The Audit Committee assists the Board in its oversight of: (i) the integrity of the <br>Company's financial statements and internal controls; (ii) the Company's <br>compliance with legal and regulatory requirements; (iii) the independent auditor's <br>qualifications and independence; (iv) the performance of the Company's <br>independent auditor; (v) the performance of the internal audit function; and (vi) the <br>Company's risk management process. The Audit Committee is directly responsible <br>for the appointment, compensation, retention, and oversight of the work of the <br>Company's independent auditor. The Audit Committee oversees management's <br>policies and activities relating to the identification, evaluation, management, and <br>monitoring of the Company's critical enterprise risks, including risks associated with <br>the Company's strategic initiatives, business plans, and capital structure. The Audit <br>Committee reviews and discusses the quarterly and annual financial statements <br>with management and the Company's independent auditor. The Audit Committee <br>establishes procedures for the receipt, retention, and treatment of complaints <br>received by the Company regarding accounting, internal controls, or audit matters. <br>The Audit Committee approves any related person transactions in accordance with <br>the Company's policies and procedures. The Audit Committee also prepares the <br>report on the Company's financial statements and its independent auditor that the <br>SEC rules require to be included in the Company's annual proxy statement or <br>annual report. The Audit Committee has been established in accordance with <br>Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (the "**Exchange Act**").<br>**Independence and Qualifications**<br>Each committee member has been determined by the Board to qualify as <br>independent under the independence criteria established by the SEC and the <br>NYSE. The Board has also determined that each committee member is "financially <br>literate" within the meaning of the NYSE listing standards and an "Audit Committee <br>financial expert" under the applicable SEC rules based on their experience and <br>qualifications.<br>|

---

**18**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

---

| | |
|:---|:---|
| **Human Resources and Compensation Committee**  | **Human Resources and Compensation Committee**  |
| **Committee Members**<br>❖Jane Okun Bomba (Chair)<br>❖Adam T. Levyn<br>❖Wendell Pritchett<br>❖Saurabh Saha<br>**Number of meetings in 2025:** 5<br>| **Responsibilities**<br>The Human Resources and Compensation Committee has been established by the <br>Board to oversee compensation of the Company's executive officers and directors, <br>to approve, administer, and evaluate all compensation and benefit plans, policies, <br>and programs of the Company (including equity-based compensation), to review <br>significant company compensation matters and policies, to review and approve the <br>corporate goals and objectives with respect to the compensation of the Chief <br>Executive Officer, to evaluate the Chief Executive Officer's performance in light of <br>these goals and objectives and set the Chief Executive Officer's compensation, to <br>review and discuss with management the Company's "Compensation Discussion <br>and Analysis," to prepare the compensation committee report required by SEC rules <br>to be included in the Company's annual proxy statement or annual report, to review <br>and assess risks arising from the Company's compensation policies and practices <br>for its employees and whether any such risks are reasonably likely to have a <br>material adverse effect on the Company, and to administer the Company's <br>Executive Compensation Recoupment Policy and such other compensation <br>recoupment policies that the Company has in effect from time to time. See <br>"Compensation Discussion and Analysis" for a more detailed description of certain <br>functions of the Human Resources and Compensation Committee.<br>**Independence**<br>Each committee member has been determined by the Board to qualify as <br>independent under the independence criteria established by the SEC and the NYSE <br>and is a "non-employee director" for purposes of Rule 16b-3 under the Exchange <br>Act. <br>|

---

---

| | |
|:---|:---|
| **Nominating and Governance Committee**  | **Nominating and Governance Committee**  |
| **Committee Members**<br>❖Wendell Pritchett (Chair)<br>❖Usama N. Cortas<br>❖Suzanne Heywood<br>❖Andrew Snyder<br>**Number of meetings in 2025:** 4<br>| **Responsibilities**<br>The Nominating and Governance Committee has been established by the Board to <br>recommend to the Board criteria for Board and Board committee membership; <br>identify individuals qualified to become members of the Board and recommend <br>director nominees to the Board consistent with criteria approved by the Board, <br>including as to director independence; recommend directors for appointment to <br>Board committees; make recommendations as to determinations of director <br>independence; develop and recommend to the Board, and oversee compliance <br>with, our Corporate Governance Guidelines; oversee management's development <br>of analyses and metrics to understand the impact of sustainability and stakeholder <br>interests on the Company and oversee the integration and balancing of these <br>interests to promote the long-term success of the Company; and oversee the <br>evaluation of the Board and management.<br>**Independence**<br>Each committee member has been determined by the Board to qualify as <br>independent under the independence criteria established by the NYSE. <br>|

---

**19**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

---

| | |
|:---|:---|
| **Finance Committee**  | **Finance Committee**  |
| **Committee Members**<br>❖Usama N. Cortas (Chair)<br>❖Anthony Munk<br>❖Suzanne Heywood<br>❖Andrew Snyder<br>❖Valeria Alberola <br>(until December 2025)<br>**Number of meetings in 2025:** 5<br>| **Responsibilities**<br>The Finance Committee has been established to review, discuss, and make <br>recommendations to the Board regarding the Company's capital structure, financial <br>outlook, financial guidance provided to investors, analysts, and ratings agencies, <br>and financial plans, policies, practices, and strategies; review, discuss and make <br>recommendations to the Board concerning proposed issuances of equity, debt, and <br>other securities and proposed credit and similar facilities; and review, discuss, and <br>make recommendations to the Board regarding significant acquisitions and <br>divestitures by the Company, including discussion of possible mergers and other <br>transactions, and their financial impact.<br>**Independence**<br>Each committee member has been determined by the Board to qualify as <br>independent under the independence criteria established by the NYSE.<br>|

---

**Board Composition and Director Nominations**

Our Board nominates directors to be elected at each annual general meeting of shareholders and appoints new directors

to fill vacancies when they arise, with any such newly appointed directors eligible for re-election at the next annual general

meeting of Clarivate. Board refreshment and succession planning is an ongoing, year-round process. The Board

recognizes that it is important for the Board to balance the benefits of continuity with the benefits of fresh viewpoints and

experience. While it is not the policy of the Board to mandate specific term limits or a specific retirement age for directors,

the Nominating and Governance Committee regularly reviews the composition of the Board and the appropriateness of

each director's continued service on the Board in light of the current challenges and needs of the Board and the Company,

and determines whether it may be appropriate to add directors or reduce the size of the Board. The Board believes the

current composition of the Board and mix of tenures provides for a highly effective and well-functioning Board.

Subject to the requirements of the Investor Rights Agreement and the Investment Agreement, the Nominating and

Governance Committee will consider persons identified by its members, management, shareholders, investment bankers,

and others. The guidelines for selecting nominees, which are specified in our Corporate Governance Guidelines, generally

provide that persons to be nominated:

❖should have demonstrated notable or significant achievements in business, education, or public service;

❖should possess the requisite intelligence, education, and experience to make a significant contribution to the Board

and bring a range of skills, diverse perspectives, and backgrounds to its deliberations; and

❖should have the highest ethical standards, a strong sense of professionalism, and intense dedication to serving the

interests of the shareholders.

The Nominating and Governance Committee will consider a number of qualifications relating to management and

leadership experience, background, technical skill, diversity of experience, judgment, integrity, and professionalism in

evaluating a person's candidacy for membership on the Board. The Nominating and Governance Committee may require

certain skills or attributes, such as financial or accounting experience, to meet specific Board needs that arise from time to

time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of Board

members. Subject to the requirements of the Investor Rights Agreement and the Investment Agreement, the Nominating

and Governance Committee will not distinguish among nominees recommended by shareholders and other persons.

Shareholders may recommend candidates for consideration by the Board by contacting the Board as indicated under

"Communications with the Board."

**20**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Communications with the Board**

Shareholders and other interested parties may contact any or all Board members (including our Board Chair or the non-

management directors as a group), any Board committees, or any committee chair by email or mail. Correspondence

should be addressed to the Board or any such individual directors or group or committee of directors by either name or

title.

The General Counsel or another member of our Legal Department opens all communications to determine whether the

contents represent a message to the directors. All correspondence that is not in the nature of advertising or promotion of a

product or service or is not trivial, irrelevant, unduly hostile, threatening, illegal, patently offensive, or similarly

inappropriate will be forwarded promptly to the addressee. If no particular director is named, the communication will be

forwarded, depending on the subject matter, to the Board Chair, the Audit Committee Chair, the Human Resources and

Compensation Committee Chair, the Nominating and Governance Committee Chair, or the Finance Committee Chair.

Correspondence can be sent:

---

| | |
|:---|:---|
| ![Image_114.jpg](clvt-20260401_g5.jpg) | **By Email:**<br>**Company.Secretary@clarivate.com**<br>|
| ![Image_115.jpg](clvt-20260401_g6.jpg) | **By Mail:**<br>**General Counsel**<br>**c/o Legal Department**<br>**Clarivate Plc**<br>**70 St. Mary Axe**<br>**London EC3A 8BE**<br>**United Kingdom**<br>|

---

The General Counsel will forward to the Audit Committee Chair any correspondence that reflects a complaint or concern

relating to accounting, auditing, or internal control matters.

**Director Compensation**

Our non-employee directors, other than those who are employees or affiliates of LGP or Onex, receive compensation for

their service on our Board. The compensation includes annual cash retainers for Board service and Committee Chair

service, an annual retainer paid in shares for Board Chair service, and an annual equity award consisting of a grant of

Restricted Share Units ("**RSUs**"). In addition, each of our non-employee directors is reimbursed for travel, lodging, and

other reasonable expenses related to meeting attendance and activities related to their duties as directors.

The following table sets forth information concerning the non-employee director compensation program in effect in 2025.

---

| | |
|:---|:---|
| **Non-Employee Director Compensation**  | **Amount**<sup>(1)</sup><br>**($)**<br>|
| **Board Annual Retainer**  | 85000 |
| **Non-Executive Board Chair Annual Retainer**  | 120000 |
| **Committee Chair Annual Retainer**  |  |
| Audit Committee  | 30000 |
| Human Resources and Compensation Committee  | 30000 |
| Nominating and Governance Committee  | 20000 |
| Finance Committee | 20000 |
| **Board Annual Equity Award (RSUs)**<sup>(2)</sup> | 165000 |

---

(1)Except for the Non-Executive Board Chair Annual Retainer, which is paid in shares, directors may elect to receive payment of their retainers in

cash, shares, or a combination of cash and shares.

(2)On the day of the Company's annual general meeting of shareholders each year, each non-employee director who receives compensation receives

an award consisting of RSUs whose underlying shares have a fair market value equal to $165,000. Such awards will vest on the date immediately

preceding the Company's next annual general meeting of shareholders.

**21**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

The Human Resources and Compensation Committee oversees director compensation and periodically evaluates the

compensation of our non-employee directors with the assistance of Pay Governance, the committee's independent

compensation consultant. Pay Governance reviews director pay levels and provides analyses on where the Company is

positioned relative to director compensation benchmarks. The Human Resources and Compensation Committee may

bring recommendations for adjustments to non-employee director compensation to the Board for review and approval.

The Articles provide that, to the fullest extent permitted by law, the Company shall indemnify its directors and officers

against any liability, action, proceeding, claim, demand, costs, damages, or expenses, including legal expenses, which

they may incur as a result of any act or failure to act in carrying out their functions in connection with the Company, other

than such liability (if any) that they may incur by reason of their own actual fraud or willful default.

The Company maintains a directors' and officers' liability policy for the benefit of any director or officer in the event of any

loss or liability the director or officer may experience with respect to any negligence, default, breach of duty, or breach of

trust, regardless of whether we may otherwise indemnify such officer or director.

**Non-Employee Director Compensation in 2025**

The following table provides information concerning the compensation of each of our non-employee directors who

received compensation during the 2025 fiscal year. Non-employee directors did not receive any stock options, non-equity

incentive plan compensation, or any other compensation that is not otherwise disclosed in the table below. Non-employee

directors do not participate in defined benefit and actuarial pension plans or nonqualified defined contribution plans.

---

| | | | |
|:---|:---|:---|:---|
| **Name**  | **Fees Earned or**<br>**Paid in Cash**<sup>(5)</sup><br>**($)** <br>| **Stock Awards**<sup>(6)</sup><br>**($)** <br>| **Total**<br>**($)**<br>|
| Andrew Snyder  | 205000 | 165000 | 370000 |
| Valeria Alberola<sup>(1)</sup> | 115000 | 165000 | 280000 |
| Michael Angelakis<sup>(2)</sup> | 29890 |  | 29890 |
| Jane Okun Bomba  | 115000 | 165000 | 280000 |
| Kenneth Cornick<sup>(3)</sup> | 37649 | 131199 | 168848 |
| Usama Cortas<sup>(4)</sup> |  |  |  |
| Suzanne Heywood | 85000 | 165000 | 250000 |
| Adam T. Levyn<sup>(4)</sup> |  |  |  |
| Anthony Munk<sup>(4)</sup> |  |  |  |
| Wendell Pritchett  | 105000 | 165000 | 270000 |
| Saurabh Saha  | 85000 | 165000 | 250000 |

---

(1)Ms. Alberola resigned from the Board and her position as Audit Committee Chair on December 31, 2025.

(2)Mr. Angelakis retired from the Board on May 7, 2025.

(3)Mr. Cornick joined the Board on July 22, 2025. Fees earned and paid in shares in lieu of cash during 2025 are from July 22, 2025.

(4)Messrs. Cortas and Levyn did not receive compensation during 2025 as each is an affiliate of LGP. Mr. Munk did not receive compensation during

2025 as he is an affiliate of Onex. Messrs. Cortas, Levyn, and Munk are not subject to the shareholding requirement set forth in the Company's

Corporate Governance Guidelines.

(5)In 2025, the following directors elected to receive shares in lieu of cash fees: Ms. Okun Bomba received 30,114 shares in lieu of 100% of her cash

retainers; Mr. Cornick received 10,643 shares in lieu of 100% of his cash retainers; and Mr. Snyder received 53,683 shares in lieu of 100% of his

cash retainers.

(6)On May 7, 2025, the date of the 2025 annual general meeting of shareholders, all non-employee directors were awarded 39,473 RSUs with a value

of $165,000. The number of RSUs granted was calculated by dividing $165,000 by $4.18, the closing price of Clarivate shares on the grant date,

rounding down to the next whole share. On July 22, 2025, the date Mr. Cornick joined the Board, he was awarded 29,954 RSUs with a value of

$131,199, as the prorated amount of the annual equity award to non-employee directors. The number of RSUs granted was calculated by dividing

$131,199 by $4.38, the closing price of Clarivate shares on the grant date, rounding down to the next whole share. These RSUs vest on the date

immediately preceding the Annual Meeting. At the end of the fiscal year, Ms. Okun Bomba, Ms. Heywood, Dr. Pritchett, Dr. Saha, and Mr. Snyder

were each holding their 39,473 unvested RSUs and Mr. Cornick was holding his 29,954 unvested RSUs. Ms. Alberola's 39,473 unvested RSUs

forfeited on her resignation date of December 31, 2025 and were cancelled.

**22**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**EXECUTIVE OFFICERS**

Set forth below is information concerning our executive officers as of the date of this Proxy Statement.

---

| | | |
|:---|:---|:---|
| **Name**  | **Age**  | **Position**  |
| Matti Shem Tov  | 65 | Chief Executive Officer  |
| Jonathan Collins  | 46 | Executive Vice President & Chief Financial Officer  |
| William Graff  | 60 | Executive Vice President, Chief Information Officer  |
| Henry Levy  | 54 | President, Life Sciences & Healthcare  |
| Maroun Mourad | 53 | President, Intellectual Property  |
| Bar Veinstein  | 53 | President, Academia & Government |

---

Executive officers are appointed by our Board. Information about Mr. Shem Tov is provided under "Business Experience

and Qualifications of Director Nominees" in this Proxy Statement. A brief biography for each of our other executive officers

follows.

**Jonathan M. Collins** joined Clarivate in December 2021 as Executive Vice President and Chief Financial Officer

managing the global financial organization and leading the development and execution of the Company's fiscal strategies.

From 2016 to December 2021, Mr. Collins served as executive vice president and chief financial officer for Dana

Incorporated, a publicly listed company. In this role, he led Dana's financial, information technology, corporate strategy,

and business development functions, as well as the digital solutions and aftermarket businesses. He was instrumental in

authoring the company's enterprise strategy and led multiple strategic acquisitions that combined with Dana's core

technologies to create a leading supplier of electric-vehicle propulsion systems. From 2013 to 2016, Mr. Collins served as

senior vice president and chief financial officer of ProQuest, LLC, a leading global education technology company, now

part of Clarivate. In that role, he worked closely with leadership across the company to profitably grow the business by

enabling the digitization of academic research. In addition, Mr. Collins has served in finance leadership roles at

International Automotive Components Group and Lear Corporation. He earned an M.B.A., with distinction, from the

University of Michigan's Stephen M. Ross School of Business and holds a bachelor's degree from Cedarville University.

**William Graff** joined Clarivate in February 2022 as Executive Vice President and Chief Information Officer, overseeing

information technology services and critical technology infrastructure. Mr. Graff brings over 35 years of experience leading

technology teams working in large-scale, global environments. Prior to Clarivate, Mr. Graff was Chief Information Officer

for Oracle Cerner, with responsibility for data center infrastructure, platform software development, information security,

and corporate IT systems. Previously, Mr. Graff held various technology and operations leadership roles, driving

productivity, increasing profit margins, and growing market share at ecommerce, software development, and retail

companies. Mr. Graff serves as Chairperson of the Kansas City Technology Council and is active in promoting technology

growth across the region. Mr. Graff was also voted the ORBIE Kansas City CIO of the Year in 2021, and he formerly

participated in technology advisory/CIO groups for Hewlett Packard Enterprise, T-Mobile, AWS, and VMware. Mr. Graff is

a graduate of Kansas State University with a bachelor's degree in agriculture economics.

**Henry Levy** joined Clarivate in May 2023 as President, Life Sciences & Healthcare. He leads the teams focused on

developing solutions that enable life sciences and healthcare companies and providers to create a heathier tomorrow by

connecting them to transformative intelligence and data technology to improve patient lives. Mr. Levy has over 30 years of

experience and is a life sciences expert who is a frequent speaker at industry forums and has published multiple articles

on drug development and technology trends. Prior to Clarivate, he held several roles at Veeva Systems Inc. from 2016 to

May 2023, including Chief Strategy Officer, General Manager for the Clinical Data Management product suite, and, most

recently, President, Global R&D and Quality. Previously, from 2014 to 2016, Mr. Levy was Chief Commercial Officer for

PPD, Inc., where he defined new models for biopharmaceutical companies to partner with contract research organizations

to drive down costs and improve the speed of drug development. Before that, he led Accenture plc's global life sciences

R&D practice from 2007 to 2014, where he helped 90% of the top 20 biopharmaceutical companies improve through

consulting, technology, and outsourcing solutions. Mr. Levy holds a bachelor's degree in bioengineering from the

University of Pennsylvania.

**Maroun S. Mourad** joined Clarivate in September 2025 as President, Intellectual Property. He leads the teams focused

on providing trusted intellectual property data, software, and expertise to help companies drive innovation, law firms

achieve practice excellence, and organizations worldwide effectively manage and protect critical intellectual property

assets. As a data analytics and software executive, Mr. Mourad has profitably grown businesses in the U.S., U.K., Europe,

and emerging markets since 1998. Prior to Clarivate, Mr. Mourad held a number of senior roles at Verisk Analytics Inc.

**23**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

since 2015, including most recently as the leader of the Claims Solutions division from July 2022 to August 2025, where

he was responsible for the product portfolio, services, and acquisitions that deliver value to clients across the insurance

policy lifecycle worldwide. His focus on team building, customer-centricity, and delivering quality results has driven

business transformations in established, start-up, and turnaround environments, in previous roles at Gen Re, AIG, Arch,

and Zurich. He holds a bachelor's degree in political science and a juris doctor, both from the University of California,

Berkeley.

**Bar Veinstein** joined Clarivate in April 2023 as President, Academia & Government. He leads the teams focused on

creating solutions that enable academia and government institutions to build a better world by connecting students,

faculty, and staff to transformative intelligence and trusted content that drives research excellence and student success.

Mr. Veinstein has over 25 years of global leadership experience. He brings deep expertise in enterprise and cloud

software, AI and analytics, research data, and technologies, as well as in setting strategic direction and building high-

performance teams across technology, sales, marketing, and services. Prior to Clarivate, Mr. Veinstein was Chief

Executive Officer for A.A.A. Taranis Visual Ltd. from 2021 to April 2023, where he transformed the company into an AI-

powered agriculture intelligence leader, driving sustainable practices across millions of acres in the United States.

Previously, from 2017 to 2021, he served as President of Ex Libris Group, now part of Clarivate. Mr. Veinstein joined Ex

Libris in 2010 as senior vice president of cloud solutions and led the transformation of its products and business to SaaS.

Under his leadership, Ex Libris became a global leader serving over 7,500 institutions in 90 countries. Mr. Veinstein holds

a bachelor's degree in computer science and economics and a master's degree in business administration from Tel Aviv

University.

**24**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**PROPOSAL 2: ADVISORY APPROVAL OF EXECUTIVE** 

**COMPENSATION**

At the 2021 annual general meeting of shareholders, we conducted an advisory, non-binding vote regarding the frequency

with which we would seek approval of the compensation of our named executive officers ("**NEOs**"). At such meeting,

shareholders expressed their preference for an annual vote on executive compensation on an advisory, non-binding basis

and, consistent with this preference, the Board determined that we will conduct such a vote on an annual basis. Our next

advisory, non-binding vote regarding the frequency with which we would seek approval of the compensation of our NEOs

will occur at the 2027 annual general meeting of shareholders.

Accordingly, in accordance with Section 14A of the Exchange Act and related SEC rules, we are providing our

shareholders with the opportunity to vote, on an advisory, non-binding basis, on the compensation of our NEOs for 2025,

as disclosed in this Proxy Statement, including the "Compensation Discussion and Analysis," "Executive Compensation

Tables," and related material.

As described in detail in the Compensation Discussion and Analysis, our executive compensation programs are designed

to:

❖Support our mission, vision, and values.

❖Provide appropriate rewards aligned to the achievement of key business objectives and growth in shareholder value.

❖Align executive compensation with key stakeholder interests and support a pay-for-performance culture.

❖Attract, retain, and motivate highly qualified executive talent.

❖Be globally consistent and locally competitive.

Under these programs, our NEOs are rewarded for achieving specific individual and corporate goals, with an emphasis on

creating overall shareholder value. Our compensation programs continue to be a key driver of shareholder value creation,

with a strong emphasis on variable/at-risk compensation as opposed to fixed compensation. Shareholders continue to

show strong support of our executive compensation programs, with **approximately 99% of the votes cast for approval** 

**of our executive compensation** proposal at our 2025 annual general meeting of shareholders.

Please read the "Compensation Discussion and Analysis" for additional details about our executive compensation

programs, including information about the fiscal year 2025 compensation of our NEOs. Below are highlights of our

program designed to ensure effective oversight of our executive compensation and strong corporate governance.

✔We have a Human Resources and Compensation Committee that is fully composed of independent directors.

✔The Human Resources and Compensation Committee engages an independent compensation consultant.

✔We have adopted share ownership guidelines for our executive officers and the Board.

✔The majority of NEO pay is at risk and dependent upon performance.

✔The mix of executive officer equity awards includes a performance-based element.

✔We engage with our shareholders to discuss executive compensation and corporate governance matters.

✔We maintain robust clawback policies that require covered executives to reimburse compensation in specified

circumstances.

✔We do not permit our employees to engage in hedging transactions.

✔We do not permit our employees to pledge Company securities to secure margin or other loans.

✔We do not reprice underwater stock options.

✔We do not provide excise tax gross-up payments.

✔We do not have an evergreen provision that automatically adds shares to our equity incentive plan.

✔We do not provide excessive perquisites.

✔We do not grant single-trigger equity awards.

**25**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

The Human Resources and Compensation Committee continually reviews the compensation programs for our NEOs to

ensure they achieve the desired goals of aligning our executive compensation structure with our shareholders' interests

and current market practices.

We are asking our shareholders to indicate their support for our named executive officer compensation program and

practices as described in this Proxy Statement. This proposal, commonly known as a "say-on-pay" proposal, gives our

shareholders the opportunity to express their views on our NEOs' compensation. This vote is not intended to address any

specific item of compensation, but rather the overall compensation of our NEOs and the philosophy, policies, and

practices described in this Proxy Statement. Accordingly, we are asking our shareholders to approve the compensation

policies and practices of our NEOs as disclosed in this Proxy Statement pursuant to the compensation disclosure rules of

the SEC (which include the Compensation Discussion and Analysis, the Executive Compensation Tables, and related

material).

**The text of the resolution with respect to Proposal 2 (which is proposed as an** 

**ordinary resolution) is as follows:**

"**RESOLVED**, that the shareholders of the Company hereby approve, on an advisory, non-binding basis, the

compensation of the Company's named executive officers as disclosed in the Proxy Statement relating to the 2026 Annual

General Meeting of Shareholders."

**Vote Required and Recommendation**

The proposal will pass if approved by a simple majority of the votes cast by, or on behalf of, the shareholders entitled to

vote in person or represented by proxy.

The vote is advisory and therefore its result is not binding on the Company, the Human Resources and Compensation

Committee, or the Board. The Board and the Human Resources and Compensation Committee value the opinions of our

shareholders, and, to the extent there is a significant vote against the NEO compensation policies and practices as

disclosed in this Proxy Statement, we will consider our shareholders' concerns and the Human Resources and

Compensation Committee will evaluate whether any actions are necessary to address those concerns.

With respect to Proposal 2, you may instruct to vote "FOR," or "AGAINST," or "ABSTAIN" from voting on, such proposal. If

you "ABSTAIN" from voting, your vote is not considered a vote cast and will have no effect on such proposal. If you do not

provide your broker or other nominee with instructions on how to vote your shares with respect to Proposal 2, your broker

or nominee will not be entitled to cast votes, and a "broker non-vote" on Proposal 2 will result. Broker non-votes are not

considered votes cast and will have no effect on the vote for this proposal.

---

| | |
|:---|:---|
| ![Image_135.jpg](clvt-20260401_g10.jpg) | **THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" THE APPROVAL, ON A** <br>**NON-BINDING BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS** <br>**DISCLOSED IN THIS PROXY STATEMENT, PURSUANT TO THE COMPENSATION DISCLOSURE** <br>**RULES OF THE SECURITIES AND EXCHANGE COMMISSION.**<br>|

---

**26**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**REPORT OF THE HUMAN RESOURCES AND COMPENSATION** 

**COMMITTEE**

*The following report of the Human Resources and Compensation Committee does not constitute "soliciting material" and* 

*shall not be deemed filed or incorporated by reference into any other filing by Clarivate under the Securities Act of 1933* 

*(the "****Securities Act****") or the Exchange Act.*

The Human Resources and Compensation Committee of the Board has reviewed and discussed with management of the

Company the Compensation Discussion and Analysis of this Proxy Statement.

Based on this review and discussion, the Human Resources and Compensation Committee recommended to the Board

that the Compensation Discussion and Analysis be included in the Annual Report and this Proxy Statement.

Respectfully submitted by the Human Resources and Compensation Committee of the Board:

**Ms. Jane Okun Bomba, Chair**

**Mr. Adam T. Levyn**

**Dr. Wendell Pritchett**

**Dr. Saurabh Saha**

**27**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**COMPENSATION DISCUSSION AND ANALYSIS**

This Compensation Discussion and Analysis ("**CD&A**") details the objectives and elements of our executive compensation

program, describes the related processes of our Human Resources and Compensation Committee ("**HRCC**") in

determining compensation provided to our NEOs, and discusses the compensation that they earned.

**2025 Business Highlights**

During 2025, Clarivate built strong momentum and focus through its Value Creation Plan by delivering in the following

areas:

❖Accelerating innovation by launching new products and features:

---

| | | |
|:---|:---|:---|
| **Academia & Government** | **Intellectual Property** | **Life Sciences & Healthcare** |
| AI-powered research assistants <br>across multiple products, including <br>Web of Science, ProQuest, and <br>Alma<br>| RiskMark, an AI-powered tool for <br>evaluating trademark risk and <br>assisting in argument drafting<br>| Cortellis AI research assistants for <br>Regulatory Intelligence, OFF-X, and <br>Drug Discovery Intelligence<br>|
| Initial release of Web of Science <br>Research Intelligence, an AI-native <br>solution informing funding, <br>collaboration, and impact<br>| AI Classifier and SEP Analyzer, <br>Innography solutions for <br>competitive benchmarking and <br>patent analysis<br>| Enhanced AI-powered search <br>functionality in Cortellis<br>|
| General release of Alma Specto, an <br>AI-native digital collection platform<br>| Derwent Patent Monitor, an AI-<br>powered patent and opposition <br>monitoring tool<br>| DRG MedTech Competitive <br>Intelligence offering<br>|

---

❖Optimizing the Company's business model by transitioning three product groups to a subscription approach in the

A&G segment (ProQuest EBooks and ProQuest Digital Collections) and the LS&H segment (DRG Fusion).

❖Serving new customers and expanding existing relationships with organizations such as the British Library, the

University of Melbourne, CAPES, Nissan, Fujifilm, Winbond, and Sinopec, highlighting our drive for improved growth

and retention achieved by scaling our customer success teams across all segments. Our focus on newly developed

products and features is reflected in a significant number of early adopters.

❖Executing programs to drive internal cost efficiencies.

❖Managing capital allocation strategies to focus on debt reduction and share repurchases to improve shareholder

value.

**2025 Financial Results**

For the year ended December 31, 2025, we generated $2.455 billion of revenues, of which approximately 83% was

recurring revenues generated through our subscription-based model and re-occurring revenue transactions. Organic

annualized contract value ("ACV") accelerated from 0.9% growth in 2024 to 1.8% growth in 2025. Recurring organic

revenue growth was 0.6% in 2025. In each of the past three years, we have also achieved annual renewal rates of

approximately 92%.

**28**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Key Financial Results**

The table below highlights our key financial results as of or for the years ended December 31, 2025 and December 31,

2024, respectively.

---

| | | |
|:---|:---|:---|
| **(in millions, except margin and per share)**  | **2025** | **2024** |
| Revenues  | $2455 | $2557 |
| Net income (loss) | $(201) | $(637) |
| Adjusted net income<sup>(1)</sup> | $468 | $525 |
| Adjusted EBITDA<sup>(1)</sup> | $1002 | $1060 |
| Net loss margin | (8)% | (25)% |
| Adjusted EBITDA margin<sup>(1)</sup> | 41% | 42% |
| Diluted EPS | $(0.30) | $(0.96) |
| Adjusted diluted EPS<sup>(1)</sup> | $0.69 | $0.73 |
| Net cash provided by operating activities  | $629 | $647 |
| Free cash flow<sup>(1)</sup> | $365 | $358 |
| Market capitalization  | $2100 | $3500 |

---

(1)Adjusted net income, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted diluted Earnings Per Share ("Adjusted diluted EPS"), and Free cash

flow are non-GAAP measures. For a description of such terms and a reconciliation of such non-GAAP measures to the most directly comparable

GAAP financial measures, see Appendix A.

**Shareholder Engagement**

Strong engagement with our shareholders is critically important to us, so we design our disclosures to be as open and

transparent as possible in order to facilitate these important discussions, which provide us with valuable input and

feedback. We hold hundreds of meetings with shareholders every year, and in the context of those meetings there is

occasionally discussion of our executive compensation and corporate governance practices, and we consider the input we

receive as we continue to refine our executive compensation program. Our advisory approval of executive compensation

proposal received a 99% approval rate among shareholders who voted on our executive compensation proposal at the

2025 annual general meeting of shareholders. Given this strong support, the HRCC determined that our approach to

compensation should remain relatively consistent in 2026.

**Our Approach to Pay**

**Our Compensation Philosophy**

Our goal is to provide an executive compensation program that reinforces a pay-for-performance culture, serving the

interests of our shareholders while supporting our mission, vision, and values. We believe that attracting and retaining

superior talent and rewarding performance are key to delivering long-term shareholder returns, and that a competitive

compensation program is critical to that end. Therefore, we strive to provide a competitive compensation package to our

executives that is heavily weighted toward performance-based pay elements that align the interests of our executives with

those of Clarivate shareholders.

**29**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Objectives to Support Our Compensation Philosophy**

In order to achieve the goals of our compensation and benefits program, we have adopted the following objectives and

guidelines:

---

| | |
|:---|:---|
| **Compensation Philosophy and Objectives**  | **Compensation Philosophy and Objectives**  |
| **Total Rewards Strategy Supports Our Mission,** <br>**Vision, and Values** <br>| The components of our compensation program encourage our <br>employees to aim for greatness by pursuing top performance and <br>challenging the status quo in the belief that human ingenuity can <br>transform the world and improve our future. <br>|
| **Incentives Aligned to Key Business Objectives**  | We aim to drive superior business and financial results by setting <br>clear, measurable short- and long-term performance targets that <br>support our business strategy and the creation of long-term <br>shareholder value while also ensuring that our executives are not <br>incentivized to take inappropriate risks. <br>|
| **Supports a Pay-for-Performance Culture**  | Total compensation should be competitive and performance should <br>be appropriately rewarded. We believe incentive design should <br>provide for meaningful variability in payouts based on the degree to <br>which performance exceeds or falls short of our goals. <br>|
| **Designed to Attract, Retain, and Motivate Top** <br>**Talent** <br>| Total compensation should be competitive in order to attract qualified <br>individuals, motivate performance, and retain, develop, and reward <br>employees with the abilities and skills needed to foster long-term <br>value creation. <br>|
| **Programs Globally Consistent and Locally** <br>**Competitive** <br>| Total compensation should be globally consistent and locally <br>competitive to attract and retain qualified talent in the markets in <br>which we operate.<br>|

---

**Determination of Executive Compensation**

**The Role of the Human Resources and Compensation Committee**

The HRCC is composed of independent, non-employee members of the Board. Details of the HRCC's authority and

responsibilities are specified in the HRCC's charter, which may be accessed on our website, **ir.clarivate.com**.

With respect to CEO and executive officer compensation, the HRCC:

❖Reviews and approves the corporate goals and objectives as they relate to incentive compensation targets and

payouts at various levels;

❖Evaluates the CEO's performance in light of these goals and objectives;

❖Sets the CEO's compensation based on the evaluation of the CEO's performance either alone or, if directed by the

Board, in conjunction with a, majority of the independent directors on the Board;

❖Reviews and sets the compensation of the executive officers other than the CEO and, if directed by the Board or if the

HRCC otherwise deems it appropriate, makes recommendations to the Board regarding the compensation of the

executive officers other than the CEO;

❖Reviews and makes recommendations to the Board regarding non-employee director compensation;

❖Reviews and approves the Company's CD&A disclosure, as required by SEC rules, and provides a recommendation

to the Board whether to include the CD&A disclosure in the Company's Proxy Statement or Annual Report on Form

10-K;

❖Recommends to the Board whether to approve the frequency (Say-When-on-Pay) with which the Company will

conduct advisory approvals of executive compensation (Say-on-Pay votes), taking into consideration the results of the

most recent shareholder advisory vote on the frequency of Say-on-Pay votes;

❖Administers our Executive Compensation Recoupment Policy and such other compensation recoupment policies that

we have in effect from time to time;

❖Reviews and assesses risks arising from the Company's compensation policies and practices and whether such risks

are reasonably likely to have a material adverse effect on the Company; and

**30**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

❖Oversees human capital management, including in the context of talent management and succession planning.

The HRCC works closely with its independent compensation consultant and senior management to consider a variety of

factors when making compensation decisions throughout the year, including:

❖Experience, responsibilities, and individual and overall Company performance;

❖Internal equity among executives;

❖Executive succession planning;

❖Competitive external market data and trends; and

❖Alignment with shareholders, customers, and other colleagues.

As part of the responsibilities described in its charter, the HRCC sets objective business performance targets and the

amounts payable at different levels of performance under each of our incentive plans. Goal setting is a critical part of the

Company's overall business planning process. As part of this process, a range of performance scenarios is developed.

Goals are then set at the threshold, target, and maximum performance levels — driven by the strategic and operational

plans as presented by management and approved by the Board. The HRCC also considers the probability of achievement

of different levels of performance when setting goals.

**The Role of the Independent Compensation Consultant**

In 2025, the HRCC engaged Pay Governance as its independent compensation consultant to advise on executive

compensation matters. Pay Governance specializes in executive compensation and related governance matters. To

ensure the HRCC receives independent and unbiased advice and analysis, the compensation consultant is prohibited

from providing any services to management, although the compensation consultant interacts with management from time

to time in order to best coordinate with and deliver services to the HRCC. The HRCC has sole authority with regard to the

decision to retain and terminate the services of the compensation consultant and to approve the compensation

consultant's fees and other retention terms. The compensation consultant maintains active engagement with the HRCC

Chair and reports to the HRCC. The HRCC annually reviews the independence of the compensation consultant's work

under rules adopted by the SEC and NYSE and has found no conflicts.

In 2025, the independent compensation consultant performed duties requested by the HRCC including:

❖Providing analysis and recommendations on the composition of the peer group;

❖Analyzing executive and director compensation in comparison to the peer group;

❖Advising the HRCC on increasing the available share reserve under the Company's incentive award plan;

❖Advising the HRCC on executive severance policies;

❖Updating the HRCC on executive compensation and governance market trends;

❖Advising the HRCC on annual incentive and long-term equity plan designs;

❖Preparing a risk review relative to compensation policies and practices; and

❖Reviewing disclosures related to executive compensation.

Pay Governance speaks with the chair of the HRCC, as well as with management, in preparing for HRCC meetings,

regularly attends HRCC meetings, and meets from time to time in executive sessions with the HRCC without the presence

of management.

**The Role of Management**

At the HRCC's request, management provides information, analyses, and recommendations regarding our executive

compensation program, as well as information regarding our achievement of performance metrics. Our CEO discusses

with the HRCC his views on the performance and compensation of the other NEOs and CEO direct reports.

**31**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**The Use of Peer Group Benchmarking and Market Data**

**Peer Group Benchmarking**

The HRCC considers several factors in structuring our executive compensation program, determining pay components,

and making compensation decisions. This includes an annual review and comparison of the compensation practices of

select peer companies in our industry. These companies were chosen with guidance from our independent compensation

consultant to be effective for 2025. It was the HRCC's intent to select companies that operate significant lines of business

similar to Clarivate's and are similar in size, and therefore compete with Clarivate for executive talent.

We established a peer group for benchmarking executive pay based on the following guiding principles:

❖Companies engaged in intelligence development, data analytics, digital delivery, cybersecurity, and intellectual

property protections;

❖Revenues between $800 million to $8.0 billion;

❖Market capitalization between $1.4 billion to $28.0 billion;

❖Business/talent competitors of Clarivate;

❖A group of 10 to 25 companies so that results are statistically reliable and the peer group is sustainable over time; and

❖Availability of sufficient pay data for companies identified as potential peers.

Based on this analysis, the following 17 companies were selected as our primary peer group for compensation

benchmarking in 2025 (the "**Peer Group**"). Changes from our prior year's peer group include removing Moody's

Corporation, MSCI Inc., and Thomson Reuters Corporation due to their market capitalization being outside our financial

scope noted above and adding ACI Worldwide, Inc.; Envestnet, Inc.; and Jack Henry & Associates, Inc. based on our

industry and financial scope noted above.

---

| | |
|:---|:---|
| **Clarivate 2025 Peer Group for Compensation Benchmarking Purposes**  | **Clarivate 2025 Peer Group for Compensation Benchmarking Purposes**  |
| ❖ACI Worldwide, Inc. (ACIW) | ❖Informa plc (INF)  |
| ❖Dun & Bradstreet Holdings, Inc. (DNB)  | ❖Jack Henry & Associates, Inc. (JKHY) |
| ❖Equifax, Inc. (EFX)  | ❖Morningstar, Inc. (MORN)  |
| ❖Envestnet, Inc. (ENV)  | ❖SS&C Technologies Holdings, Inc. (SSNC)  |
| ❖ExlService Holdings, Inc. (EXLS)  | ❖Teradata Corporation (TDC)  |
| ❖FactSet Research Systems Inc. (FDS)  | ❖TransUnion (TRU)  |
| ❖Fair Isaac Corporation (FICO)  | ❖Verisk Analytics, Inc. (VRSK)  |
| ❖Gartner, Inc. (IT)  | ❖Wolters Kluwer N.V. (WKL)  |
| ❖ICON plc (ICLR)  |  |

---

**Use of Market Comparison Data**

The HRCC approves the salary, Annual Incentive Plan ("**AIP**") targets, and Long-Term Incentive Plan ("**LTI**") equity

compensation of the NEOs at levels that are competitive with compensation paid to persons holding the same or similar

positions at members of the Peer Group using available market comparison data regarding these companies as a guide.

In addition to Peer Group market data, the HRCC also considered Willis Towers Watson compensation survey data from

similar industries and geographies in its competitive analysis of NEO compensation. The use of market comparison data,

however, is just one of the tools the HRCC uses to determine executive compensation, and the HRCC retains the

flexibility to establish target compensation at levels it deems appropriate for an individual or for a specific element of

compensation based on performance, experience, and breadth of responsibilities.

**32**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Good Governance Practices**

We are committed to having policies in place to ensure effective oversight of our executive compensation program and

strong corporate governance.

---

| | | | |
|:---|:---|:---|:---|
| **WHAT WE DO**  | **WHAT WE DO**  | **WHAT WE DON'T DO**  | **WHAT WE DON'T DO**  |
| ![Image_193.jpg](clvt-20260401_g13.jpg) | The HRCC is fully composed of independent directors | ![Image_194.jpg](clvt-20260401_g14.jpg) | We do not permit our employees to engage in <br>hedging transactions<br>|
| ![Image_195.jpg](clvt-20260401_g13.jpg) | The HRCC engages an independent compensation <br>consultant<br>| ![Image_196.jpg](clvt-20260401_g14.jpg) | We do not permit our employees to pledge Company <br>securities to secure margin or other loans<br>|
| ![Image_197.jpg](clvt-20260401_g13.jpg) | We have adopted share ownership guidelines for our <br>executive officers and Board of Directors<br>| ![Image_198.jpg](clvt-20260401_g14.jpg) | We do not reprice underwater stock options |
| ![Image_199.jpg](clvt-20260401_g13.jpg) | The majority of NEO pay is at risk and dependent <br>upon performance<br>| ![Image_200.jpg](clvt-20260401_g14.jpg) | We do not provide excise tax gross-up payments |
| ![Image_201.jpg](clvt-20260401_g13.jpg) | The mix of executive officer equity awards includes a <br>performance-based element<br>| ![Image_202.jpg](clvt-20260401_g14.jpg) | We do not have an evergreen provision that <br>automatically adds shares to our equity incentive plan<br>|
| ![Image_203.jpg](clvt-20260401_g13.jpg) | We engage with our shareholders to discuss <br>executive compensation and corporate governance <br>matters<br>| ![Image_204.jpg](clvt-20260401_g14.jpg) | We do not provide excessive perquisites |
| ![Image_205.jpg](clvt-20260401_g13.jpg) | We maintain clawback policies that require covered <br>executives to reimburse performance-based <br>compensation in specified circumstances<br>| ![Image_206.jpg](clvt-20260401_g14.jpg) | We do not grant single-trigger equity awards |

---

**Elements of Compensation at a Glance — Mix of Fixed and Variable** 

**Performance-Based Compensation**

We design our executive compensation programs to create a performance-based culture that rewards employees for

collective performance and demonstration of our values and to align our employees' interests with those of our public

shareholders.

Our executive compensation program is tailored to our strategic priorities and current business outlook, while also

designed to motivate and retain our senior management team. Multiple components, described below, are utilized to

achieve these objectives, with a heavy emphasis on pay that is variable or at risk depending directly on performance

against strategic corporate metrics.

---

| | | | |
|:---|:---|:---|:---|
| | **Pay Element**  | **Payment Form**  | **Alignment to Business Objectives**  |
| Fixed  | Base Salary  | Cash  | ❖Benchmarks base salaries to ensure market <br>competitiveness in the attraction and retention of key <br>talent<br>❖Provides a competitive fixed rate of pay relative to similar <br>positions in the market <br>|
| Fixed  | Retirement, Health, <br>and Welfare Benefits <br>| Benefits  | ❖Market-aligned programs to facilitate strong productivity <br>and provide support in times of personal need<br>❖Health, welfare, and retirement programs<br>❖Limited perquisites <br>|
| At-Risk / Variable  | Annual Incentive Plan  | Cash  | ❖Rewards performance for achievement of rigorous and <br>challenging short-term performance goals aligned with the <br>Company's annual operating plan<br>❖Motivates executives to deliver on individual objectives <br>supportive of broader business objectives<br>|
| At-Risk / Variable  | Long-Term Incentive <br>Program <br>| PSUs and RSUs  | ❖Rewards performance for achievement of rigorous long-<br>term performance goals aligned with the interests of <br>shareholders and the Company's strategy<br>❖Supports retention and mitigates excessive risk taking<br>|

---

**33**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Alignment of Pay to Business Objectives**

With regard to our variable/at-risk pay, we use multiple metrics to incentivize behavior that supports the achievement of

our corporate goals.

For our AIP, the metrics selected in 2025 to best support our short-term objectives included corporate-level Revenue,

Adjusted EBITDA, Free Cash Flow, and Voice of Customer metrics. For our segment presidents, AIP metrics also included

segment-level revenue and Adjusted EBITDA goals and an individual performance component.

Our LTI program includes performance-based restricted share units ("**PSUs**") that apply longer-term metrics including, for

our 2025 PSU grants, Recurring Organic Revenue Growth, Adjusted diluted EPS, and Adjusted EBITDA, and for our 2024

and 2023 PSU grants, Adjusted diluted EPS and Adjusted EBITDA, with, for all years, a total shareholder return ("**TSR**")

modifier comparing our stock price performance to the S&P 500 over a cumulative three-year period.

**Compensation for Our Named Executive Officers**

For 2025, our NEOs were as follows:

---

| | |
|:---|:---|
| **Name**  | **Title**  |
| Matti Shem Tov  | Chief Executive Officer  |
| Jonathan Collins  | Executive Vice President and Chief Financial Officer  |
| Bar Veinstein  | President, Academia and Government  |
| Henry Levy  | President, Life Sciences and Healthcare  |
| Maroun Mourad | President, Intellectual Property |
| Gordon Samson<sup>(1)</sup>  | Former President, Intellectual Property  |
| Melanie Margolin<sup>(2)</sup> | Former Executive Vice President and Chief Administrative and Legal Officer |

---

(1)Mr. Samson departed the Company on December 31, 2025, with his last day as President, Intellectual Property on September 7, 2025. His

departure was without cause.

(2)Ms. Margolin departed the Company on March 21, 2025, with her last day as Executive Vice President and Chief Administrative and Legal Officer

on February 28, 2025. Her departure was without cause.

**Compensation Mix — Performance-Based/At-Risk Compensation**

The graphics below show the total target compensation mix of our current CEO (Matti Shem Tov) and our other current

NEOs, excluding Gordon Samson and Melanie Margolin. These illustrate that a majority of the NEO's total target

compensation is at risk, with 88% for our CEO and an average of 82% for our other current NEOs. For purposes of these

estimates, total compensation is composed of base salary, AIP target, and RSU/PSU grant value. AIP and equity grants

are both considered at-risk pay.

![CEO pay mix.jpg](clvt-20260401_g15.jpg)

![NEO pay mix.jpg](clvt-20260401_g16.jpg)

(1)Other NEOs include Messrs. Collins, Veinstein, Levy, and Mourad.

**Base Salary**

Base salary represents annual fixed compensation and is a standard element of compensation necessary to attract and

retain executive leadership talent. In making base salary decisions for our NEOs other than the CEO, the HRCC considers

the CEO's recommendations, as well as each NEO's position and level of responsibility within the Company. The HRCC

also takes into account factors such as relevant market data, overall Company performance, individual performance and

contributions, relevant experience, and internal equity within the Company.

**34**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

During 2025, the HRCC determined the appropriate annual base salary rate for each NEO as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Name**  | **2025 Base Salary**  | **2024 Base Salary**  | **% Increase**  |
| Matti Shem Tov<sup>(1)</sup> | $900000 | $900000 | 0% |
| Jonathan Collins  | $750000 | $750000 | 0% |
| Bar Veinstein<sup>(1)</sup> | $600000 | $600000 | 0% |
| Henry Levy  | $600000 | $600000 | 0% |
| Maroun Mourad<sup>(2)</sup> | $600000 | N/A | N/A |
| Gordon Samson<sup>(1)(3)</sup> | $600000 | $600000 | 0% |
| Melanie Margolin<sup>(4)</sup> | $625000 | $625000 | 0% |

---

(1)Mr. Shem Tov is based in Israel. His 2025 and 2024 salary amounts have been converted to Israeli new shekels (ILS) for purposes of 2025 and

2024 payments using an ILS:USD exchange rate of 1:0.260 on his hire date. Mr. Veinstein is also based in Israel, and his 2025 and 2024 salary

amounts have been converted to ILS using an ILS:USD exchange rate of 1:0.273 on his hire date. Mr. Samson is based in Jersey, and his 2025

and 2024 salary amounts have been converted to pounds sterling (GBP) using a GBP:USD exchange rate of 1:1.234, which we used for 2025 and

2024 budget planning.

(2)Mr. Mourad joined the Company on September 8, 2025 as President of our Intellectual Property segment.

(3)Mr. Samson left his executive officer position on September 7, 2025 and departed the Company on December 31, 2025.

(4)Ms. Margolin left her executive officer position on February 28, 2025 and departed the Company on March 21, 2025.

**2025 Annual Incentive Plan**

Our AIP provides the opportunity for annual cash incentives to be made to approximately 85% of our employees. Our AIP

is tied primarily to pre-established corporate-level goals for Revenue, Adjusted EBITDA and Free Cash Flow. In addition,

in 2025, we set pre-established segment-level Revenue and Adjusted EBITDA goals for each of our three segments,

which, for the NEOs, applied based on the NEO's scope of responsibility within that segment (as applicable). The ultimate

payout under the AIP is determined based on a company funding pool based on consolidated pre-bonus Adjusted EBITDA

and Voice of Customer achievement, along with application of an individual performance modifier, as follows:

❖In 2025, the performance metrics applicable to Mr. Shem Tov, Mr. Collins and Ms. Margolin were based entirely on the

corporate-level goal set.

❖The performance metrics applicable to Mr. Veinstein were based on both the corporate-level goals and the A&G

segment goal set.

❖The performance metrics applicable to Mr. Levy were based on both the corporate-level goals and the LS&H segment

goal set.

❖The performance metrics applicable to Mr. Mourad were based on both the corporate-level goals and the IP segment

goal set.

❖For each of Messrs. Veinstein, Levy, and Mourad, the corporate-level goals and segment-level goals each comprised

50% of the NEO's AIP opportunity for 2025 (prior to application of the company funding pool and individual modifier).

❖Mr. Samson was ineligible to receive a 2025 AIP payout.

Each NEO has a target AIP award, which is defined as a percentage of the respective NEO's eligible base pay. The table

below provides AIP target opportunities for 2025, which reflect no changes from 2024.

---

| | |
|:---|:---|
| **Name**  | **2025 AIP Target**  |
| Matti Shem Tov | 100% |
| Jonathan Collins  | 100% |
| Bar Veinstein  | 100% |
| Henry Levy  | 100% |
| Maroun Mourad<sup>(1)</sup> | 100% |
| Gordon Samson<sup>(2)</sup>  | N/A |
| Melanie Margolin<sup>(3)</sup> | 100% |

---

(1)Mr. Mourad's 2025 AIP payment was prorated based on his date of hire.

(2)Mr. Samson departed the Company on December 31, 2025 and, pursuant to the terms of his separation agreement, was ineligible to receive a 2025

AIP payment.

**35**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

(3)Ms. Margolin departed the Company on March 21, 2025 and, pursuant to the terms of her separation agreement, was eligible for a pro rata

payment of her 2025 AIP payment assuming target performance.

**AIP Goals**

AIP bonus payouts for 2025 were determined first by measuring the achievement of the applicable corporate- and

segment-level goals described above. Then, an overall company funding pool is determined based on a combination of

consolidated pre-bonus Adjusted EBITDA performance (i.e., as determined prior to the determination of AIP payouts) and

Voice of Customer achievement, which can increase or decrease the achievement level resulting from the corporate- and

segment-level metric performance. Lastly, an individual modifier is applied, which can increase or decrease an individual's

ultimate payout.

The tables below show the weighting of each of the metrics described above and the threshold, target, and maximum

payout levels. The consolidated pre-bonus Adjusted EBITDA metrics comprise 90% of the company funding pool and the

Voice of Customer metric comprises the remaining 10% of the funding pool, with the total AIP bonus subject to adjustment

based on individual performance. Pre-bonus Adjusted EBITDA performance can be achieved between 0% and 200% of

target, while Voice of Customer performance can be achieved between 90% and 110% of target. The individual

performance modifier can be used to increase or decrease an individual's final AIP payment based on that individual's

personal performance, as determined by the HRCC, provided that the maximum payment cannot exceed 200% of the AIP

target.

---

| | | | |
|:---|:---|:---|:---|
| **2025 AIP FUNDING GOALS** | **2025 AIP FUNDING GOALS** | **2025 AIP FUNDING GOALS** | **2025 AIP FUNDING GOALS** |
| **Metric** | **Weighting** | **Payout Level** | **Goal (millions, except** <br>**Voice of Customer)**<br>|
| Pre-bonus Adjusted EBITDA | 90% | Threshold 0% | $945 |
| Pre-bonus Adjusted EBITDA | 90% | Target 100% | $1050 |
| Pre-bonus Adjusted EBITDA | 90% | Maximum 200% | $1154 |
| Voice of Customer<sup>(1)</sup> | 10% | Threshold 90% | <42 |
| Voice of Customer<sup>(1)</sup> | 10% | Target 100% | 42 |
| Voice of Customer<sup>(1)</sup> | 10% | Maximum 110% | >42 |

---

(1)The Voice of Customer metric is based on the results of surveys sent to all of our customers. Voice of Customer can directly impact our revenues

and represents a key component of our success measurements. The Voice of Customer metric represents an industry-renowned standard and

methodology that measures customer loyalty through Net Promoter Score. Voice of Customer achievement can result in achievement between 90%

and 110% of target, depending on the Net Promoter Score.

---

| | | | |
|:---|:---|:---|:---|
| **2025 CORPORATE AIP GOALS** | **2025 CORPORATE AIP GOALS** | **2025 CORPORATE AIP GOALS** | **2025 CORPORATE AIP GOALS** |
| **Metric** | **Weighting** | **Payout Level** | **Goal (millions)** |
| Revenue | 40% | Threshold 0% | $2256 |
| Revenue | 40% | Target 100% | $2340 |
| Revenue | 40% | Maximum 150% | $2400 |
| Adjusted EBITDA | 40% | Threshold 0% | $935 |
| Adjusted EBITDA | 40% | Target 100% | $970 |
| Adjusted EBITDA | 40% | Maximum 150% | $995 |
| Free Cash Flow | 20% | Threshold 0% | $298 |
| Free Cash Flow | 20% | Target 100% | $340 |
| Free Cash Flow | 20% | Maximum 150% | $370 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **2025 A&G AIP GOALS** | **2025 A&G AIP GOALS** | **2025 A&G AIP GOALS** | **2025 A&G AIP GOALS** |  |  |  |  |
| **Metric** | **Weighting** | **Payout Level** | **Goal (millions)** |  |  |  |  |
| 2025 Corporate AIP Goals | 50% | (See above) | (See above) |  |  |  |  |
| 2025 Corporate AIP Goals | 50% | (See above) | (See above) | Segment Revenue | 25% | Threshold 0% | $1141 |
| Target 100% | $1183 | Segment Revenue | 25% |  |  |  |  |
| Maximum 150% | $1213 | Segment Revenue | 25% |  |  |  |  |
| Segment Adjusted EBITDA | 25% | Threshold 0% | $519 |  |  |  |  |
| Segment Adjusted EBITDA | 25% | Target 100% | $537 |  |  |  |  |
| Segment Adjusted EBITDA | 25% | Maximum 150% | $550 |  |  |  |  |

---

**36**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **2025 LS&H AIP GOALS** | **2025 LS&H AIP GOALS** | **2025 LS&H AIP GOALS** | **2025 LS&H AIP GOALS** |  |  |  |  |
| **Metric** | **Weighting** | **Payout Level** | **Goal (millions)** |  |  |  |  |
| 2025 Corporate AIP Goals | 50% | (See above) | (See above) |  |  |  |  |
| 2025 Corporate AIP Goals | 50% | (See above) | (See above) | Segment Revenue | 25% | Threshold 0% | $378 |
| Target 100% | $392 | Segment Revenue | 25% |  |  |  |  |
| Maximum 150% | $401 | Segment Revenue | 25% |  |  |  |  |
| Segment Adjusted EBITDA | 25% | Threshold 0% | $115 |  |  |  |  |
| Segment Adjusted EBITDA | 25% | Target 100% | $121 |  |  |  |  |
| Segment Adjusted EBITDA | 25% | Maximum 150% | $124 |  |  |  |  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **2025 IP AIP GOALS** | **2025 IP AIP GOALS** | **2025 IP AIP GOALS** | **2025 IP AIP GOALS** |  |  |  |  |
| **Metric** | **Weighting** | **Payout Level** | **Goal (millions)** |  |  |  |  |
| 2025 Corporate AIP Goals | 50% | (See above) | (See above) |  |  |  |  |
| 2025 Corporate AIP Goals | 50% | (See above) | (See above) | Segment Revenue | 25% | Threshold 0% | $762 |
| Target 100% | $790 | Segment Revenue | 25% |  |  |  |  |
| Maximum 150% | $810 | Segment Revenue | 25% |  |  |  |  |
| Segment Adjusted EBITDA | 25% | Threshold 0% | $321 |  |  |  |  |
| Segment Adjusted EBITDA | 25% | Target 100% | $333 |  |  |  |  |
| Segment Adjusted EBITDA | 25% | Maximum 150% | $341 |  |  |  |  |

---

**Achievement of AIP Goals**

❖***Pre-bonus Adjusted EBITDA.*** Based on results for 2025, the company pool funding was modified over the metric

attainment, as show in the pool funding adjustments column in the table below.

❖***Voice of Customer.*** Based on the Net Promoter Score results for 2025, we determined Voice of Customer was

achieved at 110% of target.

❖***Corporate.*** Based on results for 2025, the weighted average attainment across the corporate metrics was 105%.

❖***A&G Segment.*** Based on results for 2025, the weighted average attainment across the A&G segment metrics was

99%.

❖***LS&H Segment.*** Based on results for 2025, the weighted average attainment across the LS&H segment metrics was

96%.

❖***IP Segment.*** Based on results for 2025, the weighted average attainment across the IP segment metrics was 48%.

❖***Final AIP Payments.*** For the NEOs (other than Mr. Samson and Ms. Margolin), the HRCC determined payouts to our

NEOs under the AIP based on results discussed above, which are reflected in the table below. No discretion and no

individual performance modifiers were applied with respect to any NEO's payout under the AIP.

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **AIP Target** <br>**($)**<br>| **Corporate** <br>**Goal** <br>**Weighting**<br>| **Corporate** <br>**Goal** <br>**Performance**<br>| **Corporate** <br>**Performance** <br>**Amount** <br>**Earned**<br>**($)**<br>| **Segment** <br>**Goal** <br>**Weighting**<br>| **Segment** <br>**Goal** <br>**Performance**<br>| **Segment** <br>**Performance** <br>**Amount** <br>**Earned**<br>**($)**<br>| **Voice of** <br>**Customer** <br>**Weighting**<br>| **Voice of** <br>**Customer** <br>**Performance**<br>| **Voice of** <br>**Customer** <br>**Amount** <br>**Earned**<br>**($)**<br>| **Pool Funding** <br>**Adjustments**<sup>(3)</sup><br>**($)**<br>| **Final AIP** <br>**Payment**<br>**($)**<br>| **Final AIP** <br>**% of** <br>**Target**<br>|
| Matti Shem Tov<sup>(1)</sup> | 900000 | 90% | 105% | 850500 | N/A | N/A | N/A | 10% | 110% | 99000 | (31500) | 918000 | 102% |
| Jonathan Collins | 750000 | 90% | 105% | 708750 | N/A | N/A | N/A | 10% | 110% | 82500 | (26250) | 765000 | 102% |
| Bar Veinstein<sup>(1)</sup> | 600000 | 45% | 105% | 283500 | 45% | 99% | 267300 | 10% | 110% | 66000 | 37200 | 654000 | 109% |
| Henry Levy | 600000 | 45% | 105% | 283500 | 45% | 96% | 259200 | 10% | 110% | 66000 | 39300 | 648000 | 108% |
| Maroun Mourad<sup>(2)</sup> | 189041 | 45% | 105% | 89322 | 45% | 48% | 40833 | 10% | 110% | 20795 | 9735 | 160685 | 85% |

---

(1)Mr. Shem Tov is based in Israel and his payment has been converted to USD using an ILS:USD exchange rate of 0.260. Mr. Veinstein is based in

Israel and his payment has been converted to USD using an ILS:USD exchange rate of 0.273.

(2)Mr. Mourad joined the Company on September 8, 2025 and was eligible for a pro rata payment of AIP based on the duration of his employment with

us during 2025. The AIP Target reported in this table reflects such prorated amount.

(3)Pool funding adjustments represent a combination of additional payout pool funding due to pre-bonus Adjusted EBITDA performance and allocation

across the four goal sets due to disposal wind-down performance and the impact of foreign currency exchange.

**37**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**2025 Long-Term Incentive Program**

**Amended and Restated 2019 Incentive Award Plan Grant Practices**

Annual LTI awards to NEOs are typically granted in the first quarter of the year, although LTI awards may also be granted

to NEOs as part of the hiring process, in connection with a promotion or change in responsibility, or in response to

extraordinary circumstances. The HRCC approves the type and number of awards to be granted and the performance

criteria for awards. For all such grants, the grant date is no earlier than the date of HRCC approval. Awards are not spring-

loaded or otherwise timed to take advantage of material nonpublic information, and the Company does not manipulate the

timing of the public release of information to increase the value of an award.

The HRCC has delegated to the CEO and the SVP, Head of People the authority to grant equity awards, including annual

LTI awards, to eligible employees (other than the CEO, the SVP, Head of People, and persons subject to Section 16 of the

Exchange Act), provided the total awards remain within specified limits and subject to terms and conditions approved by

the HRCC. In addition, on a quarterly basis, the HRCC reviews the shares granted from this award budget.

**Equity Programs**

We consider share ownership a key component in our compensation programs because it aligns the goals of our

employees with those of our shareholders. Through the LTI program, our most senior leaders are eligible for annual equity

awards under the Clarivate Amended and Restated 2019 Incentive Award Plan. Our key equity programs include LTI for

NEOs and senior management, which consists of PSUs and RSUs.

As discussed above, PSUs are granted to our most senior leaders, thereby placing a larger percentage of their

compensation "at risk."

The following is the mix of performance and time-based equity awarded through our annual LTI program. See footnotes to

the "2025 NEO Equity Awards" table below for a description of equity granted outside of the annual equity cycle.

---

| | | |
|:---|:---|:---|
| **Ratio of Performance to Time-Based Equity**  | **Ratio of Performance to Time-Based Equity**  | **Ratio of Performance to Time-Based Equity**  |
| **Position**  | **PSUs**  | **RSUs**  |
| CEO | 50% | 50% |
| Other NEOs  | 50% | 50% |

---

RSUs vest ratably over three years, with one-third of the award vesting on each of the first three anniversaries of the grant

date. PSUs cliff vest at the end of a three-year period, subject to achievement of performance measures and continued

employment. The 2023, 2024, and 2025 PSU awards have one three-year measurement period, with performance

achievement adjusted in accordance with our three-year relative TSR modifier.

**PSU Grants**

**2023-2025 Performance.** The table below contains the performance metrics relative to the three-year measurement

period of the 2023 awards and the TSR modifier that increases or decreases the final payout by as much as 20%, as

illustrated below. The overall payout of the PSUs was capped at 200% of the target shares granted.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **2023 PSU — 2023-2025 Measurement Period Metrics**  | **2023 PSU — 2023-2025 Measurement Period Metrics**  | **2023 PSU — 2023-2025 Measurement Period Metrics**  | **2023 PSU — 2023-2025 Measurement Period Metrics**  | **2023 PSU — 2023-2025 Measurement Period Metrics**  | **2023 PSU — 2023-2025 Measurement Period Metrics**  |
| **Adjusted diluted EPS and Adjusted EBITDA**  | **Adjusted diluted EPS and Adjusted EBITDA**  | **Adjusted diluted EPS and Adjusted EBITDA**  | **Adjusted diluted EPS and Adjusted EBITDA**  | **Modifier: 3-Year Relative** <br>**TSR vs. S&P 500** | **Modifier: 3-Year Relative** <br>**TSR vs. S&P 500** |
| **2023-2025 Goals**  | **2023-2025 Goals**  | **2023-2025 Goals**  | **2023-2025 Goals**  | **Modifier: 3-Year Relative** <br>**TSR vs. S&P 500** | **Modifier: 3-Year Relative** <br>**TSR vs. S&P 500** |
| **Performance Range**  | **Payout** <br>**Range** <br>| **Adjusted**<br>**diluted EPS** <br>**(50%)** <br>| **Adjusted**<br>**EBITDA ($m)**<br>**(50%)** <br>| **Percentile**  | **Modifier**  |
| Maximum  | 200% | $2.72 | $3653 | =>P75 | 1.4x |
| Target  | 100% | $2.59 | $3564 | P50 | 1.0x |
| Threshold  | 50% | $2.46 | $3474 | <=P25 | 0.8x |

---

The HRCC approved adjustments to both our Adjusted diluted EPS and Adjusted EBITDA results for the 2023 – 2025

period to reflect divestitures and disposals that occurred during the performance period, as contemplated by the plan.

Based on 2023-2025 financial results after these adjustments, actual performance versus the performance goals was

40.625% of target relative to the 2023 awards. Our three-year TSR performance (2023 – 2025) was less than the 25th

percentile of the S&P 500 and therefore modifies the overall performance achievement by 0.8x, resulting in a final

performance achievement at 32.5% of target for the 2023 awards.

**38**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

The table below provides details of the RSUs and PSUs granted to our NEOs in 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **2025 NEO Equity Awards**  | **2025 NEO Equity Awards**  | **2025 NEO Equity Awards**  | **2025 NEO Equity Awards**  | **2025 NEO Equity Awards**  |
| | **RSUs**  | **RSUs**  | **PSUs**<sup>(1)</sup> | **PSUs**<sup>(1)</sup> |
| <br>**NEO**  | **Units**<br>**(#)**  | **Grant Value** <br>**($)**  | **Target Units** <br>**(#)**  | **Grant Value** <br>**($)**  |
| Matti Shem Tov | 726392 | 2999999 | 726392 | 3399515 |
| Jonathan Collins  | 302663 | 1249998 | 302663 | 1416463 |
| Bar Veinstein  | 242130 | 999997 | 242130 | 1133168 |
| Henry Levy  | 242130 | 999997 | 242130 | 1133168 |
| Maroun Mourad<sup>(2)</sup> | 539568 | 2249999 |  |  |
| Gordon Samson<sup>(3)</sup>  | 242130 | 999997 | 242130 | 1133168 |
| Melanie Margolin<sup>(4)</sup> |  |  |  |  |

---

(1)The PSU grants represent all of the PSUs granted in 2025 (i.e., the PSUs with respect to the 2025 – 2027 measurement period). See footnote to the

2025 Summary Compensation Table for more information.

(2)The grant to Mr. Mourad was made in September 2025 in connection with his commencement of employment. The RSUs will vest ratably over three

years on each of the first three anniversaries of the grant date, subject to continued employment through the vest dates.

(3)In accordance with the terms of his separation agreement, Mr. Samson forfeited all of his 2025 PSU grant and the last tranche (i.e., one-third) of his

2025 RSU grant.

(4)In accordance with the terms of her separation agreement, Ms. Margolin was not entitled to receive equity awards in 2025.

**Retirement, Health, and Welfare Benefits**

We sponsor a qualified defined contribution plan for all U.S. employees, including our U.S.-based NEOs. In addition, we

sponsor a qualified defined contribution plan for U.K. employees, including our U.K.-based NEOs. Other than the qualified

plans described above, we do not provide any other pension plan, supplemental retirement plan, or deferred

compensation plan to our NEOs. We do provide company matches to employee contributions to qualified retirement

plans, and these are reported as All Other Compensation in the 2025 Summary Compensation Table.

We also provide NEOs with life and medical insurance and other benefits generally available to all employees. The only

perquisite we provide our NEOs is reimbursement for an annual executive physical, not to exceed $5,000 in any given

year. We do not provide a gross-up on taxes paid by NEOs in connection with such reimbursement.

**Share Ownership Guidelines**

We have adopted the following share ownership guidelines for our non-employee compensated directors, CEO, executive

officers, and executive leadership team. As of January 1, 2026, all have met or are on track to achieve their applicable

guideline by the end of the 5-year compliance period.

---

| | |
|:---|:---|
| **Position**  | **Share Ownership Guidelines**  |
| Chief Executive Officer  | 6 times base salary  |
| Other Executive Officers and Executive Leadership Team  | 3 times base salary  |
| Non-employee compensated directors  | 5 times annual retainer |

---

---

| | | |
|:---|:---|:---|
| **What counts as ownership**  | **What does not count as ownership**  | **What does not count as ownership**  |
| ✔Shares beneficially owned directly | ![Image_194.jpg](clvt-20260401_g14.jpg) | Unvested and unearned PSUs  |
| ✔Shares beneficially owned indirectly via a trust, other <br>entities, or estate planning vehicles <br>| ![Image_194.jpg](clvt-20260401_g14.jpg) | Unexercised stock options  |
| ✔Shares held in a 401(k) or other retirement account  |  |  |
| ✔Shares held by or jointly with spouse or dependent <br>children <br>|  |  |
| ✔Unvested RSUs |  |  |

---

**39**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Insider Trading Policy**

We have adopted an insider trading policy which governs the purchase, sale, and/or other dispositions of our securities by

directors, officers, employees, and other covered persons that we believe is reasonably designed to promote compliance

with insider trading laws, rules and regulations, and NYSE listing standards. A copy of our insider trading policy is filed as

Exhibit 19.1 to the Annual Report.

Our insider trading policy prohibits officers, directors, employees, and consultants of the Company from trading while in

possession of material, nonpublic information about the Company. We impose quarterly trading blackouts applicable to

certain designated employees who may have access to inside information prior to the release of earnings, and we require

all executive officers and other designated insider employees to pre-clear any transactions with the Company before

trading in the Company's shares.

**No Hedging Policy**

Certain forms of hedging or monetization transactions allow an individual to lock in much of the value of their ordinary

shares, often in exchange for all or part of the potential for upside appreciation in the ordinary shares. These transactions

allow the continued ownership of the covered securities but without the full risks and rewards of ownership. When that

occurs, the individual entering into the transaction may no longer have the same objectives as the Company's other

shareholders.

Our insider trading policy prohibits directors, executive officers, employees, and consultants from entering into certain

forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts.

**No Pledging Policy**

We have a policy that prohibits our directors, executive officers, employees, and consultants from pledging the Company's

securities as collateral to secure loans or otherwise. This includes a prohibition on holding the Company's securities in a

margin account, which would allow the director or executive officer to borrow against their holdings to buy securities.

**Risk Assessment and Mitigation of Compensation Policies and Practices**

The Board of Directors is responsible for the oversight of the Company's ongoing assessment and management of

material risks impacting our business. The HRCC oversees compensation risk management by participating in the

creation and approval of compensation elements, programs, and performance metrics that encourage an appropriate level

of risk taking consistent with our business strategy.

The HRCC has reviewed our incentive compensation program, taken into account the concept of risk as it relates to our

compensation program, considered various mitigating factors, and reviewed each of these items with its independent

compensation consultant. In addition, Pay Governance conducted an independent risk assessment of our executive

compensation program and determined that our compensation program does not create risks that are reasonably likely to

have a material adverse effect on our business. Based on these reviews and discussions, among other factors considered

by the HRCC, the HRCC believes that our compensation program is structured to minimize the risk of material adverse

effects on our business.

We established short-term and long-term incentive plans that include a mix of performance metrics that align with our

overall corporate goals and strategy and do not encourage excessive risk taking in order to meet one particular goal. As

noted above in "Good Governance Practices," we have share ownership guidelines and prohibitions against hedging and

pledging of our securities.

**Clawback Policies**

We maintain an executive compensation recoupment policy intended to comply with the requirements of Section 10D of

the Exchange Act and the rules of the NYSE, under which the HRCC must recover certain excess incentive-based

compensation paid to executive officers in the event of a restatement of our financial statements due to our material

noncompliance with any financial reporting required under U.S. federal securities laws.

In addition, we have adopted a detrimental conduct compensation recoupment policy under which the HRCC may recover

compensation, including time-based equity awards, from (i) any current or former CEO of the Company, (ii) any individual

who, at any time, was designated as an "officer" of the Company as defined under Rule 16a-1(f), and (iii) any current or

former employee of the Company who at any time during his or her employment was a member of our Executive

**40**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

Leadership Team. The potential recovery period is the three-year period preceding the date of certain detrimental conduct,

including conduct such as willful acts that injure the reputation, business, or any business relationship of the Company,

indictment or conviction of a crime, violations of any non-compete, non-solicitation, or confidentiality covenant, and

violations of any material Company policies. A copy of our executive compensation recoupment policy is filed as Exhibit 97

to the Annual Report.

**Impact of Accounting and Tax Treatment**

The HRCC annually reviews and considers the deductibility of the compensation paid to our executive officers, including

each of the NEOs. The HRCC considers the accounting and tax treatment to Clarivate and the NEOs in its decision-

making process. We strive to ensure that there are no significant negative accounting or tax implications due to the design

of our compensation programs; however, we will base our decisions on what we believe is necessary and appropriate to

further the growth of our Company, align with our shareholders' interests, and provide appropriate pay for performance.

**41**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**EXECUTIVE COMPENSATION TABLES**

**2025 Summary Compensation Table**

The following summary compensation table sets forth information concerning compensation earned by our NEOs in 2025.

None of our NEOs have been granted stock options.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Year**  | **Salary**<sup>(1)</sup><br>**($)**<br>| **Bonus**<br>**($)**<br>| **Stock**<br>**Awards**<sup>(2)</sup><br>**($)**<br>| **Non-Equity**<br>**Incentive Plan**<br>**Compensation**<sup>(3)</sup><br>**($)**<br>| **All Other**<br>**Compensation**<sup>(4)</sup><br>**($)**<br>| **Total**<br>**($)**<br>|
| **Matti Shem Tov**<sup>(5)</sup><br>Chief Executive Officer | **Matti Shem Tov**<sup>(5)</sup><br>Chief Executive Officer | **Matti Shem Tov**<sup>(5)</sup><br>Chief Executive Officer | **Matti Shem Tov**<sup>(5)</sup><br>Chief Executive Officer | **Matti Shem Tov**<sup>(5)</sup><br>Chief Executive Officer | **Matti Shem Tov**<sup>(5)</sup><br>Chief Executive Officer | **Matti Shem Tov**<sup>(5)</sup><br>Chief Executive Officer |
| 2025 | 900000 |  | 6399514 | 918000 | 133470 | 8350984 |
| 2024  | 352695 |  | 4209999 | 229252 | 52305 | 4844251 |
| **Jonathan Collins**<br>Executive Vice President, Chief Financial Officer | **Jonathan Collins**<br>Executive Vice President, Chief Financial Officer | **Jonathan Collins**<br>Executive Vice President, Chief Financial Officer | **Jonathan Collins**<br>Executive Vice President, Chief Financial Officer | **Jonathan Collins**<br>Executive Vice President, Chief Financial Officer | **Jonathan Collins**<br>Executive Vice President, Chief Financial Officer | **Jonathan Collins**<br>Executive Vice President, Chief Financial Officer |
| 2025 | 750000 |  | 2666461 | 765000 | 14264 | 4195725 |
| 2024  | 750000 |  | 4646938 | 487500 | 14130 | 5898568 |
| 2023  | 750000 |  | 3424506 | 547500 | 13530 | 4735536 |
| **Bar Veinstein**<sup>(5)</sup><br>President, Academia & Government | **Bar Veinstein**<sup>(5)</sup><br>President, Academia & Government | **Bar Veinstein**<sup>(5)</sup><br>President, Academia & Government | **Bar Veinstein**<sup>(5)</sup><br>President, Academia & Government | **Bar Veinstein**<sup>(5)</sup><br>President, Academia & Government | **Bar Veinstein**<sup>(5)</sup><br>President, Academia & Government | **Bar Veinstein**<sup>(5)</sup><br>President, Academia & Government |
| 2025 | 600000 |  | 2133165 | 654000 | 85418 | 3472583 |
| 2024  | 600000 |  | 3117561 | 390000 | 89416 | 4196977 |
| 2023  | 411884 |  | 8185927 | 438000 | 63472 | 9099283 |
| **Henry Levy**<br>President, Life Sciences & Healthcare | **Henry Levy**<br>President, Life Sciences & Healthcare | **Henry Levy**<br>President, Life Sciences & Healthcare | **Henry Levy**<br>President, Life Sciences & Healthcare | **Henry Levy**<br>President, Life Sciences & Healthcare | **Henry Levy**<br>President, Life Sciences & Healthcare | **Henry Levy**<br>President, Life Sciences & Healthcare |
| 2025 | 600000 |  | 2133165 | 648000 | 14264 | 3395429 |
| 2024  | 600000 |  | 3117561 | 390000 | 14130 | 4121691 |
| 2023  | 399725 |  | 4185925 | 438000 | 13420 | 5037070 |
| **Maroun Mourad**<sup>(6)</sup><br>President, Intellectual Property | **Maroun Mourad**<sup>(6)</sup><br>President, Intellectual Property | **Maroun Mourad**<sup>(6)</sup><br>President, Intellectual Property | **Maroun Mourad**<sup>(6)</sup><br>President, Intellectual Property | **Maroun Mourad**<sup>(6)</sup><br>President, Intellectual Property | **Maroun Mourad**<sup>(6)</sup><br>President, Intellectual Property | **Maroun Mourad**<sup>(6)</sup><br>President, Intellectual Property |
| 2025 | 189041 |  | 2249999 | 160685 | 6550 | 2606275 |
| **Gordon Samson**<sup>(5)(7)</sup><br>Former President, Intellectual Property | **Gordon Samson**<sup>(5)(7)</sup><br>Former President, Intellectual Property | **Gordon Samson**<sup>(5)(7)</sup><br>Former President, Intellectual Property | **Gordon Samson**<sup>(5)(7)</sup><br>Former President, Intellectual Property | **Gordon Samson**<sup>(5)(7)</sup><br>Former President, Intellectual Property | **Gordon Samson**<sup>(5)(7)</sup><br>Former President, Intellectual Property | **Gordon Samson**<sup>(5)(7)</sup><br>Former President, Intellectual Property |
| 2025 | 600000 |  | 3424387 |  | 60205 | 4084592 |
| 2024  | 600000 |  | 3117561 | 390000 | 60224 | 4167785 |
| 2023  | 588281 |  | 2776573 | 429557 | 59157 | 3853568 |
| **Melanie Margolin**<sup>(8)</sup><br>Former Executive Vice President and Chief Administrative and Legal Officer | **Melanie Margolin**<sup>(8)</sup><br>Former Executive Vice President and Chief Administrative and Legal Officer | **Melanie Margolin**<sup>(8)</sup><br>Former Executive Vice President and Chief Administrative and Legal Officer | **Melanie Margolin**<sup>(8)</sup><br>Former Executive Vice President and Chief Administrative and Legal Officer | **Melanie Margolin**<sup>(8)</sup><br>Former Executive Vice President and Chief Administrative and Legal Officer | **Melanie Margolin**<sup>(8)</sup><br>Former Executive Vice President and Chief Administrative and Legal Officer | **Melanie Margolin**<sup>(8)</sup><br>Former Executive Vice President and Chief Administrative and Legal Officer |
| 2025 | 136986 |  | 1757845 | 136986 | 1936797 | 3968614 |

---

(1)Salary earned for Mr. Mourad is for the period of hire date through the end of 2025 and salary earned for Ms. Margolin is for the period she was

employed during 2025.

(2)Amounts shown are the aggregate grant date fair value of PSUs and RSUs granted in 2025 under our long-term incentive program as described

above under "2025 Long-Term Incentive Program," computed in accordance with FASB ASC Topic 718, excluding the effect of any estimated

forfeitures. Information about the assumptions used to calculate the grant date fair value of the stock can be found in our Annual Report on Form

10-K under "Item 8. Financial Statements and Supplementary Data — Note 1: Nature of Operations and Summary of Significant Accounting

Policies — Share-based Compensation" and "Item 8. Financial Statements and Supplementary Data — Note 11: Share-based Compensation."

PSUs are reported at 100% of target performance, which was the most probable outcome of their performance conditions as of their grant date.

These amounts do not necessarily correspond to the actual value that may be realized by the NEOs. At the maximum performance level of 200%,

the grant date fair value of the PSUs would be as follows: Mr. Shem Tov, $6,799,029; Mr. Collins, $2,832,926; Mr. Veinstein, $2,266,337; Mr. Levy,

$2,266,337; and Mr. Samson, $2,266,337. The grant date fair value of the PSUs is calculated using a Monte Carlo valuation, which takes into

consideration the probability of the PSUs paying out at different levels.

The PSU grants represent all of the PSUs awarded for 2025. Since performance goals for the entire performance period of the 2025 awards were

established and approved by the HRCC in 2025, these are considered granted for accounting purposes in 2025.

Mr. Samson's and Ms. Margolin's grant value includes $1,291,222 and $1,757,845, respectively, in incremental fair value resulting from

modifications of their equity awards pursuant to the terms of their respective separation agreements. In accordance with the terms of her separation

agreement, Ms. Margolin was not entitled to receive equity awards in 2025.

(3)Represents annual incentive payments under our AIP that were paid in March 2026 for 2025 performance. Mr. Mourad was eligible for a pro rata

payment of 2025 AIP. Under the terms of their respective separation agreements, Mr. Samson was ineligible to receive a payment under the 2025

AIP and Ms. Margolin was eligible for a pro rata payment of 2025 AIP assuming target performance.

**42**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

(4)All Other Compensation includes (a) Company contributions to the Company's defined contribution plans as follows: $133,470 to Mr. Shem Tov,

$14,000 to Messrs. Collins and Levy, $85,418 to Mr. Veinstein, $6,462 to Mr. Mourad, $60,000 to Mr. Samson, and $6,731 to Mrs. Margolin; (b)

Company-paid life insurance premiums in the amount of $264 for Messrs. Collins and Levy, $88 for Mr. Mourad, $205 for Mr. Samson, and $66 for

Ms. Margolin; and (c) severance payments of $1,930,000 to Mrs. Margolin (described in more detail under "2025 NEO Changes" below). These

amounts do not include any tax equalization payments, as further described in "2025 NEO Changes."

(5)Mr. Shem Tov is based in Israel and his salary has been converted to USD using an ILS:USD exchange rate of 0.260. Mr. Veinstein is based in

Israel and his salary has been converted to USD using an ILS:USD exchange rate of 0.273. Mr. Samson is based in Jersey and his salary has been

converted to USD using a GBP:USD exchange rate of 1.234.

(6)Mr. Mourad commenced employment on September 8, 2025.

(7)Mr. Samson departed the Company on December 31, 2025.

(8)Ms. Margolin departed the Company on March 21, 2025.

**Grants of Plan-Based Awards**

The following table provides information regarding grants of plan-based awards to our NEOs. No stock options were

granted to NEOs in 2025.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | **AIP**  | **AIP**  | **AIP**  | **PSUs**  | **PSUs**  | **PSUs**  | **RSUs**  | **Grant Date Fair** <br>**Value of Stock** <br>**Awards**<sup>(4)</sup><br>**($)**  |
| | | | **Estimated Future Payouts Under**<br>**Non-Equity Incentive Plan Awards**<sup>(1)</sup> | **Estimated Future Payouts Under**<br>**Non-Equity Incentive Plan Awards**<sup>(1)</sup> | **Estimated Future Payouts Under**<br>**Non-Equity Incentive Plan Awards**<sup>(1)</sup> | **Estimated Future Payouts Under**<br>**Equity Incentive Plan Awards**<sup>(2)</sup> | **Estimated Future Payouts Under**<br>**Equity Incentive Plan Awards**<sup>(2)</sup> | **Estimated Future Payouts Under**<br>**Equity Incentive Plan Awards**<sup>(2)</sup> | **All Other Stock** <br>**Awards:**<br>**Number of Shares** <br>**of Stock or Units**<sup>(3)</sup><br>**($)**  | **Grant Date Fair** <br>**Value of Stock** <br>**Awards**<sup>(4)</sup><br>**($)**  |
| <br>**Name**  |<br>**Grant** <br>**Date** <br>| <br>**Approval** <br>**Date**<br>| **Threshold**<br>**($)** <br>| **Target**<br>**($)** <br>| **Maximum**<br>**($)** <br>| **Threshold**<br>**(#)** <br>| **Target**<br>**(#)** <br>| **Maximum** <br>**(#)** <br>| **All Other Stock** <br>**Awards:**<br>**Number of Shares** <br>**of Stock or Units**<sup>(3)</sup><br>**($)**  | **Grant Date Fair** <br>**Value of Stock** <br>**Awards**<sup>(4)</sup><br>**($)**  |
| **Matti Shem Tov**  |  |  | 0 | 900000 | 1800000 |  |  |  |  |  |
| **Matti Shem Tov**  | 03/15/2025 | 03/04/2025 |  |  |  | 290556 | 726392 | 1452784 |  | 3399515 |
| **Matti Shem Tov**  | 03/15/2025 | 03/04/2025 |  |  |  |  |  |  | 726392 | 2999999 |
| **Jonathan Collins**  |  |  | 0 | 750000 | 1500000 |  |  |  |  |  |
| **Jonathan Collins**  | 03/15/2025 | 03/04/2025 |  |  |  | 121065 | 302663 | 605326 |  | 1416463 |
| **Jonathan Collins**  | 03/15/2025 | 03/04/2025 |  |  |  |  |  |  | 302663 | 1249998 |
| **Bar Veinstein**  |  |  | 0 | 600000 | 1200000 |  |  |  |  |  |
| **Bar Veinstein**  | 03/15/2025 | 03/04/2025 |  |  |  | 96852 | 242130 | 484260 |  | 1133168 |
| **Bar Veinstein**  | 03/15/2025 | 03/04/2025 |  |  |  |  |  |  | 242130 | 999997 |
| **Henry Levy**  |  |  | 0 | 600000 | 1200000 |  |  |  |  |  |
| **Henry Levy**  | 03/15/2025 | 03/04/2025 |  |  |  | 96852 | 242130 | 484260 |  | 1133168 |
| **Henry Levy**  | 03/15/2025 | 03/04/2025 |  |  |  |  |  |  | 242130 | 999997 |
| **Maroun Mourad** |  |  | 0 | 189041 | 378082 |  |  |  |  |  |
| **Maroun Mourad** | 09/15/2025 | 07/24/2025 |  |  |  |  |  |  | 539568 | 2249999 |
| **Gordon Samson**  |  |  | 0 | 600000 | 1200000 |  |  |  |  |  |
| **Gordon Samson**  | 03/15/2025 | 03/04/2025 |  |  |  | 96852 | 242130 | 484260 |  | 1133168 |
| **Gordon Samson**  | 03/15/2025 | 03/04/2025 |  |  |  |  |  |  | 242130 | 999997 |
| **Gordon Samson**  | 07/25/2025 | 07/24/2025 |  |  |  |  |  |  |  | 1291222 |
| **Melanie Margolin**  |  |  | 0 | 625000 | 1250000 |  |  |  |  |  |
| **Melanie Margolin**  | 01/18/2025 | 02/11/2025 |  |  |  |  |  |  |  | 1757845 |

---

(1)The threshold, target, and maximum amounts shown under "Estimated Future Payouts Under Non-Equity Incentive Plan Awards" reflect the ranges

of payments that could be made under the AIP. Mr. Mourad was eligible for a prorated payment in 2025 based on his date of hire.

Ms. Margolin received a prorated target bonus for 2025 per the terms of her separation agreement. Actual payments under the AIP are shown in the

2025 Summary Compensation Table.

(2)Awards reported in this column represent the number of PSUs granted under the 2019 Incentive Award Plan.

(3)Awards reported in this column represent the number of time-based RSUs granted under the 2019 Incentive Award Plan.

(4)Represents the grant date fair value of stock awards, computed in accordance with FASB ASC Topic 718, excluding the effect of any estimated

forfeitures. PSUs are reported at target performance, which was the most probable outcome of their performance conditions as of their grant date.

At the maximum performance level of 200%, the grant date fair value of the PSUs would be as follows: Mr. Shem Tov, $6,799,029; Mr. Collins,

$2,832,926; Mr. Veinstein, $2,266,337; Mr. Levy, $2,266,337; and Mr. Samson, $2,266,337. Mr. Samson's and Ms. Margolin's grant value includes

$1,291,222 and $1,757,845, respectively, in incremental fair value resulting from modification of their equity awards pursuant to the terms of their

respective separation agreements.

Mr. Mourad received a sign-on RSU grant for 539,568 shares with a total grant date value of $2,249,999 in connection with his commencement of

employment. The RSUs will vest ratably over three years on each of the first three anniversaries of the date of grant, subject to continued

employment through the vest dates.

**43**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Outstanding Equity Awards at Fiscal Year-End**

The following table provides information concerning the outstanding equity awards held by our NEOs as of December 31,

2025. None of our NEOs held stock options as of December 31, 2025.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name**  | **Grant Date**  | **Number of Shares or** <br>**Units of Stock That** <br>**Have Not Vested**<sup>(1)</sup><br>**(#)**<br>| **Market Value of** <br>**Shares or Units of** <br>**Stock That Have Not** <br>**Vested**<sup>(2)</sup><br>**($)**<br>| **Equity Incentive Plan** <br>**Awards:**<br>**Number of Unearned** <br>**Shares, Units, or Other** <br>**Rights That Have Not** <br>**Vested**<sup>(3)</sup><br>**(#)**<br>| **Equity Incentive Plan** <br>**Awards:**<br>**Market or Payout Value** <br>**of Unearned Shares,** <br>**Units, or Other Rights** <br>**That Have Not Vested**<sup>(2)(3)</sup><br>**($)**<br>|
| **Matti Shem Tov**  | 08/13/2024 | 188172 | 628494 | 282258 | 942742 |
| **Matti Shem Tov**  | 03/15/2025 | 726392 | 2426149 | 726392 | 2426149 |
| **Jonathan Collins**  | 03/01/2023 | 72059 | 240677 |  |  |
| **Jonathan Collins**  | 03/15/2024 | 118036 | 394240 | 177053 | 591357 |
| **Jonathan Collins**  | 03/15/2025 | 302663 | 1010894 | 302663 | 1010894 |
| **Bar Veinstein**  | 05/01/2023 | 210695 | 703721 |  |  |
| **Bar Veinstein**  | 03/15/2024 | 94429 | 315393 | 141643 | 473088 |
| **Bar Veinstein**  | 03/15/2025 | 242130 | 808714 | 242130 | 808714 |
| **Henry Levy**  | 05/01/2023 | 119992 | 400773 |  |  |
| **Henry Levy**  | 03/15/2024 | 94429 | 315393 | 141643 | 473088 |
| **Henry Levy**  | 03/15/2025 | 242130 | 808714 | 242130 | 808714 |
| **Maroun Mourad** | 09/15/2025 | 539568 | 1802157 |  |  |
| **Gordon Samson**<sup>(4)</sup> |  |  |  |  |  |
| **Melanie Margolin**<sup>(4)</sup> |  |  |  |  |  |

---

(1)Awards shown are time-based RSUs. Amounts include shares earned on 2023 PSU grants for Mr. Collins, 35,573; Mr. Veinstein, 36,847; and Mr.

Levy, 36,847 since the performance period has ended, and the shares earned will vest based on their continued employment through the vest date.

These awards are scheduled to vest as shown in the table below if the individual remains continuously employed by the Company through the vest

date.

---

| | | |
|:---|:---|:---|
| **Name**  | **Vesting Date**  | **Shares Vesting**  |
| **Matti Shem Tov** | 03/15/2026 | 242130 |
| **Matti Shem Tov** | 08/13/2026 | 94086 |
| **Matti Shem Tov** | 03/15/2027 | 242131 |
| **Matti Shem Tov** | 08/13/2027 | 94086 |
| **Matti Shem Tov** | 03/15/2028 | 242131 |
| **Jonathan Collins** | 02/18/2026 | 35573 |
| **Jonathan Collins** | 03/01/2026 | 95504 |
| **Jonathan Collins** | 03/15/2026 | 100887 |
| **Jonathan Collins** | 03/01/2027 | 59018 |
| **Jonathan Collins** | 03/15/2027 | 100888 |
| **Jonathan Collins** | 03/15/2028 | 100888 |
| **Bar Veinstein** | 02/18/2026 | 36847 |
| **Bar Veinstein** | 03/01/2026 | 85007 |
| **Bar Veinstein** | 03/15/2026 | 80710 |
| **Bar Veinstein** | 05/01/2026 | 136055 |
| **Bar Veinstein** | 03/01/2027 | 47215 |
| **Bar Veinstein** | 03/15/2027 | 80710 |
| **Bar Veinstein** | 03/15/2028 | 80710 |
| **Henry Levy** | 02/18/2026 | 36847 |
| **Henry Levy** | 03/01/2026 | 85007 |
| **Henry Levy** | 03/15/2026 | 80710 |
| **Henry Levy** | 05/01/2026 | 45352 |
| **Henry Levy** | 03/01/2027 | 47215 |
| **Henry Levy** | 03/15/2027 | 80710 |
| **Henry Levy** | 03/15/2028 | 80710 |
| **Maroun Mourad** | 09/15/2026 | 179856 |
| **Maroun Mourad** | 09/15/2027 | 179856 |
| **Maroun Mourad** | 09/15/2028 | 179856 |

---

**44**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

(2)Market value reflects the $3.34 closing price of the Company's stock on December 31, 2025.

(3)Awards shown include all tranches of the PSUs granted in 2023, 2024, and 2025, reported at target performance. PSUs will vest at the end of a

three-year performance period from the grant date, subject to meeting performance metrics and the individual remaining continuously employed by

the Company through the vesting date.

(4)Mr. Samson and Ms. Margolin had no outstanding equity as of December 31, 2025.

**Option Exercises and Stock Vested**

The following table provides information concerning the vesting of RSUs and PSUs held by our NEOs during 2025. None

of our NEOs have been granted stock options.

---

| | | |
|:---|:---|:---|
| | **Stock Awards**  | **Stock Awards**  |
| <br>**Name**  | **Number of Shares**<br>**Acquired on Vesting**<br>**(#)**  | **Value Realized**<br>**on Vesting**<sup>(1)</sup><br>**($)**  |
| Matti Shem Tov  | 174731 | 744354 |
| Jonathan Collins  | 491471 | 2092530 |
| Bar Veinstein  | 518406 | 2219123 |
| Henry Levy  | 337000 | 1440891 |
| Maroun Mourad |  |  |
| Gordon Samson<sup>(2)</sup>  | 581439 | 2222337 |
| Melanie Margolin<sup>(3)</sup> | 520741 | 2096446 |

---

(1)Represents the aggregate dollar amount realized, which is calculated by multiplying the number of shares of RSUs and PSUs that vested by the fair

market value of our stock on the vesting date.

(2)Includes 285,038 RSUs that vested per the terms of Mr. Samson's separation agreement.

(3)Includes 429,791 RSUs that vested per the terms of Ms. Margolin's separation agreement.

**45**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**EXECUTIVE EMPLOYMENT AGREEMENTS**

The Company has entered into employment agreements with our current CEO and each of our other NEOs. These

employment agreements establish each NEO's employment terms and provide a description of the compensation

elements and benefits to which each NEO is entitled. None of the employment agreements provide for severance upon a

voluntary termination of employment, nor do they provide for single-trigger change-in-control payments.

The employment agreements provide each executive with an annual base salary to be reviewed at the discretion of

management and the HRCC and adjusted depending on performance. In addition, each executive is eligible to participate

in the AIP and is entitled to participate in employee benefit plans, programs, and arrangements customarily provided to

our executives. The employment agreements with Messrs. Collins, Levy, and Mourad do not constitute a contract of

employment and do not entitle them to employment for any specified period, and therefore, their employment is

considered "at will." The employment agreements with Messrs. Shem Tov and Veinstein constitute an Israeli contract of

employment. The employment agreement with Ms. Margolin did not constitute a contract of employment and did not

entitle her to employment for any specified period, and therefore, her employment was considered "at will." The

employment agreement with Mr. Samson constituted a U.K. contract of employment.

Under the terms of their employment agreements or separate restrictive covenant agreements, all of our NEOs (including

Ms. Margolin and Mr. Samson) are subject to perpetual confidentiality and intellectual property provisions and restrictive

covenants related to non-competition and non-solicitation of employees, customers, and suppliers for 12 months post-

termination, whether voluntary or involuntary.

On June 30, 2021, the Company adopted the Executive Severance Plan, which it amended and restated on March 23,

2026 (as amended and restated, the "**ESP**"). Pursuant to the ESP, each of our NEOs are eligible to receive severance

benefits upon an involuntary termination without cause (including enhanced severance benefits in connection with an

involuntary termination or resignation for good reason following a change in control). While each of our NEOs is eligible to

receive severance benefits pursuant to the terms of their employment agreement, the ESP provides that, in order to

receive benefits under the ESP, the eligible executive cannot receive benefits under another severance agreement.

Payment of severance under the ESP and each NEO's employment agreement is contingent upon the executive entering

into a release of claims with the Company. There is no eligibility for severance benefits under the employment agreements

or the ESP if the applicable executive voluntarily resigns or the Company terminates him for cause.

The following describes, for our current CEO and other NEOs (other than Ms. Margolin and Mr. Samson), the benefits that

would be received under their respective employment agreements or the ESP in various termination circumstances:

❖Pursuant to the ESP, in the event of an involuntary termination without cause, the NEOs are entitled to severance in

the amount of 18 months of annual base salary, 1.5 times AIP target, and, to the extent the Consolidated Omnibus

Budget Reconciliation Act ("**COBRA**") applies, 18 months of continued benefits coverage relative to medical, dental,

and vision plans. Any unvested RSUs granted prior to April 1, 2027 become vested to the extent the RSUs would

have otherwise vested had the NEOs' employment continued over the 18-month period following the NEOs'

termination date. Any unvested RSUs granted on or after April 1, 2027 become vested in a pro-rated amount

calculated by dividing the number of full months employed between the grant date and the termination date by the

total vesting period. All outstanding PSUs will be forfeited. The expiration date of any outstanding stock options will be

extended to two years from December 31 of the year the NEO is terminated.

❖In the event of an involuntary termination without cause or a resignation for good reason that is within 12 months

following a Change in Control, pursuant to the ESP, the NEOs are entitled to severance in the amount of 24 months of

annual base salary, 2 times AIP target and, if COBRA applies, 24 months of continued benefits coverage relative to

medical, dental, and vision plans. The expiration date of any outstanding stock options will be extended to two years

from December 31 of the year the NEO is terminated. Pursuant to the terms of the NEOs' current award agreements,

any unvested RSUs and PSUs shall immediately vest (with PSUs vesting at the performance level determined by the

Board).

❖The cash severance amount due under the ESP is paid in accordance with the terms of the ESP.

❖In the event of termination due to death or disability, the NEOs are not entitled to any severance or continuation of

benefits under their respective employment agreements or the ESP. Pursuant to the terms of the NEOs' current award

agreements, any unvested RSUs and PSUs shall immediately vest, with PSUs deemed earned at target.

**46**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**2025 NEO Changes**

On September 8, 2025, Mr. Mourad joined the Company as President of our Intellectual Property segment. Mr. Mourad's

employment agreement provides for initial annual base salary of $600,000 and a target annual cash bonus opportunity

equal to 100% of his annual base salary under the AIP, subject to the terms and conditions of the AIP (which was prorated

for 2025 based on his service during 2025). Under his employment agreement, Mr. Mourad also received a sign-on RSU

equity grant in 2025 with a grant date fair market value of $2.25 million, which will vest ratably over three years on each of

the first three anniversaries of the grant date. In the event Mr. Mourad's employment is terminated for cause, he must pay

the Company the cash value of any portion of the sign-on equity grant that has vested as of the termination date, and any

unvested portion of the sign-on equity grant as of the termination date will be cancelled. Mr. Mourad's target annual long-

term equity incentive compensation opportunity for 2026 will be provided in the form of 50% RSUs and 50% PSUs, with a

combined grant date value equal to at least $1.6 million. Thereafter, equity awards will be established by the Board in its

discretion.

On July 25, 2025, the Company entered into a separation agreement with Gordon Samson, former President, Intellectual

Property. Mr. Samson ceased to be an executive officer on September 7, 2025 and departed the Company on December

31, 2025. Pursuant to the terms of his separation agreement, in exchange for his execution of a release of claims and

continued compliance with his restrictive covenant obligations, Mr. Samson received (i) lump-sum cash payments equal to

$1,799,853 (using a GBP:USD exchange rate of 1:1.234), (ii) accelerated vesting of any unvested RSUs that would have

vested within 18 months of his termination date, totaling 285,038 shares (which, based on our closing share price on

December 31, 2025, had a value of $952,027), and (iii) if applicable, a tax equalization payment to account for days of

work in the United Kingdom.

On January 18, 2025, the Company entered into a separation agreement with Melanie Margolin, Executive Vice President

and Chief Administrative and Legal Officer. Ms. Margolin ceased to be an executive officer on February 28, 2025 and

departed the Company on March 21, 2025. Pursuant to the terms of her separation agreement, in exchange for her

execution of a release of claims and continued compliance with her restrictive covenant obligations, Ms. Margolin received

(i) lump-sum cash payments equal to $1,875,000, (ii) a lump-sum payment of $40,000 representing reimbursement for the

average monthly cost of COBRA for 18 months, (iii) a prorated target annual bonus for 2025 in the amount of $136,986,

(iv) reimbursement of legal fees related to the separation agreement up to $15,000, (v) accelerated vesting of any

unvested RSUs that would have vested within 18 months of her termination date, totaling 429,791 shares (which, based

on our closing share price on March 21, 2025, had a value of $1,757,845), and (vi) if applicable, a tax equalization

payment to account for any incremental tax liability that is not offset by a U.S. foreign tax credit for Ms. Margolin's work in

the United Kingdom.

Both of these separation agreements are consistent with the benefits provided under the ESP.

**47**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN** 

**CONTROL**

The information in the table below provides the estimated value of compensation that would have been paid to each of our

NEOs in the event the NEO was involuntarily terminated by the Company for reason other than cause on December 31,

2025. For information on termination-related benefits provided to Mr. Samson and Ms. Margolin in connection with their

separations, please see "2025 NEO Changes" above.

---

| | | | |
|:---|:---|:---|:---|
| **Name**  | **Involuntary**<br>**Termination**<br>**Without Cause**<br>**(Not Related to**<br>**Change in**<br>**Control)**<br>**($)**  | **Involuntary**<br>**Termination**<br>**Without Cause**<br>**(Change in**<br>**Control)**<br>**($)**  | **Death or**<br>**Disability**<br>**($)**  |
| **Matti Shem Tov** <br> PSUs<sup>(1)</sup> |  | 3368891 | 3368891 |
| **Matti Shem Tov** <br> RSUs<sup>(2)</sup> | 1931679 | 3054644 | 3054644 |
| **Matti Shem Tov** <br> Severance<sup>(3)</sup> | 2700000 | 3600000 |  |
| **Matti Shem Tov** <br> Continued Benefits<sup>(3)</sup> |  |  |  |
| **Total Matti Shem Tov**  | 4631679 | 10023535 | 6423535 |
| **Jonathan Collins** <br> PSUs<sup>(1)</sup> |  | 1967838 | 1967838 |
| **Jonathan Collins** <br> RSUs<sup>(2)</sup> | 1190032 | 1526998 | 1526998 |
| **Jonathan Collins** <br> Severance<sup>(3)</sup> | 2250000 | 3000000 |  |
| **Jonathan Collins** <br> Continued Benefits<sup>(3)</sup> | 28013 | 37350 |  |
| **Total Jonathan Collins**  | 3468045 | 6532186 | 3494836 |
| **Bar Veinstein** <br> PSUs<sup>(1)</sup> |  | 1660484 | 1660484 |
| **Bar Veinstein** <br> RSUs<sup>(2)</sup> | 1435188 | 1704759 | 1704759 |
| **Bar Veinstein** <br> Severance<sup>(3)</sup> | 1800000 | 2400000 |  |
| **Bar Veinstein** <br> Continued Benefits<sup>(3)</sup> |  |  |  |
| **Total Bar Veinstein**  | 3235188 | 5765243 | 3365243 |
| **Henry Levy** <br> PSUs<sup>(1)</sup> |  | 1660484 | 1660484 |
| **Henry Levy** <br> RSUs<sup>(2)</sup> | 1132240 | 1401811 | 1401811 |
| **Henry Levy** <br> Severance<sup>(3)</sup> | 1800000 | 2400000 |  |
| **Henry Levy** <br> Continued Benefits<sup>(3)</sup> | 50114 | 66818 |  |
| **Total Henry Levy**  | 2982354 | 5529113 | 3062295 |
| **Maroun Mourad** <br> PSUs<sup>(1)</sup> |  |  |  |
| **Maroun Mourad** <br> RSUs<sup>(2)</sup> | 600719 | 1802157 | 1802157 |
| **Maroun Mourad** <br> Severance<sup>(3)</sup> | 1800000 | 2400000 |  |
| **Maroun Mourad** <br> Continued Benefits<sup>(3)</sup> | 29066 | 38754 |  |
| **Total Maroun Mourad**  | 2429785 | 4240911 | 1802157 |

---

(1)As described in "Executive Employment Agreements," the vesting of PSUs will accelerate in full in the event of death or disability or upon a

termination without cause in the 12 months following a change in control. In the event of an involuntary termination without cause at any other time,

PSUs will be forfeited.

(2)As described in "Executive Employment Agreements," the vesting of RSUs will accelerate in full in the event of death or disability or upon a

termination without cause in the 12 months following a change in control. In the event of an involuntary termination without cause, any unvested

RSUs shall become vested to the extent the RSUs would have otherwise vested had the NEOs' employment continued over the 18-month period

following the NEOs' termination date.

(3)See "Executive Employment Agreements" for a description of how salary, AIP, and continued benefits are determined for each NEO.

**48**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**CEO PAY RATIO**

As required by Section 953(b) of the Dodd-Frank Act, we are providing the following information about the relationship of

the annual total compensation of our employees (other than our CEO) and the annual total compensation of our CEO, Mr.

Shem Tov, on December 31, 2025 (the "**Measurement Date**").

For 2025, our last completed fiscal year:

❖The annual total compensation of our median employee was $46,275.

❖The annual total compensation of our CEO, as annualized for purposes of the pay ratio and discussed below, was

$8,350,984.

Based on this information for 2025, the ratio of the annual total compensation of our CEO to that of our median employee

is approximately 180:1. We believe our CEO pay ratio is a reasonable estimate calculated in a manner consistent with

Item 402(u) of Regulation S-K.

To identify the median employee, as well as to determine the annual total compensation of the median employee, the

methodology and the material assumptions and adjustments that we used were as follows:

• As of the Measurement Date, our employee population for purposes of calculating our pay comprised 12,340

employees globally, with approximately 19% of our employee population located in the United States and 81%

located outside the United States.

• We included all full-time and part-time employees worldwide, excluding our CEO, except that, as permitted under

the SEC rules, we utilized the de minimis exemption to exclude 299 employees, approximately 2.4% of our

employee population, in the following countries:

---

| | | | |
|:---|:---|:---|:---|
| Azerbaijan (1) | Chile (9) | Colombia (11) | Egypt (1) |
| Hungary (5) | Malaysia (263) | Philippines (3) | South Africa (4) |
| Ukraine (1) | Uzbekistan (1) |  |  |

---

• To identify the median employee from our employee population, we relied on the base pay plus target bonus of

our employees, as reported in our centralized human resource system on the Measurement Date, as these are

the primary compensation elements for most of our employees. We did not make any cost-of-living adjustments in

identifying the median employee.

• Using this methodology, we determined that the median employee was a full-time worker in the United Kingdom.

• With respect to the annual total compensation of the median employee, we calculated the employee's

compensation for 2025 in accordance with the requirements of Item 402(c) of Regulation S-K, resulting in an

annual total compensation of $46,275.

SEC rules for identifying the median employee and calculating the pay ratio based on that employee's annual total

compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable

estimates and assumptions that reflect their employee populations and compensation practices. As a result, the pay ratio

reported by other companies may not be comparable to the pay ratio reported above, as other companies have different

employee populations and compensation practices and may utilize different methodologies, exclusions, estimates, and

assumptions in calculating their own pay ratios.

**49**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**PAY VERSUS PERFORMANCE**

The following table sets forth the compensation for each of our Chief Executive Officers (our "**PEOs**") during 2025 and the

average compensation for our other named executive officers, both as reported in the 2025 Summary Compensation

Table and with certain adjustments to reflect the "compensation actually paid" ("**CAP**") to such individuals, as defined

under SEC rules, for each of 2025, 2024, 2023, 2022, and 2021. The table also provides information on our cumulative

TSR, the cumulative TSR of our peer group, Net Income, and Adjusted EBITDA (our Company-selected measure) over

such years in accordance with SEC rules.

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Fiscal** <br>**Year**  | **Summary**<br>**Compensation**<br>**Table Total for** <br>**PEO**<sup>(1)</sup>  | **Compensation**<br>**Actually Paid**<br>**to PEO**<sup>(5)</sup>  | **Summary**<br>**Compensation**<br>**Table Total for**<br>**Second PEO**<sup>(1)</sup> | **Compensation**<br>**Actually Paid**<br>**to Second**<br>**PEO**<sup>(5)</sup>  | **Summary**<br>**Compensation**<br>**Table Total for**<br>**Third PEO**<sup>(1)</sup>  | **Compensation**<br>**Actually Paid**<br>**to Third PEO**<sup>(5)</sup> | **Average Summary**<br>**Compensation**<br>**Table Total for**<br>**Non-PEO**<br>**NEOs**<sup>(2)</sup>  | **Average**<br>**Compensation**<br>**Actually Paid**<br>**to Non-PEO**<br>**NEOs**<sup>(5)</sup>  | **Value of Initial Fixed $100**<br>**Investment Based On:**  | **Value of Initial Fixed $100**<br>**Investment Based On:**  | **Net**<br>**Income/**<br>**(Loss)**<sup>(4)</sup><br>(in millions) | **Adjusted**<br>**EBITDA** <br>(in millions) |
| **Fiscal** <br>**Year**  | **Summary**<br>**Compensation**<br>**Table Total for** <br>**PEO**<sup>(1)</sup>  | **Compensation**<br>**Actually Paid**<br>**to PEO**<sup>(5)</sup>  | **Summary**<br>**Compensation**<br>**Table Total for**<br>**Second PEO**<sup>(1)</sup> | **Compensation**<br>**Actually Paid**<br>**to Second**<br>**PEO**<sup>(5)</sup>  | **Summary**<br>**Compensation**<br>**Table Total for**<br>**Third PEO**<sup>(1)</sup>  | **Compensation**<br>**Actually Paid**<br>**to Third PEO**<sup>(5)</sup> | **Average Summary**<br>**Compensation**<br>**Table Total for**<br>**Non-PEO**<br>**NEOs**<sup>(2)</sup>  | **Average**<br>**Compensation**<br>**Actually Paid**<br>**to Non-PEO**<br>**NEOs**<sup>(5)</sup>  | **Total**<br>**Shareholder**<br>**Return** <br>| **Peer Group**<br>**Total**<br>**Shareholder**<br>**Return**<sup>(3)</sup> <br>| **Net**<br>**Income/**<br>**(Loss)**<sup>(4)</sup><br>(in millions) | **Adjusted**<br>**EBITDA** <br>(in millions) |
| 2025 | 8350984 | 5761746 | N/A  | N/A  | N/A  | N/A  | 3620536 | 1356654 | 11.24 | 134.41 | (201.1) | 1001.8 |
| 2024  | 4844251 | 3866509 | 21865641 | 1623752 | N/A  | N/A  | 4596255 | 1535438 | 17.10 | 159.23 | (668.0) | 1060.4 |
| 2023  | N/A  | N/A  | 12478373 | 10579394 | N/A  | N/A  | 5681364 | 5657407 | 31.17 | 145.19 | (986.6) | 1117.2 |
| 2022  | N/A  | N/A  | 8375608 | 5440653 | 4538176 | (2164082) | 2644643 | (226698) | 28.07 | 112.84 | (4035.6) | 1112.7 |
| 2021  | N/A  | N/A  | N/A  | N/A  | 5319950 | 2813040 | 4404432 | 3903063 | 79.17 | 142.95 | (312.0) | 800.4 |

---

(1)The PEO is Matti Shem Tov, the second PEO is Jonathan Gear, and the third PEO is Jerre Stead. Mr. Stead was Chairman Emeritus of the Board

from October 21, 2022 to May 7, 2025, and received no compensation for this position.

(2)The 2025 non-PEO NEOs are Jonathan Collins, Bar Veinstein, Henry Levy, Maroun Mourad, Gordon Samson, and Melanie Margolin. The 2024 and

2023 non-PEO NEOs are Jonathan Collins, Bar Veinstein, Henry Levy, and Gordon Samson. The 2022 non-PEO NEOs are Jonathan Collins,

Steen Lomholt-Thomsen, Gordon Samson, and Stefano Maestri. The 2021 non-PEO NEOs are Jonathan Collins, Steen Lomholt-Thomsen, Gordon

Samson, Mukhtar Ahmed, Richard Hanks, and Jeff Roy.

(3)Our TSR peer group is the peer group used for purposes of the "stock performance graph" in Clarivate's Annual Report on Form 10-K and consists

of the following companies: FactSet Research Systems Inc.; Gartner Inc.; Moody's Corporation; MSCI Inc.; S&P Global Inc.; and Verisk Analytics,

Inc.

(4)Our 2025, 2024, 2023 and 2022 net income (loss) attributable to ordinary shares, as reported under U.S. GAAP, includes goodwill and intangible

asset impairments of $15.0 million, $540.7 million, $979.9 million and $4,449.1 million, respectively.

(5)The following tables show what adjustments were made to the summary compensation table total to calculate CAP for 2025. We paid no dividends

during 2025, and thus no adjustments were made on account of dividend payments. CAP does not reflect the actual amount of compensation

earned by or paid to the PEOs and our other NEOs during the applicable year. For information regarding the decisions made by our HRCC in

regard to the PEOs' and our other NEOs' compensation for 2025, see "Compensation Discussion and Analysis," above.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Fiscal** <br>**Year** <br>| **Summary**<br>**Compensation**<br>**Table Total for**<br>**First PEO** <br>| **Exclusion of** <br>**Stock Awards &** <br>**Option Awards** <br>| **Year-End Fair** <br>**Value of Unvested** <br>**Equity Granted** <br>**During the** <br>**Current Year**<br>(a) <br>| **Change in Fair** <br>**Value of Prior** <br>**Awards That** <br>**Vested During the** <br>**Current Year**<br>(b) <br>| **Change in Fair** <br>**Value of Prior** <br>**Awards That** <br>**Remained** <br>**Unvested at End** <br>**of Current Year**<br>(c) <br>| **Fair Value at Vest** <br>**of Awards** <br>**Granted and** <br>**Vested During the** <br>**Current Year**<br>(d) <br>| **Prior Year-End** <br>**Fair Value of Prior** <br>**Awards That** <br>**Forfeited During** <br>**the Current Year**<br>(e) <br>| **Inclusion of** <br>**Equity Values**<br>(a) + (b) + (c) + (d) <br>- (e)<br>| **Compensation** <br>**Actually Paid to** <br>**First PEO** <br>|
| 2025 | 8350984 | (6399514) | 4910410 | (143279) | (956855) |  |  | 3810276 | 5761746 |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Fiscal** <br>**Year** <br>| **Summary**<br>**Compensation**<br>**Table Total for** <br>**Non-PEO NEOs**<br>| **Exclusion of** <br>**Stock Awards &** <br>**Option Awards** <br>| **Year-End Fair** <br>**Value of Unvested** <br>**Equity Granted** <br>**During the** <br>**Current Year**<br>(a) <br>| **Change in Fair** <br>**Value of Prior** <br>**Awards That** <br>**Vested During the** <br>**Current Year**<br>(b) <br>| **Change in Fair** <br>**Value of Prior** <br>**Awards That** <br>**Remained** <br>**Unvested at End** <br>**of Current Year**<br>(c) <br>| **Fair Value at Vest** <br>**of Awards** <br>**Granted and** <br>**Vested During the** <br>**Current Year**<br>(d) <br>| **Prior Year-End** <br>**Fair Value of Prior** <br>**Awards That** <br>**Forfeited During** <br>**the Current Year**<br>(e) <br>| **Inclusion of** <br>**Equity Values**<br>(a) + (b) + (c) + (d) <br>- (e)<br>| **Compensation** <br>**Actually Paid to** <br>**Non-PEO NEOs** <br>|
| 2025 | 3620536 | (2394170) | 1186959 | (335417) | (441022) | 90664 | 370896 | 130288 | 1356654 |

---

The following graphs represent the relationship between CAP for the PEOs and average CAP of the non-PEO NEOs and

Company performance in cumulative TSR, Net Income, and Adjusted EBITDA (our Company-selected measure); and

between the Company's cumulative TSR and the peer group cumulative TSR.

**50**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

![CAP to TSR graph.jpg](clvt-20260401_g17.jpg)

![CAP to income graph.jpg](clvt-20260401_g18.jpg)

**51**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

![CAP to CSM graph.jpg](clvt-20260401_g19.jpg)

![TSR to TSR graph.jpg](clvt-20260401_g20.jpg)

The following is an unranked list of the performance measures we have determined as our most important performance

measures used to link CAP to our NEOs to Company performance in the most recently completed fiscal year:

❖Recurring organic revenue growth

❖Revenue

❖Free cash flow

❖Adjusted EBITDA

❖Adjusted diluted EPS

❖Relative TSR

**52**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**PROPOSAL 3: RATIFICATION OF APPOINTMENT OF INDEPENDENT** 

**REGISTERED PUBLIC ACCOUNTANTS**

The Audit Committee of the Board has selected PricewaterhouseCoopers LLP ("**PwC**") as the Company's independent

registered public accountants to audit our books, records, and accounts and those of our subsidiaries for the fiscal year

2026. The Board has endorsed this appointment.

Ratification of the selection of PwC by shareholders is not required by law and is being sought on a non-binding and

advisory basis. However, as a matter of good corporate practice, such selection is being submitted to the shareholders for

ratification at the Annual Meeting. If the shareholders do not ratify the selection, the Board and the Audit Committee will

reconsider whether to retain PwC, but may, in their discretion, retain PwC. Even if the selection is ratified, the Audit

Committee, in its discretion, may change the appointment at any time during the year if it determines that such change

would be in the best interests of Clarivate and its shareholders.

PwC has audited the Company's consolidated financial statements and those of our predecessor since 2016.

Representatives of PwC will be present at the Annual Meeting. They will have an opportunity to make a statement, if they

desire to do so, and will be available to respond to appropriate shareholder questions.

**Audit, Audit-Related, and Tax Fees**

In connection with the audit of the Company's financial statements for the fiscal year ended December 31, 2025, we

entered into an engagement letter with PwC that sets forth the terms by which PwC performed audit services for us.

Aggregate fees for professional services rendered for us by PwC for the fiscal years ended December 31, 2025 and 2024,

respectively, were as follows:

---

| | | |
|:---|:---|:---|
| (In thousands)  | **2025** | **2024** |
| Audit Fees  | $8366 | $8514 |
| Audit-Related Fees  | 142 | 64 |
| Tax Fees  |  |  |
| All Other Fees  | 2 | 2 |
| **Total** | **$8510** | **$8580** |

---

**Audit Fees.** Audit fees consist of fees billed for professional services rendered for the audit of our consolidated financial

statements, the statutory audit of our subsidiaries, the review of our interim consolidated financial statements, and other

services that are normally provided by PwC in connection with statutory and regulatory filings or engagements and

attestation services, except those not required by statute or regulation.

**Audit-Related Fees.** Audit-related fees consist of fees billed for assurance and related services that are reasonably

related to the performance of the audit or review of the Company's consolidated financial statements and are not reported

under "Audit Fees." These services may include employee benefit plan audits, due diligence services related to

acquisitions and divestitures, auditing work in proposed transactions, attestation services that are not required by

regulation or statute, and consultations regarding financial accounting or reporting standards. For 2025, all audit-related

fees were for services associated with attestation services not required by regulation or statute.

**Tax Fees.** Tax fees consist of tax compliance consultants, preparation of tax reports, and other tax services.

**All Other Fees.** All other fees for 2025 and 2024 consisted of license fees for utilization of technical databases.

**Audit Committee Pre-Approval Policies and Procedures**

The Audit Committee has implemented pre-approval policies and procedures related to the provision of audit and non-

audit services by PwC. Under these procedures, the Audit Committee pre-approves both the type of services to be

provided by PwC and the estimated fees related to these services.

During the approval process, the Audit Committee considers the impact of the types of services and the related fees on

the independence of the registered public accountants. The services and fees must be deemed compatible with the

maintenance of such accountants' independence, including compliance with rules and regulations of the SEC, the Public

Company Accounting Oversight Board, and the NYSE.

**53**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

The Audit Committee has delegated authority to pre-approve services performed by PwC to the chair of the Audit

Committee for services of up to $1,000,000, with any approvals pursuant to such delegated authority regularly reported to

the Audit Committee. The Audit Committee has not delegated any of its responsibilities to pre-approve services performed

by PwC to management. Throughout the year, the Audit Committee will review any revisions to the estimates of audit and

non-audit fees initially approved.

**The text of the resolution with respect to Proposal 3 (which is proposed as an** 

**ordinary resolution) is as follows:**

"**RESOLVED**, that the shareholders of the Company hereby reappoint PricewaterhouseCoopers LLP as the Company's

auditors, ratify their appointment as the Company's independent registered public accountants for the fiscal year 2026 on

a non-binding and advisory basis, and authorize the Board of Directors, acting through its Audit Committee, to determine

the fees to be paid to the auditors."

**Vote Required and Recommendation**

The appointment of PwC is ratified if approved by a simple majority of the votes cast by, or on behalf of, the shareholders

entitled to vote in person or represented by proxy. Unless marked to the contrary, proxies received will be voted "FOR" this

Proposal 3 regarding the ratification of PwC as our independent registered public accountants. In the event the

appointment of PwC is not ratified, the Audit Committee will review its future selection of our independent registered public

accountants.

With respect to Proposal 3, you may instruct to vote "FOR" or "AGAINST," or "ABSTAIN" from voting on, such proposal. If

you "ABSTAIN" from voting, your vote is not considered a vote cast and will have no effect for such proposal. If you do not

provide your broker or other nominee with instructions on how to vote your shares with respect to Proposal 3, your broker

or nominee will be entitled to cast discretionary votes on Proposal 3 as such proposal is a "routine" matter.

---

| | |
|:---|:---|
| ![Image_243.jpg](clvt-20260401_g10.jpg) | **THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" THE REAPPOINTMENT OF** <br>**PRICEWATERHOUSECOOPERS LLP AS OUR AUDITORS, RATIFY THEIR APPOINTMENT AS OUR** <br>**INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR 2026 ON A NON-**<br>**BINDING AND ADVISORY BASIS, AND AUTHORIZE THE BOARD, ACTING THROUGH ITS AUDIT** <br>**COMMITTEE, TO DETERMINE THE FEES TO BE PAID TO THE AUDITORS.**<br>|

---

**54**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**REPORT OF THE AUDIT COMMITTEE**

*The following report of the Audit Committee does not constitute "soliciting material" and*

*shall not be deemed filed or incorporated by reference into any other filing by Clarivate*

*under the Securities Act or the Exchange Act.*

The Audit Committee provides assistance to the Board in fulfilling its legal and fiduciary obligations in matters involving the

Company's accounting, auditing, financial reporting, internal control, and legal compliance functions. It does so by

approving the services performed by PricewaterhouseCoopers LLP ("**PwC**"), the Company's independent registered

public accountants, and reviewing their reports regarding the Company's accounting practices and systems of internal

controls. The Audit Committee also oversees the performance of the Company's internal audit function.

The Committee's responsibilities are stated in a written charter adopted by the Board.

The Company's management is responsible for preparing the Company's financial statements, and PwC is responsible for

auditing those financial statements. The Audit Committee is responsible for overseeing the conduct of these activities by

the Company's management and PwC.

To fulfill its responsibility, the Audit Committee has met regularly and held discussions with management, with the

Company's internal auditors, and with PwC. It has discussed with PwC the applicable requirements of the Public

Company Accounting Oversight Board and the SEC. Management represented to the Audit Committee that the

Company's consolidated financial statements for fiscal year 2025 were prepared in accordance with generally accepted

accounting principles, and the Audit Committee has reviewed and discussed the consolidated financial statements with

management and PwC.

The Audit Committee has also discussed and confirmed with PwC its independence from the Company and has received

from PwC all written disclosures and correspondence required by the Public Company Accounting Oversight Board. In

addition, the Audit Committee has evaluated the non-audit services provided by PwC to the Company and has concluded

that these do not impair PwC's independence.

The Audit Committee has discussed with internal accountants, internal auditors, and PwC, with and without management

present, its evaluations of the Company's internal control over financial reporting and the overall quality of the Company's

financial reporting.

Based on the reviews and discussions described above, the Audit Committee approved the audited consolidated financial

statements for fiscal year 2025 and recommended to the Board their inclusion in the Annual Report.

Respectfully submitted by the Audit Committee of the Board:

**Kenneth Cornick, Chair**

**Jane Okun Bomba**

**Anthony Munk**

**55**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**BENEFICIAL OWNERSHIP**

The following tables set forth certain information as of March 16, 2026, unless otherwise noted, about Clarivate ordinary

shares beneficially owned by (i) each of our current directors and our NEOs, as well as all our current directors and

executive officers as a group and (ii) each person who is known by us to beneficially own more than five percent of the

Company's ordinary shares.

The percentage of ordinary shares beneficially owned is based on 642,179,542 ordinary shares issued and outstanding

as of March 16, 2026, the Record Date. We have only one class of shares issued and outstanding, that being ordinary

shares, and all holders of our ordinary shares have the same voting rights.

In accordance with SEC rules, "beneficial ownership" includes voting or investment power with respect to securities. For

purposes of this table, beneficial ownership has been determined in accordance with the provisions of Rule 13d-3 of the

Exchange Act under which, in general, a person is deemed to be the beneficial owner of a security if he or she has or

shares the power to vote or direct the voting of the security or the power to dispose of or direct the disposition of the

security, or if he or she has the right to acquire beneficial ownership of the security within 60 days of March 16, 2026. To

our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, the

persons named in the table each have sole voting and investment power with respect to all ordinary shares beneficially

owned by them. We do not know of any arrangements that would result in a change in our control.

**Beneficial Ownership of Directors and Executive Officers**

---

| | | |
|:---|:---|:---|
|  | **Clarivate Plc**<br>**Ordinary Shares** | **Clarivate Plc**<br>**Ordinary Shares** |
| **Name of Beneficial Owner**<sup>(1)</sup> | **Shares** <br>**Beneficially Owned**<br>| **% of Shares** <br>**Beneficially Owned**<br>|
| Andrew Snyder<sup>(2)</sup> | 26026464 | 4.05% |
| Jane Okun Bomba<sup>(3)</sup> | 279272 | \* |
| Kenneth Cornick<sup>(4)</sup> | 1136674 | \* |
| Usama N. Cortas<sup>(5)</sup> | 116666507 | 18.17% |
| Suzanne Heywood<sup>(6)</sup> | 51405 | \* |
| Adam T. Levyn  |  |  |
| Anthony Munk  |  |  |
| Wendell Pritchett<sup>(7)</sup> | 101811 | \* |
| Saurabh Saha<sup>(8)</sup> | 116515 | \* |
| Matti Shem Tov<sup>(9)</sup> | 854509 | \* |
| Jonathan Collins<sup>(10)</sup> | 357316 | \* |
| Henry Levy<sup>(11)</sup> | 251556 | \* |
| Maroun Mourad<sup>(12)</sup> | 105000 | \* |
| Bar Veinstein<sup>(13)</sup> | 677023 | \* |
| Gordon Samson<sup>(14)</sup> | 1007951 | \* |
| Melanie Margolin<sup>(15)</sup> | 304166 | \* |
| All current directors and executive officers as a group (15 individuals)<sup>(16)</sup> | 146994685 | 22.88% |
| \* Less than one percent | \* Less than one percent | \* Less than one percent |

---

(1)Unless otherwise stated below, the address of each beneficial owner listed in the table is c/o Clarivate Plc, 70 St. Mary Axe, London EC3A 8BE,

United Kingdom.

(2)Includes (i) 152,843 ordinary shares directly held by Mr. Snyder; (ii) 39,473 ordinary shares issuable upon settlement of RSUs held by Mr. Snyder

that will vest within 60 days of March 16, 2026; (iii) 8,821,984 ordinary shares held by Cambridge Information Group Inc. ("CIG"); (iv) 2,247,510

ordinary shares held by Cambridge Information Group I LLC; (v) 10,489,466 ordinary shares held by Cambridge Information Group II LLC; (vi)

4,033,271 ordinary shares held by Cambridge Information Group III LLC; (vii) 3,417 ordinary shares held by CSA GP Corporation; and (viii) 238,500

ordinary shares held by The Snyder 2011 Family Trust. Mr. Snyder is the Chief Executive Officer of, and a shareholder in, CIG, which acts as a

manager of Cambridge Information Group I LLC, Cambridge Information Group II LLC, and Cambridge Information Group III LLC (collectively with

CIG and CSA GP Corporation, the "CIG Entities"). CSA GP Corporation is a wholly owned subsidiary of CIG. Mr. Snyder serves as trustee and is

one of the beneficiaries of The Snyder 2011 Family Trust. Mr. Snyder disclaims beneficial ownership of the reported securities held by the CIG

Entities and The Snyder 2011 Family Trust except to the extent of his pecuniary interest therein.

(3)Includes (i) 190,049 ordinary shares directly held by Ms. Okun Bomba; (ii) 39,473 ordinary shares issuable upon settlement of RSUs held by Ms.

Okun Bomba that will vest within 60 days of March 16, 2026; and (iii) 49,750 ordinary shares held by Jane Okun Bomba Trust U/A DTD 12/20/2018.

**56**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

(4)Includes (i) 6,720 ordinary shares directly held by Mr. Cornick; (ii) 29,954 ordinary shares issuable upon settlement of RSUs held by Mr. Cornick

that will vest within 60 days of March 16, 2026; and (iii) 1,100,000 ordinary shares held by Cornick Family Investor, LLC. Cornick Family Investor,

LLC is controlled by Mr. Cornick and his spouse, its managers, who have dispositive control and voting control over the shares held by Cornick

Family Investor, LLC.

(5)Mr. Cortas may be deemed to be the indirect beneficial owner of 116,666,507 ordinary shares held by Leonard Green & Partners, L.P. See Footnote

1 of the table below "Beneficial Ownership of More Than 5% Beneficial Owners." Mr. Cortas disclaims beneficial ownership of the shares reported

herein except to the extent of his pecuniary interest therein and the information reported in this table shall not be deemed an admission that he is

the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

(6)Includes (i) 11,932 ordinary shares directly held by Ms. Heywood and (ii) 39,473 ordinary shares issuable upon settlement of RSUs held by Ms.

Heywood that will vest within 60 days of March 16, 2026.

(7)Includes (i) 62,338 ordinary shares directly held by Mr. Pritchett and (ii) 39,473 ordinary shares issuable upon settlement of RSUs held by Mr.

Pritchett that will vest within 60 days of March 16, 2026.

(8)Includes (i) 77,042 ordinary shares directly held by Mr. Saha and (ii) 39,473 ordinary shares issuable upon settlement of RSUs held by Mr. Saha

that will vest within 60 days of March 16, 2026.

(9)Includes (i) 533,906 ordinary shares directly held by Mr. Shem Tov and (ii) 320,603 ordinary shares held for the benefit of Mr. Shem Tov by IBI Trust

Management.

(10)Includes 357,316 ordinary shares directly held by Mr. Collins.

(11)Includes (i) 206,204 ordinary shares directly held by Mr. Levy and (ii) 45,352 ordinary shares issuable upon settlement of RSUs held by Mr. Levy

that will vest within 60 days of March 16, 2026.

(12)Includes 105,000 ordinary shares held by Mr. Mourad's spouse.

(13)Includes (i) 540,968 ordinary shares directly held by Mr. Veinstein and (ii) 136,055 ordinary shares issuable upon settlement of RSUs held by Mr.

Veinstein that will vest within 60 days of March 16, 2026.

(14)Includes 1,007,951 ordinary shares directly held by Mr. Samson as of December 31, 2025.

(15)Includes 304,166 ordinary shares directly held by Ms. Margolin as of December 31, 2025.

(16)Includes (i) 2,509,951 ordinary shares directly held; (ii) 144,076,008 ordinary shares indirectly held; and (iii) 408,726 ordinary shares issuable upon

the settlement of RSUs that will vest within 60 days of March 16, 2026.

**Beneficial Ownership of More Than 5% Beneficial Owners**

---

| | | |
|:---|:---|:---|
|  | **Clarivate Plc**<br>**Ordinary Shares** | **Clarivate Plc**<br>**Ordinary Shares** |
| **Name and Address of Beneficial Owner**  | **Shares** <br>**Beneficially Owned**<br>| **% of Shares** <br>**Beneficially Owned**<br>|
| Leonard Green & Partners, L.P.<sup>(1)</sup> | 116666507 | 18.17% |
| Clarkston Capital Partners, LLC<sup>(2)</sup> | 72209043 | 11.24% |
| Exor N.V.<sup>(3)</sup> | 67294884 | 10.48% |
| Onex Corp.<sup>(4)</sup> | 42855384 | 6.67% |
| Castik Capital S.a r.l.<sup>(5)</sup> | 38089963 | 5.93% |

---

(1)The information in the table above is based solely on information contained in this shareholder's Schedule 13D/A under the Exchange Act filed by

such shareholder with the SEC. GEI VII Capri Holdings, LLC ("Capri Holdings") is the record and direct holder of 116,666,507 ordinary shares held

by Capri Holdings on behalf of the following investors: (i) Green Equity Investors VII, L.P. ("GEI VII") is the indirect owner of 33,763,998 ordinary

shares, (ii) Green Equity Investors Side VII, L.P. ("GEI Side VII") is the indirect owner of 47,264,079 ordinary shares, (iii) GEI VII Capri AIV, L.P.

("AIV") is the indirect owner of 6,234,835 ordinary shares, (iv) Capri Coinvest LP ("Coinvest") is the indirect owner of 28,094,163 ordinary shares, (v)

LGP Associates VII-A LLC ("Associates VII-A") is the indirect owner of 121,171 ordinary shares, and (vi) LGP Associates VII-B LLC ("Associates VII-

B") is the indirect owner of 1,188,261 ordinary shares. The principal business of each of Capri Holdings, GEI VII, GEI Side VII, AIV, Coinvest,

Associates VII-A, and Associates VII-B is to pursue investments. Each of GEI VII, GEI Side VII, AIV, Coinvest, Associates VII-A, Associates VII-B,

GEI Capri VII, LLC ("Capri VII"), and Leonard Green & Partners, L.P. ("LGP") are members of Capri Holdings. The principal business of Capri VII is

to act as a member of Capri Holdings. GEI Capital VII, LLC ("Capital") is the general partner of GEI VII and GEI Side VII. Capital's principal

business is to act as the general partner of GEI VII and GEI Side VII. LGP is an affiliate of Capital and Capri VII. LGP's principal business is to act

as the management company of GEI VII, GEI Side VII, and other affiliated funds. LGP Management, Inc. ("LGPM") is the general partner of LGP.

LGPM's principal business is to act as the general partner of LGP. Peridot Coinvest Manager LLC ("Peridot") is an affiliate of LGP and Capital,

whose principal business is to act as the general partner of Coinvest, the manager of Capri Holdings, and the management company of Associates

VII-A, Associates VII-B, and other similar entities. Due to their relationships with GEI VII, GEI Side VII, AIV, Coinvest, Associates VII-A, and

Associates VII-B, each of Capri Holdings, Capri VII, Capital, LGP, LGPM, and Peridot may be deemed to have shared voting and investment power

with respect to the ordinary shares beneficially owned by GEI VII, GEI Side VII, AIV, Coinvest, Associates VII-A, and Associates VII-B. As such,

Capri Holdings, Capri VII, Capital, LGP, LGPM, and Peridot may be deemed to have shared beneficial ownership over such ordinary shares. Each

of Capri Holdings, Capri VII, Capital, LGP, LGPM, and Peridot, however, disclaims beneficial ownership of such ordinary shares. The address of

GEI VII Capri Holdings, LLC. is 11111 Santa Monica Boulevard, Suite 2000, Los Angeles, CA 90025.

**57**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

(2)The information in the table above is based solely on information contained in this shareholder's Schedule 13G/A under the Exchange Act filed by

such shareholder with the SEC. Clarkston Capital Partners, LLC ("CCP") is an investment adviser and the record holder of 72,209,043 ordinary

shares, having shared voting power over 36,114,483 of those shares and shared dispositive power over 39,358,818 shares. Collectively, the

securities reported in the Schedule 13G/A are held in the accounts of CCP's discretionary clients or in an account over which a control person of

CCP has beneficial ownership. The sole members of CCP are Clarkston Companies, Inc. and Modell Capital LLC. The sole owners of Clarkston

Companies, Inc. are Jeffrey A. Hakala and Gerald W. Hakala. The sole member of Modell Capital LLC is the Jeremy J. Modell Revocable Living

Trust. The address of Clarkston Capital Partners, LLC is 91 West Long Lake Road, Bloomfield Hills, 303 E. Third St., Suite 110, Rochester, MI

48307. (3)The information in the table above is based solely on information contained in this shareholder's Schedule 13D/A under the Exchange Act filed with

the SEC. Giovanni Agnelli B.V., Exor N.V., and Exor Nederland N.V. each have sole voting power and sole dispositive power over 67,294,884

ordinary shares. Exor Nederland N.V. is a wholly owned subsidiary of Exor N.V., which in turn is controlled by Giovanni Agnelli B.V. The principal

business address for each of Giovanni Agnelli B.V, Exor N.V. and Exor Nederland N.V. is Gustav Mahlerplein 25A, 1082 MS Amsterdam, The

Netherlands.

(4)The information in the table above is based solely on information contained in this shareholder's Schedule 13G/A under the Exchange Act filed by

such shareholder with the SEC. Onex Partners IV LP is the record holder of 15,874,408 ordinary shares; Onex Partners IV PV LP is the record

holder of 784,783 ordinary shares; Onex Partners IV Select LP is the record holder of 109,890 ordinary shares; Onex Partners IV GP LP is the

record holder of 453,991 ordinary shares; Onex Camelot Co-Invest LP is the record holder of 9,289,010 ordinary shares; Onex US Principals LP is

the record holder of 584,939 ordinary shares; and Onex Partners Holdings LLC is the record holder of 14,820,116 ordinary shares. Gerald W.

Schwartz beneficially owns all of the shares held by Onex Corporation and directly controls New PCo GP Inc. Mr. Schwartz may be deemed to

share beneficial ownership of the shares beneficially owned by Onex Corporation and New PCo GP Inc. Onex Corporation may be deemed to

beneficially own the ordinary shares held by each of Onex Partners IV LP, Onex Partners IV PV LP, Onex Camelot Co-Invest LP, Onex Partners IV

GP LP, and Onex Partners IV Select LP, through Onex Corporation's ownership of all of the common stock of Onex Partners Canadian GP Inc.,

which owns all of the equity of (i) Onex Partners IV GP Limited, which is the general partner of Onex Partners IV GP LP, which is the general

partner of each of Onex Partners IV LP, Onex Partners IV PV LP, and Onex Camelot Co-Invest LP and (ii) Onex Partners IV GP LLC, which is the

general partner of Onex Partners IV Select LP. In addition, Onex Corporation may be deemed to beneficially own the ordinary shares held by (a)

Onex US Principals LP, through Onex Corporation's ownership of all of the equity of Onex Private Equity Holdings LLC, which owns all of the equity

of Onex American Holdings GP LLC, the general partner of Onex US Principals LP and (b) Onex Partners Holdings LLC, through Onex

Corporation's ownership of all of the equity of Onex Private Equity Holdings LLC, which owns all of the equity of Onex American Holdings Subco

LLC, which is the majority owner of Onex Partners Holdings LLC. New PCo A LP is the record holder of 938,247 ordinary shares. New PCo GP Inc.,

the general partner of New PCo A LP, is an independent entity that is controlled by Mr. Schwartz and as such may be deemed to beneficially own all

of the ordinary shares beneficially owned by New PCo GP Inc. Mr. Schwartz, the Chairman, President, and Chief Executive Officer of Onex

Corporation, owns shares representing a majority of the voting rights of the shares of Onex Corporation and as such may be deemed to beneficially

own all of the ordinary shares beneficially owned by Onex Corporation. Mr. Schwartz disclaims any such beneficial ownership. Mr. Schwartz has

indirect voting and investment control of Onex Corporation. The business address of each of Onex US Principals LP, Onex American Holdings GP

LLC, Onex Partners IV GP LP, Onex Partners IV GP LLC, Onex Private Equity Holdings LLC, Onex American Holdings Subco LLC, and Onex

Partners Holdings LLC is 165 W Center Street, Suite 401, Marion, Ohio 43302. The business address of each of Onex Partners IV LP, Onex

Partners IV PV LP, Onex Camelot Co-Invest LP, and Onex Partners IV Select LP is 712 Fifth Avenue, 40th Floor, New York, NY 10019. The

business address of each of the other holders is 161 Bay Street, Toronto, A6, M5J2S1.

(5)The information in the table above is based solely on information contained in this shareholder's Schedule 13D/A under the Exchange Act filed by

such shareholder with the SEC. Selige Co-Investor Pooling Limited, Selige Co-Investor Pooling S.C.Sp, and Castik Capital S.a r.l., have shared

voting power and shared dispositive power over 38,089,963 ordinary shares. Selige Co-Investor Pooling Limited has its registered office at 22

Grenville Street, St. Helier, Jersey JE4 8PX, Channel Islands. Selige Co-Investor Pooling S.C.Sp has its registered office at 1 Route d'Esch, L-1470

Luxembourg. Castik Capital has its registered address at 1 Route d'Esch, L-1470 Luxembourg.

**58**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS**

**Review and Approval of Related Person Transactions**

We follow processes and policies, including our written policy on related person transactions, that are designed to detect

and, if appropriate, approve and disclose any transaction that would constitute a "related person transaction" under SEC

rules. Such transactions would include material transactions and transactions involving an amount exceeding $120,000 in

which any Clarivate directors, nominees for director, executive officers, greater than five percent shareholders or any of

their respective immediate family members or affiliates, or the employers of any of them, has a direct or indirect material

interest.

The Board has delegated the responsibility for reviewing related person transactions to the Audit Committee. To support

this process, each year we solicit internal disclosure of any transactions between Clarivate and its directors and officers,

their immediate family members, and their affiliated entities and employers, including the nature of each transaction and

the amount involved.

The Audit Committee annually reviews and evaluates such information for each director as part of its assessment of each

director's independence.

In addition, all directors, officers, and employees of Clarivate are governed by the Clarivate Code of Conduct, which

requires individuals to act in the best interest of Clarivate and avoid or seek approval for conflicts of interest. Individuals

are responsible for identifying conflicts of interest as soon as they arise and contacting our compliance team prior to

engaging in the conduct if they are unsure whether such relationship or transaction poses a conflict.

If the Audit Committee were presented with a proposed related person transaction, it would evaluate the relevant facts and

circumstances to determine whether to approve it. Factors include the terms of the transaction relative to the terms that

could be obtained in arm's-length dealings with an unrelated person, the extent of the related person's interest in the

transaction, the conflicts of interest (if any), and the provisions of the Clarivate Code of Conduct and whether the

transaction meets any of the criteria for pre-approval.

**Transactions Involving Related Persons**

**Assumed Finance Lease**

On December 1, 2021, Clarivate completed the acquisition of ProQuest from CIG and certain other equity holders. As part

of the acquisition, Clarivate assumed a finance lease in which CIG is the lessor. Mr. Snyder serves as Chief Executive

Officer of CIG. For the year ended December 31, 2025, Clarivate recognized interest expense of $2.0 million and

amortization expense for the finance lease right-of-use ("**ROU**") asset of $0.5 million. The finance lease ROU asset of $8.0

million is shown on Clarivate's financial statements, and the corresponding lease liability of $28.1 million is treated as

indebtedness.

**Sublease**

CIG is a subtenant for certain office space leased by Clarivate through June 2, 2026, with annual renewals through March

31, 2029 unless not renewed by either party. CIG pays Clarivate a monthly subtenancy fee of $22,000.

**Customer and Vendor Arrangements**

Mr. Snyder is affiliated with a Clarivate customer and vendor. During the year ended December 31, 2025, the Company

recognized revenues of $0.5 million and incurred expenses of $4.9 million related to such customer and vendor

arrangement.

Exor is affiliated with a Clarivate customer and with a Clarivate vendor. In the aggregate, during the year ended December

31, 2025, the Company recognized revenues of $3.0 million and incurred expenses of $3.8 million related to such

customer and vendor arrangements.

**Reimbursement of Tax Adviser Fees**

In connection with an IRS examination of ProQuest's tax returns, CIG engaged its tax adviser to provide the Company

with certain historical tax information relating to ProQuest that the Company requires to effectively manage the tax

examination. The Company agreed to pay for the expenses of CIG's tax adviser related to the provision of such

information, paid directly to the tax adviser. The Company currently expects the expense reimbursement to CIG's tax

adviser to be up to $0.4 million.

**59**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**Investment Agreement with Exor N.V.**

On March 4, 2024, Clarivate entered into an Investment Agreement with Exor in connection with Exor's investment in the

Company. Pursuant to the Investment Agreement, the Company agreed to include Ms. Heywood in the Board's slate of

nominees for election as director at the 2024 annual meeting of shareholders. In addition, Exor is subject to certain

customary standstill restrictions.

**Registration Rights Agreement**

On December 1, 2021, Clarivate entered into an amendment to its existing Registration Rights Agreement with various

shareholders under which such shareholders are entitled, in certain circumstances, to cause Clarivate to register their

ordinary shares for resale under the Securities Act.

**Investor Rights Agreement**

On October 1, 2020, Clarivate entered into an Investor Rights Agreement with various shareholders, including, among

others, affiliates of LGP, pursuant to which LGP was given the right to nominate two members to the Board for so long as

LGP maintains ownership of at least 10% of Clarivate and one member of the Board for so long as LGP maintains

ownership of at least 5% of Clarivate.

**60**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**SECTION 16(A) COMPLIANCE**

Section 16(a) of the Exchange Act requires directors, officers, and greater than 10 percent beneficial owners of our

ordinary shares to file reports concerning their ownership of, and transactions in, such ordinary shares.

Based solely on our review of these reports filed by the Company's officers, directors, and shareholders, and written

representations from our executive officers and directors that they filed such reports, we believe that our officers,

directors, and shareholders complied with all filing requirements under Section 16(a) of the Exchange Act on a timely

basis during fiscal year 2025 and fiscal year 2026 up to the date of this Proxy Statement, except as follows:

❖On February 18, 2026, Michael Easton was settled certain performance share unit awards representing

4,266 ordinary shares upon the achievement and certification of the performance condition relating to the

performance share unit awards granted in 2023 and which remained subject to time-based vesting terms. Mr. Easton

should have filed a Form 4 on or before February 20, 2026. Due to administrative oversight by the Company which

was assisting Mr. Easton with his filings, Mr. Easton reported this transaction on a Form 4 filed with the SEC on March

3, 2026; and

❖On February 18, 2026, William Graff was settled certain performance share unit awards representing 4,266 ordinary

shares upon the achievement and certification of the performance condition relating to the performance share unit

awards granted in 2023 and which remained subject to time-based vesting terms. Mr. Graff should have filed a Form 4

on or before February 20, 2026. Due to administrative oversight by the Company which was assisting Mr. Graff with

his filings, Mr. Graff reported this transaction on a Form 4 filed with the SEC on March 3, 2026.

**SHAREHOLDER PROPOSALS FOR THE 2027 ANNUAL** 

**GENERAL MEETING**

**Shareholder Proposals Eligible for Inclusion in the Company's Proxy Statement**

A shareholder wishing to present a proposal to be included in our proxy statement for the 2027 Annual General Meeting of

Shareholders must comply with these instructions and the proxy proposal submission rules of the SEC pursuant to Rule

14a-8. One important requirement is that the proposal be received by the General Counsel of Clarivate no later than

December 2, 2026. Proposals we receive after that date will not be included in the proxy statement for the 2027 Annual

General Meeting of Shareholders.

We urge shareholders to submit proposals by registered or certified mail, return receipt requested, to: **General Counsel,** 

**c/o Legal Department, Clarivate Plc, 70 St. Mary Axe, London EC3A 8BE, United Kingdom**.

You may obtain a copy of the current rules for submitting shareholder proposals through the SEC's website at

**www.sec.gov** or from the SEC at: **Securities and Exchange Commission, Division of Corporation Finance, 100 F** 

**Street, NE, Washington, DC 20549**.

**Shareholder Proposals Not Eligible for Inclusion in the Company's Proxy** 

**Statement**

A shareholder proposal not included in our proxy statement for the 2027 Annual General Meeting of Shareholders will be

ineligible for presentation at the 2027 Annual General Meeting of Shareholders unless the shareholder gives timely notice

of the proposal in writing to the General Counsel at the principal executive offices of Clarivate and complies with the

requirements of the Articles, which are summarized below.

A proposal may be properly brought before an annual general meeting by any shareholder of the Company who is a

shareholder of record on both the date of the giving of the notice by such shareholder provided for in the Articles and the

record date for the determination of shareholders entitled to vote at such annual general meeting, and who complies with

the notice and other procedures set forth in the Articles, which are summarized below. Please see the Articles for the full

procedures.

**Shareholder Proposals Other Than Director Nominations**

The Articles set forth requirements for shareholders wishing to propose business other than the nomination of directors at

an annual general meeting. An eligible shareholder who follows these procedures is not entitled to have their proposal

**61**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

included in the Company's proxy statement and therefore would be required to solicit their own proxies in accordance with

any applicable laws and rules.

To be timely, such shareholder's notice must be delivered to the General Counsel at the principal executive offices of the

Company no earlier than January 14, 2027, and no later than February 13, 2027, unless the 2027 Annual General

Meeting of Shareholders occurs on a date more than 30 days earlier or later than the 2026 Annual General Meeting of

Shareholders. In that case, the Board will determine a date that is a reasonable period prior to the 2027 Annual General

Meeting of Shareholders by which the shareholder's notice must be delivered and publicize that date in a filing with the

SEC or via press release at least 14 days prior to the date set by the Board.

To be in proper written form, in summary, a shareholder's notice to the Company must set forth as to such matter such

shareholder proposes to bring before the annual general meeting, among other things:

❖a reasonably brief description of the business desired to be brought before the annual general meeting, including the

text of the proposal or business, and the reasons for conducting such business at the annual general meeting;

❖the name and address, as they appear on the Company's Register of shareholders, of the shareholder proposing

such business and any Associated Person (as defined below);

❖the class or series and number of shares of the Company that are held of record or are beneficially owned by such

shareholder or any Associated Person and any derivative positions held or beneficially held by the shareholder or any

Associated Person;

❖whether and the extent to which any hedging or other transaction or series of transactions has been entered into by or

on behalf of such shareholder or any Associated Person with respect to any securities of the Company, and a

description of any other agreement, arrangement, or understanding (including any short position or any borrowing or

lending of shares), the effect or intent of which is to mitigate loss to, or to manage the risk or benefit from share price

changes for, or to increase or decrease the voting power of, such shareholder or any Associated Person with respect

to any securities of the Company;

❖any material interest of the shareholder or an Associated Person in such business, including a reasonably detailed

description of all agreements, arrangements, and understandings between or among any of such shareholders or

between or among any proposing shareholders and any other person or entity (including their names) in connection

with the proposal of such business by such shareholder; and

❖a statement as to whether such shareholder or any Associated Person will deliver a proxy statement and form of

proxy to holders of at least the percentage of the Company's voting shares required under applicable law and the

rules of the Designated Stock Exchange to carry the proposal.

An Associated Person of any shareholder includes:

❖any affiliate (as defined in the Articles) of, or person acting in concert with, such shareholder;

❖any beneficial owner of shares of the Company owned of record or beneficially by such shareholder and on whose

behalf the proposal or nomination, as the case may be, is being made; and

❖any person controlling, controlled by, or under common control with a person referred to in the preceding two bullets.

**Shareholder's Nomination of a Director**

The Articles also set forth requirements for shareholders wishing to nominate directors. An eligible shareholder who

follows these procedures is not entitled to have their nomination included in the Company's proxy statement and therefore

would be required to solicit their own proxies in accordance with any applicable laws and rules.

In summary, for a nomination for election of a director to be made by a shareholder of the Company (other than directors

to be nominated by any series of preferred shares, voting separately as a class), or nominations made pursuant to a

contract with the Company, such shareholder must, among other things:

❖be a shareholder of record on both the date of the giving of the notice by such shareholder provided for in the Articles

and the record date for the determination of shareholders entitled to vote at such annual general meeting;

❖on each such date beneficially own more than 15% of the issued ordinary shares; and

❖have given timely notice thereof in proper written form to the Secretary of the Company.

**62**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

If a shareholder is entitled to vote only for a specific category of Directors at a meeting of the shareholders, such

shareholder's right to nominate one or more persons for election as a Director at the meeting shall be limited to such

category of directors.

To be timely, a shareholder's notice must be delivered to or mailed and received at the principal executive offices of the

Company not less than 90 nor more than 120 days prior to the meeting; provided, that if less than 130 days' notice or prior

public disclosure of the date of the meeting is given or made to shareholders, notice by the shareholder to be timely must

be so received not later than the close of business on the tenth day following the earlier of the day on which such notice of

the date of the meeting was mailed or such public disclosure was made.

In addition to satisfying the advance notice provisions in the Articles relating to nominations of director candidates,

including the earlier notice deadlines set out above, to comply with the SEC's universal proxy rule, shareholders who

intend to solicit proxies in support of director nominees other than the Company's nominees in compliance with Rule

14a-19 under the Exchange Act must also provide notice that sets forth the information required by Rule 14a-19 no later

than March 15, 2027.

To be in proper written form, in summary, a shareholder's notice to the Secretary must set forth, among other things:

❖as to each nominating shareholder:

❖the information about the shareholder and its Associated Persons specified above under "Shareholder

Proposals Other Than Director Nominations"; and

❖any other information relating to such shareholder that would be required to be disclosed pursuant to any

applicable law and rules of the SEC or of the NYSE, including pursuant to Rule 14a-19(b); and

❖as to each person whom the shareholder proposes to nominate for election as a director:

❖all information that would be required if such nominee was a nominating shareholder, as described above,

except such information shall also include the business address and residence address of the person;

❖the principal occupation or employment of the person;

❖all information relating to such person that is required to be disclosed in solicitations of proxies for appointment

of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the

Exchange Act or any successor provisions thereto, and any other information relating to the person that would

be required to be disclosed pursuant to any applicable law and rules of the SEC or of the NYSE; and

❖a description of all direct and indirect compensation and other material monetary arrangements and

understandings during the past three years, and any other material relationship, between or among any

nominating shareholder and its affiliates and associates, on the one hand, and each proposed nominee, and

their respective affiliates and associates, on the other hand, including, without limitation, all information that

would be required to be disclosed pursuant to Item 404 under Regulation S-K of the Exchange Act if such

nominating shareholder were the "registrant" for purposes of such rule and the proposed nominee were a

director or executive officer of such registrant.

Such notice must be accompanied by a written consent of each proposed nominee to being named as a nominee and to

serve as a director if elected. The Company may require any proposed nominee to furnish such other information as may

be reasonably required by the Company to determine the eligibility of such proposed nominee to serve as an independent

director of the Company in accordance with the rules of the NYSE.

**63**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**ADMISSION PROCEDURE**

**Admission**

Admission is limited to shareholders of record at the close of business on March 16, 2026, or one individual designated as

a shareholder's authorized proxy holder, or one representative designated in writing to present a shareholder proposal. If

you plan to attend the Annual Meeting in person, we encourage you to request an admission ticket in advance.

Failure to request an admission ticket in advance will not preclude your attendance at the Annual Meeting in person.

However, in each case, an individual must have a valid government-issued photo identification (e.g., a driver's license or a

passport) and should arrive in advance, with sufficient time to be admitted to the Annual Meeting.

No weapons, cameras, audio or video recording equipment, electronic devices, large bags, briefcases, or packages will

be permitted in the Annual Meeting. Please note that, for security reasons, all bags may be searched. We will be unable to

admit anyone to the Annual Meeting who does not comply with these security procedures. No one will be admitted to the

Annual Meeting once the meeting has commenced.

**Ticket Requests**

Ticket requests should include all information specified in the applicable table below and be submitted in writing and

received by the General Counsel at **General Counsel, c/o Legal Department, Clarivate Plc, 70 St. Mary Axe, London** 

**EC3A 8BE, United Kingdom** or by email to **Company.Secretary@clarivate.com**.

**Authorized Proxy Representative**

A shareholder may appoint one representative to attend the Annual Meeting and/or vote on their behalf. The admission

ticket should be requested by the shareholder but will be issued in the name of the authorized representative. The

shareholder information specified below and a written proxy authorization must accompany the ticket request.

**Proponent of a Shareholder Proposal**

For each shareholder proposal included in this Proxy Statement, the shareholder sponsor should notify the Company in

writing of the individual authorized to present the proposal on behalf of the shareholder at the Annual Meeting. One

admission ticket will be issued for the designated representative if the advance registration instructions in this section are

followed. Shareholder sponsors and their designated representatives must present valid government-issued photo

identification to be admitted to the Annual Meeting.

---

| | |
|:---|:---|
| **Registered Shareholders**<br>**For ownership verification provide:** <br>| **Beneficial Holders** <br>**For ownership verification provide one of the following:** <br>|
| <u>Option A</u>:<br>❖Name(s) of shareholder(s);<br>❖Address;<br>❖Phone number; and<br>❖Shareholder account number or social security number<br><u>Option B</u>:<br>❖A copy of your proxy card or notice showing shareholder <br>name and address<br><u>Also include</u>:<br>❖Name of authorized proxy representative, if applicable<br>❖Email address to which the ticket should be sent and <br>phone number <br>| ❖A copy of your March 2026 brokerage account statement <br>showing Clarivate share ownership as of the Record <br>Date (March 16, 2026); or<br>❖A letter from your broker, bank, or other nominee <br>verifying your Record Date (March 16, 2026) ownership; <br>or<br>❖A copy of your brokerage account voting instruction card <br>showing shareholder name and address<br><u>Also include</u>:<br>❖Name of authorized proxy representative, if applicable<br>❖Email address to which the ticket should be sent and <br>phone number<br>|

---

In order to be admitted to the Annual Meeting, shareholders will need proof of ownership of the Company's ordinary

shares and may be asked to present a form of personal government-issued photo identification. If your ordinary shares

are not registered in your name (for instance, if you hold Clarivate ordinary shares through a broker, bank, or other

institution), please advise the shareholder of record that you wish to attend; that firm will then provide you with evidence of

ownership that will be required for admission to the Annual Meeting.

**64**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**OTHER MATTERS**

The Board does not know of any other business that will be presented at the Annual Meeting. If any other business is

properly brought before the Annual Meeting, your proxy holders will vote on it as they think best unless you direct them

otherwise in your proxy instructions.

We urge you to submit your signed proxy promptly.

**BY ORDER OF THE BOARD OF DIRECTORS**

![JD signature.jpg](clvt-20260401_g8.jpg)

**John Doulamis**

**General Counsel**

April 1, 2026

![](clvt-20260401_g21.gif)

Our Annual Report for the year ended December 31, 2025, has been mailed with this Proxy Statement.

You may also review that document and all exhibits on our website (**ir.clarivate.com**). We will provide printed copies of

exhibits to the Annual Report but will charge a reasonable fee per page to any requesting shareholder. Send that request

in writing to: **General Counsel, c/o Legal Department, Clarivate Plc, 70 St. Mary Axe, London EC3A 8BE, United** 

**Kingdom**. The request must include a representation by the shareholder that as of the Record Date the shareholder was

entitled to vote at the Annual Meeting.

**65**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

**APPENDIX A**

**NON-GAAP FINANCIAL MEASURES**

We use non-GAAP financial measures to evaluate our business and trends, measure performance, prepare financial

projections, and make strategic decisions. Although we believe these measures may be similarly useful to investors in

evaluating our business, these measures are not a substitute for GAAP financial measures or disclosures. Reconciliations

of our non-GAAP financial measures to the most directly comparable GAAP measures are provided below.

**Adjusted EBITDA and Adjusted EBITDA margin**

We use Adjusted EBITDA as a basis for evaluating our ongoing operating performance, and we believe it is useful for

investors to understand the underlying trends of our operations. Adjusted EBITDA represents Net income (loss) before the

Provision (benefit) for income taxes, Depreciation and amortization, and Interest expense, net, adjusted to exclude

acquisition and/or disposal-related transaction costs, share-based compensation, restructuring expenses, impairments,

the impact of certain non-cash fair value adjustments on financial instruments, unrealized foreign currency gains/losses,

legal settlements, and other items that are included in Net income (loss) for the period that we do not consider indicative

of our ongoing operating performance. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by Revenues.

Our presentation of Adjusted EBITDA and Adjusted EBITDA margin should not be construed as an inference that our

future results will be unaffected by any of the adjusted items, or that our projections and estimates will be realized in their

entirety or at all. In addition, because of these limitations, Adjusted EBITDA should not be considered as a measure of

liquidity or discretionary cash available to us to fund our cash needs, including investing in the growth of our business and

meeting our obligations.

The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA margin for the years ended

December 31, 2025 and 2024, and reconciles these non-GAAP measures to our Net income (loss) and Net income (loss)

margin for the same periods:

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| <br>(in millions) | **2025** | **2024** |
| **Net income (loss)** | **$(201.1)** | **$(636.7)** |
| Provision (benefit) for income taxes | 7.2 | 82.9 |
| Depreciation and amortization | 757.2 | 727.0 |
| Interest expense, net | 265.4 | 283.4 |
| Share-based compensation expense | 63.0 | 60.6 |
| Goodwill and intangible asset impairments | 15.0 | 540.7 |
| Restructuring and other impairments | 50.7 | 19.6 |
| Fair value adjustment of warrants |  | (5.2) |
| Transaction related costs | 22.5 | 17.9 |
| Other<sup>(1)</sup> | 21.9 | (29.8) |
| **Adjusted EBITDA** | **$1001.8** | **$1060.4** |
| Net income (loss) margin | **(8.3)%** | **(24.9)%** |
| Adjusted EBITDA margin | **40.8%** | **41.5%** |

---

(1)Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our

ongoing operating performance.

**Adjusted net income and Adjusted diluted EPS**

Adjusted net income represents Net income (loss), adjusted to exclude amortization related to acquired intangible assets,

share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments

on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses,

legal settlements, and other items that are included in net income (loss) for the period that we do not consider indicative of

our ongoing operating performance and the associated income tax impact of such adjustments.

Adjusted diluted EPS is calculated by dividing Adjusted net income by Adjusted diluted weighted average shares. The

Adjusted diluted weighted average shares calculation assumes that all instruments in the calculation are dilutive.

**66**

[**TABLE OF CONTENTS**](#i4d1987239dbc4a93b1fc759704cab4f3_13)

**Clarivate 2026 Proxy Statement**

The following table presents our calculation of Adjusted net income and Adjusted diluted EPS for the years ended

December 31, 2025 and 2024 and reconciles these non-GAAP measures to our Net income (loss) and diluted EPS for the

same periods:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| <br>(In millions, except per share amounts) | **Amount** | **Per Share** | **Amount** | **Per Share** |
| **Net income (loss) and Diluted EPS** | **$(201.1)** | **$(0.30)** | **$(636.7)** | **$(0.92)** |
| Amortization related to acquired intangible assets | 545.5 | 0.81 | 554.1 | 0.80 |
| Share-based compensation expense | 63.0 | 0.09 | 60.6 | 0.09 |
| Goodwill and intangible asset impairments | 15.0 | 0.02 | 540.7 | 0.78 |
| Restructuring and other impairments | 50.7 | 0.08 | 19.6 | 0.03 |
| Fair value adjustment of warrants |  |  | (5.2) | (0.01) |
| Transaction related costs | 22.5 | 0.03 | 17.9 | 0.03 |
| Other<sup>(1)</sup> | 24.8 | 0.04 | (29.8) | (0.08) |
| Income tax impact of related adjustments | (52.3) | (0.08) | 4.1 | 0.01 |
| **Adjusted net income and Adjusted diluted EPS** | **$468.1** | **$0.69** | **$525.3** | **$0.73** |
| **Adjusted weighted average ordinary shares, diluted** | **679.3** | **679.3** | **721.5** | **721.5** |

---

(1)Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our

ongoing operating performance.

**Free cash flow**

We use Free cash flow in our operational and financial decision-making and believe it is useful to investors because

similar measures are frequently used by securities analysts, investors, ratings agencies, and other interested parties to

measure the ability of a company to service its debt. Our presentation of Free cash flow should not be considered as a

measure of liquidity or discretionary cash available to us to fund our cash needs, including investing in the growth of our

business and meeting our obligations.

We define Free cash flow as Net cash provided by operating activities less Capital expenditures.

The following table reconciles our non-GAAP Free cash flow measure to Net cash provided by operating activities for the

years ended December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| <br>(in millions) | **2025** | **2024** |
| **Net cash provided by operating activities** | **$628.5** | **$646.6** |
| Capital expenditures | (263.2) | (289.1) |
| **Free cash flow** | **$365.3** | **$357.5** |

---

![CLARIVATE PLC_PRXY_P45136_26(#94910) - C3_1.jpg](clvt-20260401_g22.jpg)

![CLARIVATE PLC_PRXY_P45136_26(#94910) - C3_2.jpg](clvt-20260401_g23.jpg)